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ABSTRACT 
 
Foot-and-mouth disease virus (FMDV) 2A is an oligopeptide composed of 
only 18 amino acids that can mediate a co-translational cleavage at its own C-
terminus. It has been observed that 2A sequences do not show cleavage activity 
within bacterial organisms. Why 2A lacks activity in a prokaryotic organism such as 
E.coli is unclear. A series of plasmids designed to provide a phenotypic screen for 
2A-mediated cleavage (in prokaryotes) were developed. Even though no active 2A 
sequences were found in bacteria, this system can easily be adapted to eukaryotic cells 
and will also be very useful in mutagenic studies on 2A sequences. Furthermore, 
2AFMDV has been used in the construction of a reporter of stress in the cell. This may 
allow us to open a new approach in the use of 2A oligopeptide, which had already 
been widely used to co-express genes of interest with reporter proteins, in 
biotechnology and gene therapy. 
Theiler’s murine encephalomyelitis cardiovirus (TMEV) 2A has the same role as 
in FMDV but is 150 aa in length instead of the 18 aa in FMDV. It also presents the 
same C-terminal motif but what is the function of the remaining -85% of the 
cardiovirus 2A sequence remains a mystery. To this end we have produced antibodies 
against TMEV-2A, to study the role of 2ATMEV within the cell. 
Database searches probing for 2A’s C-terminal conserved motif (-
DxExNPGP-) has identified many 2A-like sequences, not only within picornaviruses 
but also in trypanosomes, insect and cellular genes. These remarkable findings 
indicate that the control of protein synthesis by 2A is not solely confined to the 
Picornaviridae. Bioinformatics analyses of all the known 2A-like sequences, 
comparing all the different upstream sequences, show a clear pattern on the 
organization of residues in the upstream region. 
The discovery of this 2A oligopeptide has led to a breakthrough in protein co-
expression technology. It has been used as a highly effective new tool for the co-
expression of multiple proteins from a single ORF in plant biotechnology and also 
gene therapy applications. Although we have gained substantial insights into the 
general features and biological significance of this process, a great deal still needs to 
be uncovered about the structural and mechanistic details of this unique mechanism of 
action. 
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    1. INTRODUCTION 
 
1.1. Viruses 
Viruses are obligate intracellular parasites which consist of a genetic material 
(RNA or DNA) encapsidated within a protein coat which may also be surrounded by a 
lipid membrane. 
The concept of infectious particles smaller than a bacterium, such as viruses, 
was developed in 1892 by Dimitri Ivanosfsky (1864-1920), who found such particles 
in the sap of mosaic tobacco plants (reviewed by Horzinek, 1997 and Lustig & 
Levine, 1992). These studies were followed by Martinus Beijerinck (1851-1931) and 
lead him to propound a new concept: a filterable agent too small to observe in the 
light microscope but able to cause disease by multiplying in living cells. 
 In 1898 Friedrich Loeffler and Paul Frosh isolated the first infectious filterable 
particle from animals, foot and mouth disease virus (FMDV). In 1901 Walter Reed 
described the first human virus, the causative agent of yellow fever. 
 Further studies not only helped in the description of new viruses and their 
properties but also in the successful production of vaccines to prevent specific 
diseases. From the 1960’s virologists began to use viruses as tools to gain an in-depth 
knowledge and understanding of life processes, from the replication of nucleic acid to 
protein synthesis and transport. 
Viruses have been classified in different ways. These classifications are based 
on phenotypic characteristics such as morphology, mode of replication, cell host, 
disease that the virus causes and also the type of nucleic acid that it carries. The 
Baltimore Classification separates viruses into several groups, based on their mode of 
replication and type of genome. Other classifications use chemical and physical 
characteristics, such as type of nucleic acid, symmetry and presence/absence of 
envelope, while others are based on the host organism that the virus attacks.   
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1.2. Positive stranded RNA viruses 
 Positive stranded RNA viruses comprise over one-third of all virus genera and 
include pathogens such as poliovirus, hepatitis C virus, severe acute coronavirus 
syndrome SARS, winter vomiting calicivirus, among others. These viruses have a 
relatively small genome that can, directly, be translated in the first step of infection 
without having to be transcribed first. Their RNA acts like cellular mRNA and can be 
translated by the host’s cells machinery. They need to encode their own RNA-
dependent RNA-polymerase to replicate their RNA and they use different strategies to 
express their proteins. These expression strategies will be discussed in section 1.4. 
 
1.3. Picornaviruses  
 Picornaviruses are non-enveloped positive-stranded RNA viruses, which 
encode a single, long, open reading frame (ORF) comprising a polyprotein of ~225 
kDa. The Picornaviridae is one of the largest families of human and animal pathogens 
and contains many important human and animal viruses, including: poliovirus, 
hepatitis A virus and foot-and-mouth disease virus.  
 The Picornaviridae consists of 9 genera: Enterovirus (Poliovirus, Human 
enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D, 
Simian enterovirus A, Bovine enterovirus and Porcine enterovirus B.), Rhinovirus 
(human rhinovirus1-2), Cardiovirus (Encephalomyocarditis virus and Theilovirus), 
Aphthovirus (Foot-and-mouth disease virus, Equine rhinitis A virus, Bovine 
rhinovirus 2), Hepatovirus (Hepatitis A virus and Avian encephalomyelitis-like virus), 
Parechovirus (Human parechovirus and Ljungan virus), Erbovirus (Equine rhinitis B 
virus), Kobuvirus (Aichi virus and Bovine Kobuvirus) and Teschovirus (Porcine 
Teschovirus). Three new genera have been proposed and provisionally named: 
Sapelovirus (Porcine enterovirus A, SV2-like virus, Duck Picornavirus TW90A), 
Senecavirus (Seneca valley virus) and Tremovirus (Avian encephalomyelitis virus, 
which now belongs to Hepatovirus). In the near future, the genera Rhinovirus will be 
removed, its two members placed in the genus Enterovirus. In addition, two new 
species have recently been identified: duck hepatitis virus 1 and seal picornavius 1. 
These will form two novel genera. The family Picornaviridae will thus consist of 13 
genera and 28 species (Table 1). 
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Family Picornaviridae
Genus Species
Enterovirus
Aphthovirus
Hepatovirus
Parechovirus
Kobuvirus
Teschovirus
Senecavirus
Tremovirus
New unnamed genera:
Poliovirus, Human enterovirus A, Human enterovirus B, Human 
enterovirus C, Human enterovirus D, Simian enterovirus A, 
Bovine enterovirus and Porcine enterovirus B
Human rhinovirus 1-2
Encephalomyocarditis virus and Theilovirus
Foot-and-mouth disease virus and Equine rhinitis A virus
Bovine rhinovirus
Hepatitis A virus and Avian encephalomyelitis-like virus
Human parechovirus and Ljungan virus
Equine rhinitis B virus
Cardiovirus
Aichi virus and Bovine Kobuvirus
Porcine Teschovirus
Porcine enterovirus A, SV2-like virus,Duck Picornavirus TW90ASapelovirus
Seneca valley virus
Avian encephalomyelitis virus, which now belongs to Hepatovirus
Erbovirus
duck hepatitis virus 1 and seal picornavirus 1
Rhinovirus
 
 
 
Table 1. The Picornaviridae. Table showing the classification of all the genera and species within the 
family. 
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 1.3.1 Picornavirus genera 
  
    1.3.1.1 Enteroviruses  
  
 Enteroviruses have been implicated in chronic as well as acute diseases. These 
chronic diseases include dermatomyositis, polymyositis, dilated cardiomyopathy and 
diabetes mellitus.  
 Poliovirus is a well-known virus within this family, which causes 
poliomyelitis, an acute viral infectious disease that spreads from person to person via 
the faecal-oral route. 
 Most of these virus infections are asymptomatic, although, in a few cases, the 
virus can enter the central nervous system leading to acute flaccid paralysis (figure 1). 
Poliovirus is a widely studied virus, whose genome (~7400 nucleotides) functions as 
single genome sized RNA and is representative of most positive-sense RNA viruses 
(shown in figure 2). Extensive studies of this virus allied to successful vaccine 
production, and vaccination program have led to the almost complete eradication of 
polio. This will be the second virus eradicated from the world, smallpox being the 
first. 
 
 
 
 
Figure 1. Poliomyelitis, flaccid muscular 
paralysis disease cause by poliovirus. 
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Figure 2. Schematic diagram of the poliovirus genome and proteolytic processing of its 
polyprotein. Poliovirus has a single-stranded, positive-sense RNA genome, which encodes a single 
polyprotein. Its genome is covalently liked at the 5´end to a viral protein encoded by 3B (VPg). The 5' 
untranslated region (UTR) contains a 5’terminal stem-loop, cloverleaf-like structure, and a type I or II 
internal ribosome entry site (IRES). The 3'UTR is poly-adenylated. Proteolytic processing is mediated 
by the virally-encoded proteinases 2Apro and 3Cpro/3CDpro to ultimately generate eleven mature viral 
proteins. Three intermediate products are produced (2BC, 3AB, and 3CD).   
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 1.3.1.2 Rhinovirus  
 Rhinoviruses, aetiological agents of the common cold, are the most commonly 
isolated viruses from individuals experiencing mild upper respiratory illnesses (Figure 
3). In contrast to enteroviruses, rhinoviruses do not replicate in the intestinal tract. 
Constant efforts towards producing effective vaccines have been unsuccessful and 
remain as an important goal. This genus contains 99 human rhinovirus serotypes 
classified into 2 species, Human rhinovirus A and B. This genus will disappear soon, 
its 2 species moved into the enterovirus genera (http://www.picornaviridae.com/). 
 
 
 
 
Figure 3. One of the classic symptoms caused by 
rhinovirus in the common cold.
 
  
   
 
 
 
 
 
 
 
 
 
 
 
1.3.1.3 Cardiovirus  
 This genus consists of two species: encephalomyocarditis virus (EMCV), 
which is represented by a single serotype of the same name, and theilovirus, which 
comprises 4 different serotypes: Theiler´s murine encephalomyelitis virus (TMEV), 
Vilyuisk human encephalomyelitis virus (VHEV), Theiler’s-like virus (TLV) isolated 
from rats and human pathogen Saffold virus (SAF-V). These are distinguished from 
other genera by special features of their genome organization (presence of a poly(C) 
tract - except TMEV - and the dissociability of their capsid at pH 5-7, among others). 
 Several strains of EMCV have been determined: encephalomyocarditis virus 
(strain EMC-B nondiabetogenic), Encephalomyocarditis virus (strain EMC-D 
diabetogenic), Maus-Elberfeldvirus, Mengo virus and Porcine encephalomyocarditis 
virus (http://www.picornaviridae.com/). 
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TMEV strains were first isolated by Max Theiler at the Rockefeller 
Foundation during the 1930’s, (Lipton, 1975) from the central nervous system of 
paralysed mice and later from the intestine of apparently uninfected mice.  
 These investigations demonstrated that the virus caused widespread, 
asymptomatic, enteric infection and chronic progressive demyelination in mice.  Such 
symptoms were later identified as being similar to those observed in humans with 
multiple sclerosis (Lipton, 1975; Roos, 2002). 
There are several strains classified on the basis of differences in their 
biological activities: i) GDVII sub-group (GDVII and FA), which are extremely 
virulent and produce an acute disease that is similar to poliomyelitis; and ii) TO sub-
group (DA, BeAn, TO, WW, Yale, etc), which produce a biphasic disease (reviewed 
by Racaniello, 2001; Roos, 2002). 
   
  1.3.1.4 Aphthovirus  
 Foot-and-mouth disease virus (FMDV) is a member of this genus and is 
responsible for Foot-and-mouth disease (FMD). This disorder principally affects 
domesticated and wild cloven-hoofed animals and is known to spread by direct 
contact between infected and susceptible animals by the airborne route, by animal 
products such as meat and milk, and mechanical transfer via people, wild animals, 
birds, and by vehicles. It is accepted as a significant epidemic disease that infects 
primarily cattle, goats, pigs, and sheep and rarely humans (reviewed by: Rossmann, 
2002; Agol, 2002).  
 FMD is one of the most contagious animal diseases, with important economic 
losses. It is endemic in Asia, Africa, the Middle East and South America. On the 
domestic front, the 2001 outbreak cost the UK something in the region of £10 billion 
with the loss of eight million cattle, sheep, pigs and goats (DEFRA, March 2002) 
Unfortunately, presently available inactivated vaccines are not entirely effective. 
Vaccination blocks disease symptoms, making detection of infection difficult, but 
does not always block transmission of the virus to other animals. Sheep can harbour 
the virus for several months; cows for up to a year or even longer. Occasional 
vaccine-linked disease outbreaks occur as a result. 
Its genome is unique in that it encodes three VPg genes whereas the other 
picornaviruses encode only one, and it also has the shortest poly(A) tract compared to 
other genera. Equine rhinitis A virus (ERAV) also belongs to the aphthoviruses 
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(Pringle et al., 1999) and is the only non-FMDV member of this genus. The genome 
organisation of this virus possesses two features which distinguish it from FMDV; (i) 
there is no poly C tract and (ii) ERAV has only one copy of 3B (VPg) (Wutz et al., 
1996). 
 
1.3.1.5 Hepatovirus  
 Hepatitis A is an acute infectious disease caused by Hepatitis A virus (HAV). 
It is transmitted via the faecal-oral route and may be mistaken for flu. Symptoms 
typically appear 2 to 6 weeks after the start of infection and may return over the 
following 6-9 months. The most common symptoms are: fatigue, fever, nausea, 
abdominal pain and diarrhoea. 
 In contrast with other picornaviruses, Hepatovirus 2A protein does not show 
any proteolytic function with regards to polyprotein processing. Cleavage between 
2A/2B, leading to separation of 5’ terminal structural proteins from the non-structural 
proteins, is achieved by the 3C protease (Jia et al., 1993; Martin et al., 1995).     
 
1.3.1.6 Parechovirus  
 Two species form this genus, Human parechovirus (HePV), which comprises 
five serotypes (Ito et al., 2004; Al-Sunaidi et al., 2007), and the recently described 
Ljungan virus (LV), which may be comprised of two or more serotypes. 
 Human parechovirus causes mostly mild gastrointestinal or respiratory illness, 
with a few cases of myocarditis and encephalitis. It commonly infects children 
between 2 to 5 years old. In contrast, Ljungan virus causes diabetes, neurological 
disease, myocarditis and intrauterine foetal death in humans (Niklasson et al., 2007). 
It is a zoonotic virus, which was isolated from bank voles (Niklasson et al., 1999). Its 
genome contains two 2A proteins in tandem. The N-terminal 2A1 has the -
DxExNPGP- motif and is related to the type of 2As encoded by aphthoviruses, 
cardioviruses, erboviruses and teschoviruses. In contrast, the 2A2 belongs to the type 
of 2As encoded by kobuviruses and hepatoviruses (Johansson et al., 2002).  
 
  1.3.1.7 Erbovirus  
 Equine rhinitis B virus (ERBV) is the only member of this genus and causes 
acute upper febrile respiratory disease in horses (Dynon et al., 2007). There are two 
serotypes, ERV-1 and ERV-2, which are closely related to FMDV, although the 
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symptoms they cause more closely resemble those produced by rhinovirus. ERV-1 
proteins are very similar to the FMDV proteins, whereas, most ERV-2 proteins are 
more closely related to EMCV proteins (Wutz et al., 1996). 
  1.3.1.8 Kobuvirus  
 This genus consists of 2 species, Aichi virus, which infects humans 
(Yamashita et al., 1998) and Bovine Kobuvirus, which infects cattle (Yamashita et 
al., 2003). 
 Aichi virus, first recognized in 1989 as the cause of oyster-associated non-
bacterial gastroenteritis in humans, has been recently classified into the new 
Kobuvirus genus (Pham et al., 2007) 
 
 1.3.1.9 Teschovirus  
Teschovirues constitute a recently defined genus within the Picornaviridae. It 
is represented by a single species, Porcine Teschovirus (PTV), which causes porcine 
enteroviral encephalomyelitis disease. PTV-1 Talfan is the reference strain for this 
genus, and, as mentioned earlier, its genome contains a significantly shorter IRES 
compared to the other genera, and requires part of the 5´UTR sequence for its activity 
(Kaku et al., 2002). 
 
1.3.1.10 Proposed novel genera 
  Sapelovirus consists of three species: Porcine enterovirus A, SV2-like virus, 
Duck Picornavirus TW90A. The name of this proposed genus derives from Simian, 
Avian and Porcine Entero-Like viruses.  
     Senecavirus contains Seneca valley virus (SVV), whose proteins closely resemble 
some cardiovirus proteins (P1, 2C, 3Cpro and 3Dpol). However, the 5’UTR, leader, 2A 
and 3A proteins are very different to all known picornaviruses. SVV-2A protein 
presents the same conserved motif found in aphthoviruses (Luke et al., 2008)
 Tremovirus consists of a single species, Avian encephalomyelitis virus (AEV), 
which currently belongs to hepatovirus. 
 
  1.3.1.11 Novel species 
Two novel picornaviruses, whose entire genomes have recently been sequenced, have 
been allocated their own genera. 
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 Duck hepatitis virus 1 (DHV-1) is one of the three viruses causing Duck virus 
hepatitis, an acute highly contagious disease affecting young ducklings up to the age 
of 28 days. Its genome features three in-tandem 2A genes. The 2A1 and 2A3 proteins 
are aphthovirus-like and human parechovirus-like 2A proteins respectively, whereas 
2A2 is not related to any known picornavirus protein. These 2A proteins are only 12 
amino acid long (Tseng et al., 2007b) Another exclusive feature of this new species is 
the length of 3’ UTR, which is composed of 314 nucleotides, the largest among the 
picornaviruses (Tseng et al., 2007a). On the bases of these findings it is proposed that 
DHV-1 should be assigned to a new genus in the Picornaviridae. 
 Seal picornavius 1 (SePV-1) is a new picornavirus species that was isolated 
from Arctic ringed seals (Phoca hispida) in Canada. The SePV-1 genome contains 
two 2A genes, whose sequence correspond to the canonical co-translational cleavage 
site DxExNPG↓P, found in cardioviruses, apthoviruses, teschoviruses and erboviruses 
(explained in sections 1.4.5 and 1.4.6). Furthermore, the absence of a predicted 
maturational cleavage site between 1A and 1B (VP0) was also observed in other 
species within the family, such as LV, HPeV and DHV.    
         
 1.3.2 Genome structure and organization 
 The name Picornaviridae conveys two important features of the family, the 
small size (Pico-) and the type of nucleic acid that the viral genome carries (-
rnaviridae). This family has played a major role in the development of modern 
virology. Foot-and-mouth disease virus was the first animal virus discovered, 
followed by poliovirus, which was isolated ten years later. Picornavirus virions are 
spherical particles with a diameter of 30 mm and are simply composed of a protein 
shell surrounding the naked RNA genome. Their capsid is composed of four structural 
proteins (VP1, VP2, VP3, and VP4), excepting parechoviruses, DHV-1 and SePV 
with only three (VP1, VP3 and VP0, which is equivalent to the uncleaved VP2 plus 
VP4 precursor of other picornaviruses). 
 Picornavirus RNAs have certain features that differ from most mammalian 
mRNAs. The lack of the 5’ terminal cap structure (m7GpppN) and the presence of 5’ 
untranslated regions are among their distinctive properties. The naked RNA genome 
of picornaviruses is infectious because it can be translated on entry into the cell using 
the host´s cell machinery. Its genome is covalently liked at the 5´end to a protein 
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called VPg (3B; virion protein, genome linked). FMDV is the only one in the family 
that has three Vpgs instead of one (Forss & Schaller, 1982).  The picornavirus 
genome can be divided in three regions: a 5´untranslated region (5´UTR), which is 
600 to 1,200 nucleotides long, the coding region, which comprises 6,500 to 7000 
nucleotides and a short 3´untranslated region (3´UTR) that contains a 
heteropolymeric segment and a poly(A) tail (Rueckert, 1996; Palmenberg, 1990). The 
5’UTR contains a 5’terminal stem-loop, cloverleaf-like structure,  and a type  I or II 
internal ribosome entry site (IRES), which allows a cap-independent mode of 
translation by binding to eIF4G (Kolupaeva et al., 1998, 2003; Clark et al., 2003). In 
aphthoviruses, cardioviruses (except TMEV) and erboviruses the 5’UTR also includes 
a poly(C) tract. The poly(C) tail is longer in cardioviruses and is associated with 
higher virulence in animals (Duke et al., 1990; Hahn & Palmenberg, 1995; Wutz et 
al., 1996). IRES’s enable the eukaryotic ribosome to bind directly to the internal site 
without first having to scan from the 5’ terminus, thus allowing 5’cap-independent 
translation (reviewed in Jang, 2005). There are four different IRES types, one of them 
belatedly discovered in porcine teschovirus-1 (Kaku et al., 2002). These viral 
elements are widely used in vectors for gene therapy and their ability to enhance 
expression of an upstream gene in dicistronic vectors, has been recently discovered 
(Niepman, 2007). The 3’ poly (A) tail is essential for infectivity. Its removal in 
poliovirus leaves the viral genome non-infectious (Spector & Baltimore, 1974). 
 The picornavirus polyprotein is divided into three regions: P1, which encodes 
the structural proteins, and P2-P3, which encodes the non-structural proteins that are 
involved in polyprotein processing (2A or 2Apro, 3Cpro and 3CDpro) and genome 
replication (2B, 2C, 3AB, 3BVPg, 3CDpro, 3Dpol). 
Unlike other genera, cardio-, aphtho-, erbo-, kobu-, tescho- and sapelovirus 
have an L protein region at the N-terminus of the polyprotein (figure 4). In aphtho- 
and erboviruses this acts as a protease (Lpro), cleaving at its own C-terminus, to 
produce the first cleavage of the polyprotein (van Pesch et al., 2001; Hinton, 2002; 
van Eyll et al., 2002). 
The next stage in processing is the primary even that separates the 
encapsidation functions (P1; capsid proteins) from the replicative functions of the 
polyprotein (referred to as the P2-P3 region). 
 The 3C protease (3Cpro) accomplishes the final primary cleavage, between the 
2C and 3A regions and is also responsible for secondary proteolytic processing.  Both 
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the 3C and L-proteases are involved in the degradation of certain host-cell proteins, to 
enhance virus replication (for reviews see: Leong et al., 2002; Grubman et al., 1995; 
Ryan & Flint, 1997; Piccone et al., 1995; Robert & Belsham, 1995; Gradi et al., 
2004). Each of these proteins are described in the following sections and important 
intra-genera variations discussed. 
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Figure 4. Picornavirus genome and proteolytic processing. A) General representation of
picornavirus genome. Leader protein (L) is only present in aphthoviruses and cardioviruses and is a
protease in the former genus. B) Proteolytic processing in picornaviruses. Grey vertical arrow: 3Cpro
cleavages, also including those for which 3CDpro are required. Black curved arrow: 2Apro, a trypsin
family member found in rhinoviruses and enteroviruses. Red curved arrow: 2A co-translational
cleavage in aphthoviruses and cardioviruses. 1AB cleavage mechanism is unknown and it does not
occur in parechoviruses.   
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 1.3.3 Replication cycle 
 
 The replication cycle starts with attachment of the viral particle to specific cell 
receptors on the membrane, followed by uncoating of the capsid to release the RNA 
genome inside the cell. The entire replication process takes place in the cytoplasm, 
where the RNA is translated to yield viral proteins necessary for replication, 
polyprotein processing and encapsidation of new virus particles (figure 5). 
The single positive RNA strand replicates itself by producing a negative 
stranded RNA intermediate that is used as a template to create new single positive 
strands. This process occurs in small membranous vesicles that are stimulated by 
certain virus proteins. The synthesis rates of the positive RNA strand is ~100 fold 
greater than the negative strand since the daughter positive strands may fulfil one of 
three functions (i) as templates for the negative strand synthesis, (ii) they act as 
mRNAs to direct the synthesis of viral proteins or (iii) they are encapsidated into 
virions.  
 Once the pool of capsid proteins is sufficient for encapsidation, coat protein 
precursor P1 is cleaved and assembled into pentamers. These associate with newly 
synthesized positive-stranded RNAs to form fresh infectious particles that are released 
from the cell in a number of ways depending on the virus type. The majority of 
picornaviruses release their new particles by cell lysis, in others, such as Hepatitis A 
virus, release occurs in the absence of as cytophatic effect. 
 This process takes from 5 to 10 hours, depending on the virus species, 
temperature, pH, host cell, and multiplicity of infection.  
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Figure 5. Picornavirus replication cycle. The entire replication takes place in the cytoplasm. The viral 
capsid attaches to specific cell membrane receptors and releases the positive single stranded RNA 
(+ssRNA) genome into the cytoplasm. The genome is translated into a large polyprotein, which can 
process itself during and after translation leading to the production of non-structural and structural 
proteins, required for replication and capsid formation, respectively.  The replication machinery produces 
a negative-stranded RNA from the input positive-stranded template. This new strand will be used as a 
template to produce new positive-stranded RNAs that will be encapsidated once the pool of capsid 
proteins is large enough. Thus, new infectious viruses will be produced. 
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 1.3.4. Picornavirus polyprotein 
   1.3.5.1 L protein 
 In contrast to other picornaviruses, the first protein encoded in the genome of 
cardioviruses, aphthoviruses, erboviruses, kobuviruses, teschoviruses as well as two 
members of the proposed genera Sapelovirus (Human enterovirus-8 and simian virus 
2), is the Leader protein (L) (Zell et al., 2005).  In aphthoviruses, it is a protease (Lpro) 
(Strebel & Beck, 1986), which appears in two different forms (Lb and Lab) in FMDV 
(Clarke et al., 1985). Lpro cleaves at its own C-terminus releasing itself from the N-
terminus of VP4. Furthermore, it also cleaves the translation initiation factors eIF4GI 
and eIF4GII, together with 3Cpro, leading to inhibition of cap dependent translation in 
infected cells (Gradi et al., 2004; Belsham et al., 2000). Like aphthovirus, erbovirus L 
protease cleaves at the L/VP4 junction but does not have a role in eIF4G cleavage 
(Hinton et al., 2002).  
In cardioviruses, the L protein does not have proteolytic activity but plays 
other important roles during infection. The TMEV L protein interferes with 
trafficking of the cytoplasmic interferon regulatory factor 3 (IRF-3), a factor critical 
for transcriptional activation of alpha/beta interferon genes (Delhaye et al., 2004) and 
interacts with Ran-GTPase, disrupting nucleocytoplasmic transport (Porter et al., 
2006). L protein also plays an essential role in persistence by inhibiting the production 
of alpha/beta interferon (van Pesch et al., 2001). Moreover, Cardiovirus L protein also 
has a role in alteration of nucleocytoplasmic traffic, although this function is not 
essential for viral reproduction (Lidsky et al., 2006). 
  
   1.3.4.2 L* protein 
 L* protein is a unique feature of translation of the TO subgroup strains of 
TMEV (DA, BeAn). It encodes an 18 kDa protein, which is translated from an 
alternative open reading frame starting 13 nucleotides downstream from the AUG 
codon of the main protein (Kong & Roos, 1991; Yamasaki et al., 1999). In vivo 
studies of the L* protein have shown a direct effect in viral persistence of infections 
and also enhancement in infection of macrophage cell lines (reviewed by Brahic et 
al., 2005). This complementary AUG codon appears as an ACG in other strains, such 
as GDVII. L* can not only be translated from the second downstream AUG codon but 
it can also be initiated from this uncommon ACG codon in this non-persistent strain 
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(van Eyll & Michiels, 2000). Saffold virus (SAF-V) is a novel human cardiovirus, 
which has been recently discovered. In contrast to TMEV strain DA, which has 156 
amino acids, the L* open reading frame of SAF-V encodes only 57 amino acids. It is 
still unknown if this open reading frame encodes for a protein (Jones et al., 2007). 
   
   1.3.4.3 Capsid proteins 
 The structural proteins are encoded towards the 5’end of the open reading 
frame, which appears to fold into a structure closely related antigenically to the viral 
proteins VP0, VP1 and VP3 (Jackson et al., 2003). The structural capsid proteins, 
VP1, VP2, VP3, and VP4 (VP1, VP3 and VP0 in parechoviruses) form an assembled 
icosahedral structure (shown in figure 6).  
 
 
 
VP1 (1D)
VP2 (1B)
VP3 (1C)
 
 
 
Figure 6. Icosahedral symmetry of the capsid if picornaviruses. The 
structural capsid proteins, VP1, VP2 and VP3 are shown in different colours. 
VP4 is not shown because it is internal to the capsid. Figure by courtesy of 
Professor Martin Ryan. 
    
 
 
 16
   1.3.4.4 Protein 2A 
 The 2A protein is variable between genera, in contrast to the other non-
structural proteins, which have the same structure. Kobuviruses, HePV, DHV-1 (2A3) 
and hepatovirus 2A proteins are not involved in polyprotein processing (Jia et al., 
1993; Schultheiss et al., 1995; Yamashita et al., 1998). In other genera, 2A is 
involved in the separation of the P1 structural proteins from the P2 and P3 non-
structural proteins. In enteroviruses and rhinoviruses 2A is a protease (2Apro), while in 
cardio-, aphtho-, erbo- and tescho-, LV (2A1), DHV-1 (2A1) and SePV (2A1-2) it is an 
oligopeptide also responsible for the primary cleavage between structural and non-
structural proteins (Donnelly et al., 2001a). This ‘cleavage’ is not proteolysis but a 
translational effect -‘ribosome skipping’ (Ryan et al., 1991; Ryan & Drew, 1994; 
Ryan et al., 1999; Donnelly et al., 2001b; Ryan et al., 2002). This novel mechanism is 
explained in more detail in section 1.2.5. 2A in the aphtho-, erbo- and teschovirus is 
an oligopeptide of ~18 aa whereas in the cardioviruses 2A is a longer track (~150 aa). 
EMCV-2A protein activates the translation initiator factor 4E binding protein 1, 
which binds eIF4E, the cap binding subunit of the initiation factors complex. Thus, it 
suppresses cap-dependent translation (Gingras et al., 1996; Aminev et al., 2003 a, b; 
Svitkin et al., 2005). In entero- and polioviruses 2A protease also plays a role in 
translation repression by cleaving eIF4GI, both directly and indirectly, through the 
activation of cellular proteases (Zamora et al., 2002). In addition, 2A protease, 
together with 3C protease, cleaves the poly(A)-binding protein (PABP) during 
infection, and thus, inhibits host cell translation (Joachims et al., 1999; Kuyumcu-
Martinez et al., 2002). Poliovirus 2A protease also increases RNA stability (Jurgens et 
al., 2006). 
 New 2A sequences with the same conserved motif ‘DxExNPGP’ (where x= 
any amino acid) found in aphtho- and cardioviruses have also been found within the 
Picornaviridae. In addition, this motif has been identified in species outwith this 
family (section 1.3.6). 
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    1.3.4.5 Protein 2B 
 Enterovirus 2B protein is a viroporin, a transmembrane pore-forming protein, 
which participates in different viral functions (Gonzalez & Carrasco, 2003). This kind 
of protein alters membrane permeability through the formation of pores, and thus, 
induces disassembly of the Golgi complex (Sandoval & Carrasco, 1997). 
Coxsakievirus 2B protein inhibits vesicular protein transport by reducing the 
endoplasmic reticulum (ER) and Golgi´s Ca2+ content. This disturbance on 
intracellular Ca2+ homeostasis leads to two different events: the enhancement of viral 
RNA genome replication and the suppression of apoptotic host-cell responses 
(Kuppeveld et al., 2006; Doedens & Kirkegaard, 1995). Little is known about the 
function of the other picornavirus 2B proteins, although it is been recently shown that 
rhinovirus 2B is also localized in the ER and Golgi apparatus and functions similarly 
to enterovirus 2B. In contrast, HAV, FMDV and EMCV 2B protein is not localized in 
the ER and Golgi apparatus and does not cause relevant effects on Ca2+ homeostasis 
and intracellular protein trafficking (de Jong et al., 2008). 
   
    1.3.4.6 Protein 2C 
  Protein 2C is a highly conserved non-structural protein that binds to 
membranes and RNA, and is crucial in poliovirus replication (reviewed in 
Goodfellow et al., 2003). It also plays a role in encapsidation (Vance et al., 1997) and 
also has ATPase/GTPase activity (Rodríguez & Carrasco, 1993). 2C and its precursor 
2BC are responsible for poliovirus RNA binding to the cytoplasmic vesicles, whose 
formation is also induced by this precursor. Its mechanism of action has yet to be 
determined. FMDV 2C protein is localized in juxtanuclear structures, vesicles that 
could be derived from Golgi compartements. However, the origin of these vesicles is 
not clear yet; recent studies argue against the relation with the Golgi (Knox et al., 
2005; Moffat et al., 2005). For instance, in FMDV and EMCV infected cells treated 
with Brefeldin A (BFA), which inhibits membrane transport between the ER and the 
Golgi by preventing the formation of COPI-dependent secretory transport vesicles 
(Duden et al., 1994), 2C juxtanuclear localization and replication is not inhibited 
(Gazina et al., 2002). In contrast, replication is inhibited in PV and Rhinoviruses 
when infected cells are treated with BFA (Cuconati et al., 1998). 
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   1.3.4.7 Protein 3A 
  3A protein has a role in disrupting ER-to-Golgi protein trafficking, 
which inhibits the secretion of cytokines such as interleukins (IL-6, IL-8) and 
interferon-β (IFN-β) (Dodd et al., 2001). It has an anti-apoptotic effect; it provokes 
the release of intracellular calcium via permeabilization of cellular membranes (Liu et 
al., 2003). Poliovirus 3A exists as a dimer and is a critical component of the viral 
replication complex (Strauss et al., 2003). Additionally, it also inhibits TNF-induced 
apoptosis by elimination of TNF receptor from the cell surface due to the inhibition of 
protein trafficking (Neznanov et al., 2001). FMDV 3A plays an essential role in the 
determination of host-range. For instance, it has been shown that a single mutation 
within 3A mediated adaptation of FMDV to the guinea pig (Nuñez et al., 2001). 
Furthermore, mutations within poliovirus 3A also affected host-range (Lama et al., 
1998). 
 
   1.3.4.8 Protein 3B (VPg) 
 Protein 3B is covalently bound to the 5’end of viral RNA and functions as a 
primer for the initiation of viral genome replication. FMDV 3B encodes three 
different types of VPg, which are uridylylated by 3Dpol, making possible the initiation 
of the viral RNA replication (Nayak et al., 2005). The poliovirus VPg NMR structure 
has been solved and will hopefully improve our understanding of the mechanism of 
action of VPg, which is essential for virus replication, and also the interactions 
between this protein and the viral polymerase (Shein et al., 2006). 
 
   1.3.4.9 Protein 3C 
 Protein 3C is a chymotrypsin-like protease responsible for the primary 2C/3A 
cleavage of the polyprotein (Palmenberg et al., 1992; reviewed by Ryan & Flint, 
1997; Ryan et al., 2004). In the case of HePV, kobuvirues, DHV-1 (2A3) and 
hepatoviruses the primary 2A/2B polyprotein cleavage is mediated by the 3C protease 
(Stanway & Hyypiä, 1999). 3Cpro also induces the cleavage of the translation initiator 
factors eIF4A and eIF4GI-II (Belsham et al., 2000) and is involved in cell apoptosis 
in poliovirus and enterovirus (Barco et al., 2000). Poliovirus 3Cpro, combined with 
unknown host-cell activity, degrades p53 (Weidman et al., 2001). Furthermore, this 
protease cleaves poly(A)-binding protein (PABP) and removes the C-terminal domain 
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(CTD) that interacts with several translation factors. This mechanism of translation 
inhibition complements the effect of eIF4G cleavage by 2Apro (Kuyumcu-Martinez et 
al., 2004). In addition, 3Cpro contains RNA-binding domains (Blair et al., 1998). 
 
   1.3.4.10 Protein 3Dpol
 3Dpol is a RNA-dependent RNA polymerase (RdRp) that does not possess 
proof-reading activity. Its mechanism of action is still unknown. Studies have shown 
specificity of 3Dpol for each virus type and specificity also between 3Dpol and the 
other viral replicative proteins within the same virus species. A chimeric poliovirus, 
its 3Dpol replaced by coxsackievirus 3Dpol, showed a lack of replication due to the 
inefficient recognition of the P1 protein substrate by the chimeric 3CD protease 
(3CDpro) (Bell et al., 1999). Atomic structures of 3Dpol are available for poliovirus 
(Hansen et al., 1997) and FMDV (Ferrer-Orta et al., 2004), both showing the classical 
architecture: ‘fingers’, ‘palm’ and ‘thumb’ domains.
 
   1.3.4.11 Cleavage intermediates 
   There are three different intermediates, 2BC, 3AB and 3CDpro, which have 
different roles from their cleavage products. Accumulation of small ER- and Golgi-
derived membrane vesicles in the cytosol has been observed in enterovirus-infected 
cells, and is where viral replication takes place. 2BC is responsible for this 
accumulation (Bienz et al., 1994). 3AB is thought to be an integral membrane protein 
(Ciervo et al., 1998) and it also induces 3Dpol activity, most likely by recruiting 3Dpol 
to the 3’termini of chain elongation sites (Richards & Ehrenfeld, 1998). On the other 
hand, 3CDpro binds the 5’ RNA ‘cloverleaf’ structure, an essential step in replication 
(Blair et al., 1998). 
Poliovirus 3CD forms a ribonucleoprotein complex (RNP), together with a 
3kDa ribosome-associated cellular protein at the 5’ UTR region. This complex is 
essential for positive RNA synthesis but not for the negative strands (Andino et al., 
1993). 
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 1.3.5. Polyprotein processing  
 In picornaviruses the first step of infection, following cell entry, is translation 
of the RNA genome into a polyprotein (reviewed in Palmenberg, 1990). The viral 
RNA, which has a poly (A) sequence at its 3’ end, like cellular mRNAs, sequesters 
the cell’s own translational machinery for its protein synthesis. One important 
peculiarity of most viral mRNAs is their uncapped 5’ end. Picornaviruses have a ~22 
amino acid long protein, VPg, which is covalently attached to its 5´end that has an 
important role in initiation of RNA synthesis and may also have a role to play in the 
virulence of the virus (reviewed in Reuckert, 1996). This polyprotein precursor does 
not appear in infected cells because it undergoes co-translational cleavage while it is 
being translated. The different products appear in equimolar quantities due to their 
common origin from a single precursor (reviewed in Palmenberg, 1990). 3Cpro and 
3CDpro are responsible for the main polyprotein processing events cleaving all the 
structural and non-structural protein precursors, except i) Lpro, which cleaves itself at 
its C-terminus, ii) 1AB precursor, whose cleavage mechanism is still unknown, and 
iii) 2AB, except in hepato- and parechoviruses. 2Apro, is the other enzyme involved in 
polyprotein processing and is responsible for the 1D/2A cleavage in rhino- and 
enteroviruses. 2Apro separates the structural protein domain from the non-structural 
domain and it was first thought to be present in a wide range of picornaviruses. 
However, we now know that the majority of picornaviruses use another method (see 
section 1.5.1.4: ribosome skipping). This novel 2A protein, first discovered in FMDV 
(Ryan et al., 1991) expands the repertoire of translation strategies used by RNA 
viruses.        
RNA viruses have evolved a remarkable variety of ways to translate their 
RNA genomes into structural and nonstructural proteins. Production of subgenomic 
mRNAs, synthesis of polyprotein precursors from single mRNAs, ribosomal 
readthrough, and frameshifting are all ways to produce more than one protein product 
from a single RNA genome.  Picornaviruses translation strategy is the synthesis of 
polyprotein precursors that will be co-translationally or immediately post-
translationally cleaved. 
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1.4. Control of protein biogenesis within positive stranded RNA viruses 
 
   1.4.1. Ribosomal Frameshifting 
 The majority of RNA viruses are single-stranded. The majority of these are 
positive-sense, single-stranded RNA viruses, such as the family Picornaviridae, 
Coronaviridae, Caliciviridae and Flaviviridae. Their genome is transcribed into a 
polycistronic mRNA, which is translated into a polyprotein that is subsequently 
cleaved into individual mature proteins. 
 One of the replication strategies that positive-sense, single-stranded RNA 
viruses RNA viruses use is programmed ribosomal frameshifting, in which ribosomes 
change reading frame within the mRNA, leading to the synthesis of alternative 
proteins. There are two essential signals needed for this process to occur; (i) a 
‘slippery’ hepta-nucleotide sequence (eg. UUUAAAC), where the ribosome changes 
frame and (ii) an RNA pseudoknot structure situated downstream of the slippery 
sequence and consisting of two helical segments connected by single-stranded regions 
or loops. The current model proposes that the ribosome finds the pseudoknot while 
the slippery sequence is being translated causing the ribosome to pause on the 
slippery sequence, where it slips back one nucleotide and subsequently continues 
translation in the -1 reading frame (Somogyi et al., 1993). This recoding mechanism 
is found in several positive-stranded viruses such as infectious bronchitis virus (IBV), 
which is a member of the Coronaviridae (Brierley et al., 1987; reviewed by Spaan et 
al., 1988; reviewed by Brierley et al., 2007; figure 7). 
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Figure 7. Ribosomal frameshift representation in IBV.  A) Frameshifting allows translation to 
continue at the end of protein 1a, thus, producing protein 1a-1b. B) A ‘slippery’ sequence 
(UUUAAAC), where the ribosome changes frame and an RNA hepta-nucleotide sequence 
pseudoknot structure situated downstream of the slippery sequence are two essential signals 
needed for this frameshift process to occur.   
23
   1.4.3. Leaky scanning 
 The majority of eukaryotic mRNAs are monocistronic and initiate translation 
when the 40S ribosomal subunit and initiation factors bind to the 5’ end of the mRNA 
(m7G cap). This preinitiation complex moves in a 3´direction on the mRNA in a 
process called scanning, until it reaches (generally) the first AUG codon. Then 
initiation factors are released allowing the 60S subunit to associate with the small 
subunit. The efficiency of initiation is affected by the nucleotide sequence 
surrounding a certain codon. The consensus sequence accepted as the most efficient in 
eukaryotic cells is 5’GCC(A/G)CCAUGG 3’, where the presence of a purine at the 
position -3  followed by a G at position +4 is essential for high levels of translation. 
Nevertheless, only 5% of eukaryotic sequences contain this ideal consensus sequence, 
most of them have suboptimal ones (reviewed in Flint et al., 2000). Some viral 
mRNAs encode two or more proteins in overlapping reading frames, initiation of 
translation occurring not only at the first 5’ AUG but also at downstream AUGs. This 
occurs when ribosome preinitiation complexes bypass the 5´AUG due to the fact that 
this codon is surrounded by suboptimal nucleotide sequences. An example of this can 
be found in Sendai virus P/C gene mRNA, a member of the family Paramyxoviridae 
that contains a non-segmented negative sense single-stranded RNA genome, from 
which 6 mRNAs are transcribed. One of them, the P/C mRNA, is polycistronic and 
has two open reading frames that start near the 5´end (Girogi et al., 1983; figure 8). 
The P protein starts at the 5’ proximal ATG in the first open reading frame, the last 95 
amino acids being expressed as a different protein (X). The second open reading 
frame produces a nested set of non-structural C proteins (C’, C, Y1, and Y2).  
Translation of the first 3 initiation sites on P/C mRNA is arranged in such a manner 
that leaky scanning is enhanced. The first non-structural protein, C’, starts at an 
unusual non-ATG unusual codon, ACG, whereas the rest of proteins initiate on 
AUGs. Although ACG is in a good context, because it is an unusual start codon, this 
leads to an inefficient initiation, in which some ribosomes bypass ACG and initiate 
translation at the next initiator codon (AUG). This second initiator, which translates P 
protein, is an AUG but is in a poor initiation context (a pyrimidine at position -3), 
while the third AUG is in good context (an A at -3) and translates for C protein 
(Curran & Kolakofsky, 1989). 
 Another case of leaky scanning is observed in influenza B virus RNA segment 
6. Influenza viruses belong to the family of Orthomyxoviridae, which are negative-
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sense single-stranded RNA viruses. Influenza B virus RNA segment 6 is bicistronic 
and encodes NB and NA proteins in overlapping reading frames. NB translation starts 
at the 5’ proximal AUG codon, while the NA AUG codon is four nucleotides 
downstream. Even if the NA initiation codon is in a good context for translation 
initiation compared to the NB one, both proteins accumulate in almost equal amounts 
in infected cells. This suggests a unique model in which ribosomes randomly choose 
which AUG to use. Certain cellular factors and surrounding mRNA sequences might 
have an effect on the selection of these codons (Williams & Lamb, 1988).  
 
 
  
5’ 3’
P/ 104
C’/ 81
C/ 114
Y 1/ 183
Y 2/ 201
X/ 1523
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Figure 8. Schematic representation of the P/C mRNA of Sendai virus. The mRNA is shown in 
orange. The different ORFs are shown in boxes. The initiation site of C’ is a non-ATG codon (ACG), 
whereas C, Y1 and Y2 start on ATGs. Numbers refer to the position of the first base of the initiation 
codons. The position of the termination codons is also indicated. 
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   1.4.4. Reinitiation 
 Reinitiation is a very common strategy among prokaryotic cellular and viral 
RNAs. It is another mechanism by which two proteins are produced from a single 
mRNA. An example for this strategy is influenza virus RNA segment 7, which 
encodes two proteins, M1 and BM2, from a bicistronic mRNA. The ATG initiation 
codon for BM2 protein overlaps the termination codon for the M1 protein. Therefore, 
BM2 protein synthesis is dependent upon the initiation and termination of the 
upstream protein M1 (figure 9). A coupled translational termination-initiation 
mechanism is essential for the downstream protein to be produced (Horvath et al., 
1990). 
 In caliciviruses, which are non-segmented positive single-stranded RNA 
viruses, translation initiation of the 3’terminal open reading frame is also achieved via 
a termination-reinitiation process. Its genome contains two open reading frames for 
member of the genera Lagovirus and Sapovirus, and three open reading frames in 
Vesivirus and Norovirus (Green et al., 2000). The minor capsid protein VP2 is 
expressed via reinitiation of translation after termination of the upstream VP1 protein 
synthesis. A sequence of about 80 nucleotides, called termination upstream ribosomal 
binding site (TURBS), is essential for this termination-reinitiation mechanism to 
occur. TURBS has a specific conserved motif, which is complementary to 18S rRNA, 
and may be important to prevent release of post-termination ribosomes, hence, 
increasing the chance of reinitation (Meyers, 2007).   
 
 
5’ 3’
M1  ORF
-UAAUG-
BM2  ORF  
 
 
 
Figure 9. Influenza virus RNA segment 7. Bicistronic mRNA is represented in orange. 
The two ORFs are represented in boxes. The BM2 initiation codon (AUG) overlaps the M1 
termination codon (UAA).  
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   1.4.5. Suppression of termination 
 Suppression of termination can lead to the generation of a second protein with 
an extended carboxy-terminus. This occurs when one of the three termination codons 
UAG (amber), UGA (opal) and UAA (ochre) are suppressed as a result of leaky 
termination. 
 In murine leukaemia virus (MuLV), which is member of the family 
Retroviridae, the gag and pol coding regions are separated by an in-frame UAG 
termination codon. Read-through suppression of the UAG codon results in the 
production of a gag-pol fusion protein, which is cleaved later to produce the Pol 
proteins (protease, reverse transcriptase and integrase). This event happens because 
the tRNA is misreading the UAG termination codon for a Gln codon. A purine-rich 
sequence 3’ of the termination codon, as well as a pseudoknot structure further 
downstream enhances suppression of termination (Yoshinaka et al., 1985; Feng et al., 
1992) (shown in figure 10). 
 Another example of translational suppression is observed in Sindbis virus, 
which belongs to the genus alphaviruses from the Togaviridae family. This 
phenomenon is required for the synthesis of nsP4 protein, the viral RNA-dependent 
RNA polymerase. A single cytidine residue immediately 3’ to the termination codon 
is essential for translational read-through (Li & Rice, 1993). 
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Figure 10. Supression of termination in MuLV. Read-through suppression of the termination codon 
(UAG) produces the gag-pol fusion protein, which is, later, processed to produce the Pol proteins. 
This event happens because the tRNA is misreading the UAG termination codon for a Gln codon. 
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   1.4.6. Subgenomic mRNA 
Another gene expression strategy involves subgenomic mRNAs, which allows 
structural and replicative proteins to be synthesized separately and in different 
amounts. Togaviruses, which are the smallest enveloped animal viruses, use this 
translation strategy. Their genome is dicistronic, the gene closest to 5´end encodes the 
replication proteins and the one at the 3´end encodes the structural proteins. The 
replication proteins are produced in the early stage of infection, using the viral RNA 
as a template. Structural proteins are not synthesized until the later stages since its 
translation initiation codon is masked from the ribosome. A subgenomic mRNA, 
which is produced from an internal initiation site on the negative strand RNA, is used 
as a template for capsid protein production (reviewed in Schlesinger & Schlesinger 
1996).  These structural and non-structural products will be proteolytically processed 
once they have been translated (shown in figure 11). The replicative product is 
cleaved by a viral proteinase, which is located in the nsP2 region (Ding & 
Schlesinger, 1989 and Hardy & Strauss, 1989), whereas the capsid proteins are 
obtained in different ways depending on the genera. In rubivirus the polyprotein is 
cleaved by host cell proteinases while a mixture of viral and host cell enzymes 
process the alphavirus subgenomic mRNA (ten Dam et al., 1999). 
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Figure 11. Togavirus subgenomic mRNA. mRNA is represented in orange, and the protein in 
blue. Structural proteins are encoded by a subgenomic mRNA copied from the negative strand 
RNA. 
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  1.4.7. Nested subgenomic mRNAs 
The order Nidovirales includes the Coronaviridae (torovirus and coronavirus) 
Roniviridae and Arteriviridae. They have single-stranded, polycistronic RNA 
genomes of positive polarity. The non-structural proteins are encoded at the 5’end, 
and structural proteins at the 3’end. After uncoating inside the host cell cytoplasm, the 
genome is translated into two replicase open reading frames (ORF1a and ORF1b) by 
the host ribosome, ORF1b is produced by ribosomal frameshifting. The large 
polyprotein precursor is autoproteolytically cleaved to produce a membrane-bound 
replicase/transcriptase complex that mediates the synthesis of the genome RNA and a 
nested set of subgenomic RNAs. Structural proteins are synthesized from these 
3´coterminal set of subgenomic RNAs, which are composed of a leader and a body 
(illustrated in figure 12). The leader and body are transcribed from sequences in the 3’ 
end and 5’-terminal one third of the genomic negative-strand, respectively, by 
discontinuous RNA synthesis.  These two segments are connected by a conserved 
junction site sequence, which is found both at the 3’ end of the common leader 
sequence and at the 5’ end of the mRNA body (Snijder & Meulenberg, 1998). During 
synthesis of the negative-stranded RNA, the nascent RNA strand is transferred from 
one site in the genomic template to another to yield subgenomic RNA molecules. This 
process is guided by conserved transcription-regulating sequences (TRSs) found at the 
genomic positive-stranded RNA (Pasternak et al., 2004). 
The number of subgenomic RNAs produced varies between families, being 4 
in Torovirus, 7 in Arteriviridae and 9 in Coronavirus (Gorbalenya et al., 2006; Snijder 
& Meulenberg, 1998). 
 31
 Proteolytic processing
Translation
Protein 1a
Protein 1a-1b
Replicase/transcriptase 
complex
Translation
ORF 1a 
ORF 1b
5’ 3’
Ribosomal frameshift site
2
3
4
5
6
7
Discontinuous
Subgenomic mRNAs 
synthesis
7  5’ 3’
3
4
6
5
25’
5’
5’
5’
5’ 3’
3’
3’
3’
3’
Translation
Structural proteins
Genome 
replication
Subgenomic mRNA 
transcription
 
 
 
Figure 12. Schematic diagram of the genome organization and expression of equine arteritis 
virus, the artevirus prototype. The mRNA is represented in orange, the proteins in blue and the 
leader sequence in green. The nested set of subgenomic mRNAs are produced by a discontinuous 
transcription mechanism, where the body translocates to the 5’ end of the genomic RNA to complete 
synthesis of the leader sequence. 
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1.5 2A oligopeptide    
 
 1.5.1 Aphthovirus 2A 
   1.5.1.1 Characteristics  
 2A is a short peptide located between the capsid protein domain and the 
downstream replicative domain. It is a proteolytic enzyme in some viruses, such as 
enteroviruses and rhinoviruses whereas in cardioviruses, aphthoviruses, erboviruses, 
DHV-1 (2A1), LV (2A1), SePV (2A1-2) and teschoviruses, it appears to be an 
oligopeptide with a self-cleaving activity (reviewed by Glaser et al., 2003). 
 FMDV-2A is an oligopeptide of only 18 amino-acids in length, whereas in 
Cardioviruses it is ~150 aa in length. This protein is responsible for the separation of the 
structural protein domain from the non-structural domain during primary polyprotein 
processing. The ‘cleavage’ of the 2A protein occurs at its C-terminus, during translation. 
Thus, 2A remains attached to the upstream capsid protein precursor (P1) after processing. 
Subsequent secondary polyprotein processing, mediated by 3Cpro and 3CDpro, separates 
2A from P1, “delineating” 2A as just 18 amino acids.  
Both FMDV 2A and TMEV 2A have a completely conserved C-terminal 
sequence that consists of an Asparagine, Proline and Glycine (-NPG-) (shown in figure 
13). Furthermore, the first amino acid of the next protein (2B), a proline, is essential for 
the cleavage. Without this highly conserved amino acid cleavage does not occur and 
translation of the uncleaved polyprotein precursor continues (Hahn & Palmenberg, 1996; 
Hahn & Palmenberg, 2001; Donnelly et al., 1997).   
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 -QLLNFDLLKLAGDVES NPG P- FMDV 
Aphthovirus 2A region3C
2A
L
P1 P2 P3
2A Cardiovirus 2A region
-KAVRGYHADYYRQRLIH TMEV (BeAn) 
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Figure 13. Illustration of aphthovirus and cardiovirus 2A protein. 2A is responsible for the 
separation between the capsid protein (P1) and the replicative proteins (P2-P3). 3C is also 
represented, as responsible for the primary cleavage between P2 and P3. L is a protease in 
aphthovirus but not in cardioviruses. 2A protein sequence is shown; the most conserved part in 
red. 
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1.5.1.2 Studies on FMDV 2A   
The mechanism by which 2A is separated from 2B protein is now becoming 
understood and remains the focus of a number of studies. Several models of 2A 
cleavage have been proposed in the past 20 years. It was first suggested that 2A 
sequence may be recognized by host cell proteinases. However, these proteinases 
would have to be conserved among different cell types and also be present in in vitro 
systems. Other explanations suggest that 2A protein possesses a novel type of 
proteolytic activity or is able to disrupt normal peptide bond formation. Some of them 
are explained below.  
  Initial suggestions focused on the possibility that FMDV-2A had proteolytic 
activity like the other picornavirus proteins involved in polyprotein processing (Ryan et 
al., 1989). Deletions in the N-terminus coding regions around 2A showed that the active 
site was only 19 amino acids long and contained the first amino acid of protein 2B, a 
proline (Ryan et al., 1991). A plasmid with the 18 amino acid 2A sequence together with 
the N-terminal proline of 2B, inserted between chloramphenicol acetyltransferase (CAT) 
and β-glucuronidase (GUS) in a single long open reading frame [CAT-2A-GUS], 
demonstrated that 2A cleavage was still active in a completely foreign context (shown in 
figure 14). This experiment clearly eliminated the involvement of additional sequence 
elements elsewhere in the FMDV polyprotein, such as Lpro and 3Cpro. Uncleaved protein 
was observed in vitro, using rabbit reticulocyte lysate systems but not in vivo. Further, 
deletions at the N-terminus of FMDV 2A showed that cleavage required only 13 amino 
acids, thus, the N-terminal region is not essential for cleavage activity (Ryan et al., 1994). 
However, it has an influence on efficiency of cleavage and it also comprises the cleavage 
site required by 3Cpro and 3CDpro to cleave 2A away from P1 (Ryan et al., 1989).  
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Figure 14. Artificial reporter polyprotein [CAT-2A-GUS].  FMDV-2A sequence was 
inserted between CAT and GUS, in a single long ORF. The translation profiles showed three 
products, the uncleaved protein [CAT-2A-GUS] and the two processed products [CAT-2A] 
and [GUS]. CAT-GUS polyprotein was used as a control. 
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 Further experiments using a [CAT-2A-GUS] artificial polyprotein and in vitro 
translation systems were performed. As a result of translation in vitro, it was observed 
that not only the uncleaved product [CAT-2A-GUS] appeared, but also GUS and 
[CAT-2A] cleavage products were produced. It was also shown that the products are 
separated co- and not post-translationally since prolonged incubation of the 
“uncleaved” translation products did not result in increased cleavage. Additionally, in 
these experiments it was observed that an imbalance in the translation products 
occurred.  Analysis of the translation profiles obtained from [CAT-2A-GUS] 
constructs showed higher accumulations of [CAT-2A] compared to GUS (Donnelly et 
al., 1997). These results provided the first indication that the mechanism of 2A-
mediated ‘cleavage’ was not proteolytic. If this was the case, equimolar quantities of 
the cleavage products would be obtained. 
Although degradation rates of neither protein were significant, studies of these 
translation products showed a slower degradation of GUS with respect to [CAT-2A].  
It was concluded from this work that more [CAT-2A] than [GUS] was being 
translated. This was further verification than 2A cleavage was not caused by a 
proteolytic event but more likely by a translational phenomenon (Donnelly et al., 
2001b).  
 Another artificial reporter polyprotein system comprising green fluorescent 
protein (GFP) linked via FMDV-2A to β-glucuronidase (GUS), [GFP-2A-GUS] was 
analysed. The results of translation reaffirmed earlier findings and showed a molar 
excess of the upstream product [GFP2A] over [GUS]. When GUS was the N-terminal 
protein, [GUS-2A-GFP], then it too was the one in molar excess. This demonstrated 
that the N-terminal product was always in excess. This imbalance was observed in in 
vitro systems but not in vivo. A possible explanation for this is the suboptimal 
functioning of 2A because, in these experiments, the whole native protein was not 
being used but only a fragment. Increasing the length of FMDV 2A sequences, by 
adding parts of the 1D region to the N-terminus of 2A reduces the amount of 
unprocessed material detected in in vitro systems. Therefore, three possible outcomes 
were observed during translation of [GFP-2A-GUS]: (i) the cessation of the process at 
the C-terminus of [GFP-2A] consequently with the dissociation of the ribosome, (ii) 
the continuation of translation after cleavage with the synthesis of the downstream 
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GUS product and (iii) the translation of the uncleaved full-length protein [GFP-2A-
GUS] (Ryan & Drew, 1994).  
    1.5.1.4 Translational Model and Mechanism of 2A Action 
The translational model for 2A activity suggested that 2A protein may have 
esterase activity rather than of a proteinase (Ryan et al., 1999). In this model 2A 
mediates an attack on the ester linkage between the nascent peptide and the tRNA 
moiety preventing peptide bond formation between the Glycine residue of 2A and the 
N-terminal proline of 2B. 
 During elongation, translocation of the peptidyl-tRNA from the acceptor site 
(A) into the peptidyl site (P) site occurs, mediated by eukaryotic translation 
elongation factor 2 (eEF2). This allows the ingress of prolyl-tRNA into the A site. 
The next step would be formation of the peptide bond between the glycine and proline 
but nucleophilic attack by the prolyl-tRNA amide nitrogen upon the peptidyl-tRNAgly 
carbonyl carbon is inhibited by 2A. Thus, prolyl-tRNA is unable to attack the 
peptidyl(2A)-tRNAgly ester linkage, and the nascent peptide is released by the 
hydrolysis of the glycyl-tRNA ester bond. The ribosome re-initiates translation of the 
downstream protein, not with the normal initiator amino acid methionine but with 
proline.  
This model is represented in figure 15 (from Donnelly et al., 2001b). 
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Figure 15. Proposed model of the mechanism 2A’s action. The nascent 2A peptidyl-tRNA present in 
the A site (i), is translocated to the P site (ii), leaving the A site free for the ingress of the prolyl-tRNA 
(iii). The nascent 2A peptide interacts with the ribosome exit tunnel and re-orients the tight-turn at the 
base of the peptide. This re-orientation of the peptide inside the exit tunnel inhibits the peptide 
formation between glycyl-tRNA and prolyl-tRNA, leading to the release of the nascent peptide by 
hydrolysis of the glycyl-tRNA ester bond (iv-v).  The ribosome re-initiates translation of the 
downstream protein with a proline. 
          Recent studies have shown translation (‘release’ or ‘termination’) factors that 
are the key for 2A-mediated ‘cleavage’ (Doronina et al., 2008).  
Firstly, another line of evidence proved what was already suspected: the 2A 
reaction occurs in the ribosomal peptidyl transferase centre (PTC) of the ribosome. 
PTC is formed at the interface between the ribosomal small and large subunits, at the 
entrance of the ribosome exit tunnel and comprises the activity responsible for peptide 
bond formation. A series of mRNAs ending at positions spanning the region from 
glutamic acid at position 14 to the final proline 19 of a 2A were generated and used to 
program translation reactions assembled with wheat germ extract. Ribosomes stalled 
at the 3’ end of truncated transcripts, with nascent chains remaining covalently 
attached to ribosome-associated tRNA. Further, the ribosomal pausing that occurs 
during translation of 2A is consistent with the hypothesis that the 2A peptide interacts 
with the ribosomal exit tunnel. Toe-print signals showed that the ribosome pause 
when the glycine 18 codon (-DxExNPGP-) is at the P site and the proline final codon 
is at the A site of the ribosome. Replacement of the proline final codon resulted in 
loss of 2A activity.  
It was also shown that translation terminating release factors (RFs) play an 
essential role in this reaction.  Termination of protein synthesis requires two classes of 
RFs. Class-I release factors (RF1 and RF2 in prokaryotes, and eRF1 in eukaryotes) 
recognize the three different stop codons (UAG, UGA, UAA) and trigger hydrolysis 
of peptidyl-tRNA at the ribosomal peptidyl transferase center. Although the function 
of class-I RFs is similar in prokaryotes and eukaryotes, they exhibit different 
structural and functional features. eRF1, recognizes all three termination codons, 
whereas each prokaryotic factor recognizes two out of three stop codons (Scolnick et 
al., 1968). Class-II release factors (RF3 and eRF3 in prokaryotes and eukaryotes, 
respectively) are guanine-nucleotide-binding proteins possessing GTPase activity. 
eRF3’s activity depends entirely on the ribosome and the eRF1 (Frolova et al., 1996) 
and it binds to eRF1. eRF3 can recycle both class-1 RFs (mediated by RF3 in 
bacteria) and ribosomes (mediated by the ribosome recycling factor (RRF) in 
bacteria) (Kisselev et al., 2003; Mitkevich et al., 2006). It has also been observed that 
RF3 can abort protein synthesis by inducing premature dissociation of peptidyl-tRNA 
from the ribosome (`drop-off') (Heurgue-Hamard et al., 1998), but the mechanism for 
this side reaction remains unexplained. 
 40
Recent experiments where RF activity was altered revealed an influence in the 
outcome of the 2A reaction both in vitro and in vivo. Reduced eRF1 levels were 
accompanied by reduced synthesis of separated upstream and downstream products, 
consistent with RF catalysing the hydrolytic termination event. Impaired GTP 
hydrolysis on eEF3 led to increased production of upstream product and reduction in 
both extension and downstream products (Doronina et al. 2008). The way this factors 
release the protein without recognizing any stop codon is still unknown, but several 
hypotheses have been suggested.  
To date release factors are only known to function at stop codons, and the A 
site must be empty for them to gain entry into the ribosome. Prolyl-tRNAPro could be 
unstably bound to 2A paused ribosomes, possibly due to inability to form a peptide 
bond or, as a second possibility, the ribosomal conformation imposed by 2A could 
disfavour entry of the tRNA. Prolyl-tRNAPro and RF might compete on ribosomes 
paused by 2A. However, over-expression of tRNAPro did not reverse the toxic effects 
of over-expressing 2A in RF-limited cells. Thus the peptidyl(2A)-ribosome 
interaction and the conformation of the complex disfavours further extension unless 
RF acts to release the nascent chain or the 2A-ribosome interaction is lost. 2A may 
also influence and by-pass the necessity for stop codon decoding by RF through 
directing the ribosome into a conformation similar to that which it takes once RF has 
bound productively to the A site.  
It is interesting to contrast eRF’s action with the well-studied tmRNA system 
in prokaryotes. tmRNA is a specialized RNA involved in trans-translation, a 
ubiquitous pathway for removing stalled translational complexes from bacterial cells. 
Alanine-charged tmRNA, in association with the SmpB protein, recognizes stalled 
ribosomes, binds like a tRNA to the A-site and donates its alanine to the nascent 
polypeptide chain in a standard transpeptidation reaction. TmRNA then acts as a 
surrogate mRNA, replacing the defective mRNA with the self-encoded peptide 
reading frame, to direct translation (trans-translation) of the degradation tag. 
Translation terminates normally at a stop codon provided by the mRNA-like domain 
of tmRNA. The final translation product of this process carries an 11-residue 
degradation tag at its C-terminus and thus becomes a substrate for C-terminal specific 
cellular proteases (Keiler et al., 1996; Yakamoto et al., 2003). This translation quality 
control system is only present in prokaryotic organisms, leaving a gap in the 
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knowledge of the control of eukaryotic stalled ribosomes, making possible the 
involvement of RFs in this case.  
 All these new findings need to be more extensively studied to find out how 
the process occurs, however, it is clear that interaction between the ribosome and 2A 
must exist, as seen in other systems (see section 1.5.1.5), and the presence of RFs add 
a new piece to the yet to complete puzzle of  the 2A mechanism of action. 
  
    1.5.1.5 Ribosome-Nascent peptide interactions 
Inside the ribosome there is an exit channel, which is made of RNA and where 
the nascent peptides are located. During synthesis this original protein, once it reaches 
a certain length, enters the tunnel. 
It has been shown that this tube is not totally neutral for nascent peptides. 
There can be some interactions between them that modify the ribosomes action, for 
example the bacteriophage T4 gene 60 (Farabaugh, 1996; Gesteland & Atkins, 1996) 
and, also, chloramphenicol (Cm)-resistance genes cat and cmlA (Rogers & Lovett, 
1994; Harrod & Lovett, 1994; 1995). T4 gene 60 interacts with the ribosome, leading 
to a ribosomal “hop” from codon 47 to codon 50 downstream (Weiss et al., 1990; 
Herr et al., 2000). It is also called “translational bypassing” or “subversion of 
contiguity” because the determinate gene sequence can control the translation in this 
way. As has been demonstrated it is essential for the peptide to be a certain length (16 
amino acids in T4). Thus the peptide reaches the interior of the tunnel and can interact 
with the ribosome producing the translational bypass (Gesteland & Atkins; 1996). 
Another striking example of this nascent peptide-ribosome exit tunnel interaction is 
the one reported by Nakatogawa and Ito (2002). SecA is a protein involved in peptide 
export, whose expression is regulated by another protein called SecM, which is 
encoded in an ORF upstream of SecA ORF. SecM contains an export signal at its N-
terminus and an effector motif at its C-terminus, which can block protein elongation 
stalling the ribosome complex. This occurs only when translocation of SecM through 
the membrane is impaired by low SecA activity. Thus, the translation initiation region 
for SecA, which  is normally ‘hidden’ by a strong RNA secondary structure 
preventing initiation of SecA synthesis, is accessible by rearranging of this mRNA 
secondary structure once the ribosome is stalled. This mechanism creates an efficient 
intracellular feedback loop for adjusting the supply of SecA proteins to the 
intracellular demand for protein export. The way this interaction (and others) works is 
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still unclear but experiments, where mutations where produced in different parts of 
the ribosome exit tunnel, revealed the interaction to be in the segment of ribosomal 
protein L22, which is located at the entrance of the exit tunnel (illustrated in figure 
16). 
 secM             secA
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Figure 16. Representation of the translational control of Sec A by Sec M. Above, illustration of 
a ribosome with the Sec M nascent protein within the exit tunnel. Below, representation of the Sec 
M sequence being translated and translocated through the membrane by the Sec A protein. When 
there is low Sec A, Sec M is able to stall the ribosome, leading to the exposure of the initiation 
region of SecA, which is normally ‘hidden’ by a strong mRNA secondary structure. In red, shine 
delgarno sequences (SD). In yellow, effector motif located at the C-terminus of Sec M. 
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 The peptidyl transferase is responsible for catalysis of the transpeptidation 
reaction in the elongation cycle of translation. In prokaryotes the exit tunnel measures 
~80-100Å in length and has a bend some 20-35Å from the peptidyl transferase centre. 2A 
interacts with the exit channel of eukaryotic ribosomes and this interaction leads to 
the inhibition of the peptide bond formation between the last amino acid of 2A and 
the first amino acid of 2B.  
The C-terminal –NPG- residues of 2A could play a role in the reorientation of 
the peptidyl (2A)-tRNAgly substrate to inhibit peptide bond formation and then, 
stimulate hydrolysis when the A site is occupied by prolyl-tRNA (Donnelly et al., 
2001). The length of the suggested helical part of the 2A sequence is 27Å, which 
could fit inside the exit tunnel of the ribosome. 
 This translational model presents a plausible explanation for 2A cleavage 
activity. First of all a structural model of 2A has been developed that consists of an N-
terminal helical portion followed by a tight turn fragment at its own C-terminus 
(represented in figure 17). 
 The upstream sequence stabilises and extends the helix and increases 
interaction with the ribosome exit pore. This α-helix, which interacts with the 
ribosome exit pore, fixes stereochemistry of tight-turn in peptidyl transferase centre 
and could have a dipole moment. Inside this fragment there is a glutamate possibly 
involved in interaction with tRNA and inhibition of peptidyl transferase. 
 
 
 
PFFF--- ---Q LLNFDLLKLAGDVES  NPG 
Tight Turn:
• re-orientation of ester bond  
 
 
Figure 17: FMDV 2A structural model.  2A sequence is formed by an N-
terminal helical portion followed by a tight turn fragment at its own C-terminus. 
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The highly conserved sequence NPG is proposed to form a tight-turn that 
reorients the ester bond. Once the peptide bond between proline and glycine (2A 
fragment NPG) is synthesized, translocation occurs and the 2A peptidyl-tRNA, which 
was in the A site, is located into the P site. Then, the helical part of 2A interacts with 
the exit pore and this promotes a specific orientation of the base of the helix within 
the peptidyl-tranferase centre of the ribosome. Thus, the NPG portion with its tight 
turn structure reorients the peptide tRNA ester linkage promoting an unusual 
conformation, different to the usual one that leads to peptide bond formation.  
In the model proposed earlier the peptidyl-tRNA ester group would be 
attacked and thus cut because of the coordination of a water molecule and magnesium 
ions (Mg2+), which are necessary for the peptidyl-transferase activity. Magnesium 
ions attach at the base of the 2A helix axis and promote the cleavage in conjunction 
with a water molecule (Ryan et al., 2004). Thus, when the prolyl-tRNA enters the A 
site the formation of the peptide bond is not possible because the usual nucleophilic 
attack performed by prolyl-tRNA upon the electrophilic centre is hampered. The 2A-
peptidyl-tRNAgly ester bond is, then, hydrolysed and the nascent polypeptide released 
(reviewed by Ryan et al., 2002). 
Prolyl-tRNA is the poorest nucleophile among all the aminoacyls-tRNAs since 
its secondary amino group is sterically constrained due to its specific structure in a 
five membered pyrrolidine ring. 
The suggested model represents yet another trick used by viruses to modify 
the host cell’s translation apparatus to their own ends. However, as other 
modifications such as suppression of termination or leaky scanning, this one has not 
only been observed in picornaviruses but in other viruses and cellular sequences (see 
section 1.6). 
 
1.5.1.6 Length of 2A oligopeptide 
Although FMDV 2A region was first described as an oligopeptide of only 16 
amino acids in length (Roberston et al., 1985) its activity was mapped at 19 amino 
acids (Ryan et al., 1991). Further experiments have shown an increase in cleavage 
efficiency when 2A length is up to 25 amino acids (adding the upstream 1D 
sequence). 2A activity maps, therefore, not only to the 18 amino acids but 25-30 
amino acids.  The seven C-terminal amino acids of 2A plus the N-terminal proline of 
2A, form the highly conserved motif, the upstream sequence being variable. However, 
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even if the C-terminal region of 1D is quite variable, it also presents some conserved 
residues. 2A is cleaved from 1D by 3Cpro, or more efficiently 3CDpro (Ryan et al., 
1989). This provides an additional constraint on the 2A region. 
 
1.6. 2A-like sequences 
 Although originally identified in foot-and-mouth disease virus, new active 2A 
sequences have been found in other picornaviruses, plus quite different RNA viruses. 
The identification of these functional 2A-like sequences has led to speculation about 
the possible roles of the 2A in regulation of translation in the different organisms in 
which the sequence has been found. It also demonstrates that this type of protein 
biogenesis is not only confined to the picornaviruses but is a more widely adopted 
strategy. 
    
 1.6.1 Insect 2A-like sequences 
2A-like sequences were identified in single-stranded RNA insect viruses; 
Dicistroviridae and Tetraviridae, and also the double-stranded RNA (dsRNA) 
viruses: Reoviridae. These families are represented in table 2. 
 The activity of representatives of these 2A-like sequences was tested in 
artificial polyproteins encoding a single open reading frame (ORF) comprising [GFP-
2A-GUS]. In vitro transcription-translation reactions were performed to check the 
efficiency of the cleavage within different species. Some 2A sequences not 
completely matching the -DxExNPGP- motif were also tested. In contrast to previous 
experiments (Donnelly et al., 2001a), longer versions of 2A (30aa) were tested to 
more closely represent the situation in vivo (Luke et al., 2008). 
 Single-stranded RNA insect viruses contain the Dicistroviridae (cripaviruses), 
the unassigned iflaviruses and tetraviruses. Three species belonging to iflavirus 
(infectious flacherie virus (IFV), Perina nuda picorna-like virus (PnPV) and ectropis 
obliqua picorna-like virus (EoPv)) were tested and showed ~99% cleavage activity, in 
contrast with the previously tested shorter versions with only ~63% active cleavage 
(Donnelly et al., 2001a). Interestingly, PnPV and EoPV have a second 2A between 
the structural VP2 and VP4 proteins (shown in figure 18) that is also highly efficient. 
In Cripaviruses, whose 2A is in the N-terminal region of the replicative proteins open 
reading frame (figure 18), 2A is highly efficient in agreement with earlier reports in 
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drosophila C virus (DCV) and acute bee paralysis virus (ABPV), except in cricket 
paralysis virus (CrPV), where cleavage was not very efficient and is hardly improved 
in the longer 2A.  
 The Tetraviridae has 2 genera, betatetravirus (euprosterna elaeasa virus 
(EeV) and providence virus (PrV), which contains three 2As (figure 18) and 
omegatetravirus (thosea asigna virus (TaV)). The tested members of this family also 
showed high cleavage activity. PrV 2A3, which is situated at the N-terminus of the 
structural open reading frame, and 2A1, within a non-structural open reading frame, 
cleave very efficiently; whereas 2A2 showed lower activity. 
 The Reoviridae is a family of segmented dsRNA viruses, which contains 13 
genera that affect a wide host range from humans to bacteria. 2A has been found in 
two genera within this family, rotavirus, which are mammalian 2A-like sequences 
(see section 1.6.2) and cypovirus (Bombyx mori cypovirus 1 (BmCPV-1) and 
Operophtera brumata cypovirus 18 (OpbuCPV-18). These 2A-like sequences are 
located on the segments encoding non-structural proteins and are highly active (Luke 
et al., 2008). 
Phylogenies were constructed from polymerase domains and 2A-like 
sequences. Examination of the distribution of those viruses possessing 2A within the 
phylogeny lead the authors to conclude that 2As in different viruses can either be 
homologous (common ancestral origin), or, homoplasic (arising from multiple, 
independent, evolutionary origins). The latter is not surprising due to their short 
length and the location of these sequences in known recombinational hot-spots (Luke 
et al., 2008). 
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Unassigned
Ectropis obliqua picorna-like virus (EoPV)
Infectious flacherie virus (IFV )
Perina nuda picorna-like virus (PnPV) 
Varroa destructor virus-1 (VDV-1) 
Bombyx mori cypovirus type1 (BmCPV-1) 
Operophtera brumata cypovirus-18 (OpbuCPV-18) 
Reoviridae
Cricket paralysis virus (CrPv) 
Drosophila C virus (DCV)
Acute bee paralysis virus (ABPV)
Kashmir bee virus (KBV)
Israel acute paralysis virus of bees (IAPV) 
Dicistroviridae
Providence virus (PrV) 
Euprosterna elaeasa virus (EeV)
Thosea asigna virus (TaV)
Tetraviridae
Insect  viruses with 2A-like sequences
Genus SpeciesFamily
Iflavirus
Cripavirus
Betatetravirus
Omegatetravirus
Cypovirus
 
 
 
Table 2. Classification of insect viruses containing 2A-like sequences. 
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Figure 18. Genome organization of insect viruses containing 2A-like sequences. 
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1.6.2. Other 2A-like sequences 
 2A-like sequences are also present in the genome of four species of the 
eukaryotic unicellular parasite Trypanosoma, T.cruzi, T.brucei, T.congolense and 
T.vivax. These 2A-like sequences are located at the N-terminus of the non-LTR retro-
element, being L1Tc in T.cruzi and ingi in T.brucei. 20% of L1Tc-2A sequences 
contain a histidine residue instead of asparagine at position 17 (N17?H; HPGP) that 
is highly active in common with the normal motif in vivo (Heras et al., 2006). 
 A 2A-like sequence was also identified in the eubacterial α-glucuronidase 
augA gene of Thermatoga maritima, a hyperthermophilic bacterium, but does not 
show any activity (Donnelly et al., 2001a). No active 2A-like sequences have been 
identified in prokaryotic organisms (Donnelly et al., 1997). It should be noted that the 
exit tunnels of prokaryotic and eukaryotic ribosomes bear substantial differences (see 
discussion section 4.1). This could explain why there are no active 2As in bacteria and 
supports the hypothesis that 2A needs to interact with eukaryotic ribosomes to be 
active.  
 Rotaviruses, which belong to the family Reoviridae, consist of bovine 
rotavirus C (BoRV) porcine rotavirus C (PoRV), human rotavirus C (HuRV) and the 
new adult diarrhoea virus (ADRV-N), which has recently been added to the family 
and is closer to group B than group A or C rotaviruses (Yang et al., 2004). The 
genome of rotaviruses is composed of 11 segments of dsRNA that encode six 
structural and five non-structural proteins (James et al., 1999). The type C rotavirus 
gene 6 encodes the non-structural protein 3 (NSP3; NS34), which is an ssRNA-
binding protein equivalent to the group A rotaviruses (Qian et al., 1991). 2A-like 
sequences are present on the segment 6 in bovine, porcine and human rotavirus C, 
whereas in ADRV-N is encoded in segment 5 with the non-structural protein 1 
(NSP1). In type C rotaviruses, 2A links the NSP3 with the dsRNA-binding protein, 
which sequesters viral dsRNA from the cellular sensors of dsRNA, neutralizing the 
activation of the cellular antiviral interferon system (Lagland et al., 1994). NSP3 also 
binds the non-polyadenylated 3’ end of the rotavirus mRNAs, enhancing its 
translation and subverting the host translation machinery (Piron et al., 1999; Jayaram 
et al., 2004). In vivo and in vitro translation analysis on [NSP3-2A-dsRBP] showed 
three products, a small amount of the uncleaved protein [NSP3-2A-dsRBP] and the 
two processed products [NSP3-2A] and [dsRBP] in equimolar amounts (Lagland et 
al., 1994). It is remarkable that NSP3 forms dimers, which may add a further 
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complexity since NSP3 could form heterodimers with [NSP3-2A-dsRBP]. Analyses 
of 2A- mediated cleavages showed that the 2A-like sequence in segment 5 ADRV-N 
was highly active, whereas in segment 6 of PoRV and HuRV it was lower. This lower 
cleavage efficiency is involved in translational control of products and allows the 
production of a complex array of products at high levels (Luke et al., 2008). 
 Penaeid shrimp infectious myonecrosis virus (IMNV) was recently isolated 
from farmed Penaeus vannamei in north-eastern Brazil and classified as a member of 
Totiviridae, which is a family of non-segmented dsRNA viruses. Their genome 
contains two overlapping ORFs, ORF1, which encodes a 179 kDa protein that 
includes the N-terminal sequence of the major capsid protein (MCP) and ORF2, 
which encodes a 85 kDa protein that contains a series of motifs characteristic of an 
RNA-dependent RNA polymerase (RdRp) (Poulos et al., 2006). New examinations of 
the IMNV genome revealed the presence of two 2A-like motifs located at the N-
terminal third of ORF1 preceding MCP and probably involved in co-translational 
processing of the IMNV polyprotein into consecutive 93, 284 and 1228 amino acids 
fragments. The fragment 1228 would be further cleaved co- or post-translationally by 
a different mechanism to yield a 327 fragment and the 901 amino acids MCP. The 
functions of the 93 and 284 and 327 amino acids fragments of ORF1 are still 
unknown although the 93 amino acids fragment encompasses the N-terminal region 
previously noted, by Poulos et al. (2006), to share sequence similarities with double-
stranded RNA-binding proteins (Nibert, 2007). IMNV 2A-like proteins have been 
tested and are highly active (Luke et al., 2008). 
 The recent determination of the genome sequence of a marine invertebrate, the 
purple sea urchin Strongylocentrotus purpuratus (Sea Urchin Genome Sequencing 
Consortium, 2006), revealed ~150 2A-like sequences present within a range of genes. 
These sequences are found in two types of cellular sequences. The first type are genes 
involved in innate immunity, such as, nucleotide-binding oligomerization 
domain/leucine-rich repeat family (NOD-LRR), NACHT domain/leucine-rich repeat 
(NACHT-LRR family) or ‘CATERPILLER’ (CARD, transcription enhancer, R 
(purine)-binding, pyrin, lots of LRRs) genes. The second group of genes are 
associated with non-LTR retrotransposons, although is still unclear if 2A is part of 
these elements or forms a genomic site favourable for their transposition. All of the 
2A sequences tested mediate ribosome ‘skipping’ except one that has a very short N-
terminal tract. This is consistent with previous analysis of truncated FMDV 2A forms 
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(Ryan et al., 1994). Although many of them still need to be tested, results obtained 
recently show 2A as an essential mechanism for the control of protein biogenesis, not 
only in viruses but also in cellular organisms. (Illustrated in figure 19).  
 
 
CATERPILLER Proteins
2A
DEATH NACHT Leu-RR
Non-LTR Retrotransposons
2A
PHD APE RT
2A
? APE RT
2A
? APE RT
~100 genes
~17 genes
~4 genes
~4 genes
Exemplar gene
XP_001180308
XP_797143
(Similar to amphioxus BfCR1)
GLEAN3_18025
(Similar to Medaka Reo_6)
GLEAN3_14631
(Similar to pufferfish Maui)
Number of genes
 
 
 
 
 
Figure 19. Schematic representation of the two major groups of genes (CATERPILLER proteins 
and Non-LTR retrotransposons), where 2A is found within the S. pupuratus genome. Protein 
domains are indicated in boxed areas. Grey areas indicate other part of the genome that do not correspond 
to these two group of genes (? = unidentified domains).  
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  1.6.3 Picornavirus 2A-like sequences 
 New 2A sequences within picornaviruses include: bovine rhinovirus 2 (BRV-
2), Theiler-like virus of rats (T-LV), human Saffold virus (SAF-V), porcine  
teschovirus (PTV),  Ljungan virus, Seneca valley virus (SVV) and duck hepatitis 
virus (DHV1). 
 The activity of these 2A-like sequences was tested in artificial polyproteins 
encoding a single open reading frame (ORF) comprising [GFP-2A-GUS]. In common 
with the insect virus experiment (see 1.6.1) longer versions of 2A (30 aa) were also 
tested. The longer 2A versions within the Picornaviridae showed highly efficient 
cleavage. Furthermore, a change in the conserved motif (Ser?Pro; -DVEPNPGP-) 
showed efficient cleavage (Luke et al., 2008). 
 By studying more functional 2A-like sequences and comparing them with 
FMDV 2A oligopeptide, we will be able to achieve a better understanding about this 
protein and its mechanism of action. 
     
    1.6.3.1 TMEV 2A 
 Like FMDV 2A, the TMEV 2A is a polypeptide responsible for the 
autocatalytic, co- translational primary cleavage of the polyprotein (Ryan et al., 
2002). It cleaves between LP12A and 2BCP3 and although it is approximately 144 
amino acids longer than FMDV 2A, both act in the same way. It also shares the highly 
conserved sequence at its C-terminus (-DxExNPGP-), which is responsible for the 
cleavage (Donnelly et al., 2001b). The upstream sequence of TMEV 2A diverges 
remarkably from that of EMCV and its function is not known (Donnelly et al., 1997). 
  
      1.6.3.1.1 Studies on TMEV 2A  
 A plasmid with the C-terminal part of Theiler´s murine encephalomyelitis virus 
(TMEV) 2A together with the N-terminal proline of 2B, inserted between 
chloramphenicol acetyltransferase (CAT) and β-glucuronidase (GUS) was constructed. 
This particular recombinant polyprotein was able to mediate cleavage with a very high 
efficiency (85%). As before, this means that no other viral protein domain is contributing 
to the cleavage event. In addition, it is not necessary to have all the upstream 2A 
sequence to make the cleavage possible. However, the efficiency can be significantly 
reduced when the length of the 2A sequence is decreased. Thus, this N-terminal 
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sequence influences cleavage but it is not essential. In some cases, the efficiency is 
hardly reduced (Donnelly et al., 1997). 
 
  
The variability of the 2A protein among picornaviruses is remarkable: this 
small region of the genome is highly plastic compared to the other non-structural 
proteins, which have homologous structures and functions. The 2A self-cleaving 
peptide, first discovered in FMDV, has also been found in the majority of 
picornavirus genera. Something that seemed to be very particular has turned out to be 
widely spread between different organisms, except bacteria. The mechanism of 2A 
action is becoming much clearer but there are still lots of questions to answer, such as; 
why is it not active in bacteria? How this interaction between the nascent peptide and 
the ribosome occurs and how the peptide bond formation is avoided without the 
presence of a stop codon? By studying all these new 2A sequences, which present the 
same C-terminal motif but variable upstream sequences, and comparing them, we 
should be able to increase our knowledge of how 2A functions. 
We now know that the presence of the –DxExNPGP- motif alone does not 
confer cleavage activity, for example, it is not active in Thermatoga maritima aguA 
gene. This conserved motif, found in all 2As, must be accompanied by an appropriate 
upstream context to be active. The combination of this conserved motif with a 
determinate upstream sequence may make the interaction between the sequence and 
the ribosomal exit tunnel suitable and, thus the process to occur. Recent work has 
proved the involvement of release factors in this reaction. Further mutational studies, 
will expand our understanding of this ‘ribosome skipping’ process and will fill some 
of the gaps in our knowledge of this unique mechanism of action. 
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    2. MATERIALS AND METHODS 
  
2.1 Cloning: 
 2.1.1 Polymerase Chain Reaction (PCR)  
 PCR was used to amplify segments of DNA, introduce mutations and insert 
2A-like sequences. Typically, reactions were catalysed by Taq DNA polymerase 
(Promega Ltd., Southampton, UK) containing 10 x buffer (330mM Tris-acetate, pH 
7.9, 660mM potassium acetate, 100mM magnesium acetate, 5mM DTT). This 
reaction was carried out in a final volume of 50µl using 80pmol of the forward and 
reverse primer, 5ng of template DNA and dNTPs at a final concentration of 250 µM. 
Each round of PCR synthesis involves three steps: denaturation (94ºC for 1 minute), 
annealing (56ºC for 30 seconds) and elongation (72ºC, 2 minutes per kb of template). 
This three-step ‘PCR-cycle’ was repeated 35 times. The termination is the final step, 
where elongation is carried on at 72ºC for 10 minutes.  
 All PCR products were purified using the Wizard PCR Prep purification 
system (Promega Ltd., Southampton, UK) as per the manufacturers instructions. 
    
 2.1.2 Preparative Restriction Enzyme Digests 
 Restriction enzymes (purchased from Promega and New England Biolabs) 
were used following the conditions specified by the suppliers. 
 Typically, 1µg of DNA was digested in 1 unit of enzyme, to a final volume of 
20 µl including 2 µl of 10 x restriction buffer. The reaction was incubated at the 
optimum temperature for the specific enzyme (normally 37ºC) for 2 hours. 
 
 2.1.3 Analytical Restriction Enzyme Digests 
 Typically, 0.4 µg of DNA were digested with 0.2 units of enzyme, in a total 
volume of 10 µl, including 1 µl of x10 restriction buffer.  The reactions were 
incubated at the optimum temperature indicated for the specific enzyme for 1 hour. 
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 2.1.4 Agarose-gel Preparation 
 0.8 % (w/v) agarose gels were prepared with 50 x TAE buffer (242 g Tris 
base, 57.1 ml glacial acetic acid, 100 ml 0.5 M EDTA, pH) with a final addition of  4 
µl of ethidium bromide (5mg/ml) to a final volume of 100 ml. The 50 x TAE running 
buffer was diluted to 1 x with distilled water when preparing the gel.  
  
 2.1.5 Gel Electrophoresis 
 DNA samples were prepared by adding 6 x agarose gel loading buffer (50% 
[v/v] glycerol, 0.005% [w/v] bromophenol blue) and loaded onto the gel. The 
electrophoresis was performed at 100 V in 1 x TAE buffer (40mM Tris-acetate, 1mM 
EDTA). DNA bands were subsequently visualized by illumination using a UV 
transilluminator. 
      
 2.1.6 Purification of DNA fragments from Agarose gel 
 The bands of interest were localized and the area in front of them excised and 
filled with low-melting-point agarose (LMP). The band was run into the LMP agarose 
and cleaned using the Wizard Prep DNA Purification system (Promega Ltd., 
Southampton, UK) as per the manufacturers’ instructions. 
 
 2.1.7 Ligations 
 Typically, ligation reactions were set up in a final volume of 10 µl using DNA 
ligase (Promega Ltd., Southampton, UK) and 10 x buffer (300mM Tris-HCl, pH 7.8, 
100mM MgCl2, 100mM DTT, 10mM ATP). The concentrations of vector and insert 
were estimated during electrophoresis along with molecular weight standards of a 
known concentration. Normally, the concentrations used were 50 ng of vector DNA 
and an equal to 3-fold concentration of insert. The reactions were incubated at 4ºC 
overnight. 
 
 2.1.8 Preparation of E. coli (JM109) by Calcium Chloride Method 
 1 ml of a JM109 overnight culture was added to 50 ml in a LB broth flask and 
incubated shaking at 37ºC until the OD600 of 0.3 was reached. The cells were then 
cooled to 0ºC for 10 minutes in ice cold polypropylene tubes and centrifuged at 
4000rpm for 10 minutes at 4ºC. The pellets were re-suspended in 10 ml of ice-cold 
0.1 M calcium chloride after the supernatants were discarded. Then, the samples were 
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kept on ice for 15 minutes and centrifuged 3,000 rpm for 10 minutes to recover the 
pellets. Pellets were re-suspended in 1 ml of ice cold 0.1M calcium chloride and 
stored on ice for 30 minutes. 
 20 µl of ligation was added into 200 µl of the prepared cells in a 0.5 ml 
eppendorf and kept on ice for 30 minutes. The cells were heat shocked in a water bath 
at 42ºC for 50 seconds and then, placed on ice for 2 minutes. After this, 950 µl of LB 
medium (10g Bacto-tryptone, 5g Bacto-yeast extract, 5g NaCl, deionized water, pH 
7.5) was added to the mixture and incubated with shaking at 37ºC for 1 hour. Cells 
were then spread on agar plates supplemented with a suitable antibiotic.  
 
 2.1.9 Transformation of Competent E. coli (JM109) cells 
 DNA constructs were transformed in competent E. coli cells JM109 
(purchased from Promega or prepared by the Calcium Chloride technique), by adding 
50 µl of cells to the 10 µl ligation reaction in a 1.5 ml microcentrifuge tube. The tubes 
were flicked gently to mix the contents and placed on ice for 15 minutes. Heat-shock 
was carried out at 42ºC in a water bath for 50 seconds. The tubes were immediately 
placed on ice for 2 minutes. After this, 950 µl of LB medium (10g Bacto-tryptone, 5g 
Bacto-yeast extract, 5g NaCl, deionized water, pH 7.5) were added to the mixture and 
placed in a shaking incubator at 37ºC for 1 hour. Cells were spread on agar plates 
supplemented with a suitable antibiotic and incubated at 37ºC overnight. 
 Individual colonies from plates were picked, the following day, placed in 
universals with 5 ml of LB medium containing antibiotic, and incubated overnight at 
37 ºC with moderate shaking. 
 
 2.1.10 Mini-preparation of plasmid DNA 
 Plasmid DNA was extracted from cells using Wizard Plus SV Minipreps DNA 
purification System (Promega Ltd., Southampton,UK). 
 
 2.1.11 Midi-preparation of plasmid DNA 
 Midi-preps were prepared using the Midi-prep Pure YieldTM Plasmid Midiprep 
System (Promega Ltd., Southampton, UK) as per the manufacturers instructions. A 
colony was grown in a universal containing 25 ml of LB and the appropriate amount 
of antibiotic and incubated overnight with shaking at 37ºC. 
 
 57
 2.1.12 DNA sequencing 
600 ng of DNA, in a final volume of 15 µl, was sent to the Sequencing Service 
MSI/WTB Complex (School of Life Sciences, University of Dundee). T7 and SP6 
promoter primers were normally used for sequencing and provided by the sequencing 
service. All clones were verified by the Sequencing Service MSI/WTB Complex 
(School of Life Sciences, University of Dundee). 
 
 
2.1.13 Alkaline Phosphatase, Calf Intestinal treatment (CIAP) 
 
 Removal of 5’ phosphate groups from DNA was performed using CIAP 
(purchased from Promega Ltd., Southampton, UK) to avoid self-ligation and re-
circularization of linearized plasmids. This enzyme is active on 5’ overhangs, 5’ 
recessed and blunt ends. 
 A reaction containing linearized DNA (up to 10 pmol of 5’ ends), 10 x CIAP 
buffer and CIAP enzyme (0.01 u/µl) was incubated at 37ºC for 30 minutes in a final 
volume of 250 µl. The reaction was stopped by adding 0.8 µl of EDTA (0.5M) and, 
subsequently purified using the Wizard SV gel and PCR clean up kit (Promega Ltd., 
Southampton, UK) as per manufacturers instructions. 
 
 2.1.14 TOPO® cloning 
 PCR products were inserted into pcDNA3.1/V5-His-TOPO® vector 
(Invitrogen Ltd, Paisley, UK) (shown in figure 20). This vector was linearized with 
single 3’ thymidine (T) overhangs for TA cloning. The BIO-X-ACTTM DNA 
polymerase (Bioline Ltd, London, UK) used for the PCR assays has a nontemplate-
dependent terminal transferase activity that adds a single deoxyadenosine (A) to the 3’ 
ends of PCR products. This allows PCR inserts to ligate efficiently with the TOPO 
vector. 
 The TOPO cloning reaction was carried out in a final volume of 6 µl 
containing 3 µl PCR product, 1 µl salt solution, 1 µl sterile water and 1 µl TOPO 
vector. After 30 to 60 minutes of incubation at room temperature (22-23ºC), 
transformation was carried out using E. coli competent cells (JM109). 
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Figure 20. Schematic representation of the pcDNA 3.1/V5-His-TOPO vector.  
Vector diagram showing positions of the multiple cloning site. (pcDNA 3.1/V5-
His-TOPO vector map; www.invitrogen.com)  
   
2.1.15 pGEM®-T Easy cloning 
PCR products were inserted into pGEM®-T Easy Vector (Promega Ltd., 
outhampton, UK) (represented in figure 21). This vector was prepared by cutting 
ith EcoRV and adding a 3´terminal thymidine to both ends, creating single 3’ T 
verhangs, which improves the efficiency of ligation and prevents recircularization. 
he multiple cloning site is flanked by restriction enzymes sites BstZI, NotI and 
coRI, providing three options for removal of the insert with a single digest. 
The ligation reaction can be preformed in 1 hour at room temperature. 
urthermore, this vector contains T7 and SP6 RNA polymerase promoters flanking 
he multiple cloning region inside the α-peptide coding region of β-galactosidase. 
hus, there will be inactivation of the α-peptide if the PCR product is inserted 
orrectly. This allows the possibility of selection of recombinant clones by colour 
creening through the use of indicator plates that contain IPTG (Isopropyl β-D-1-
hiogalactopyranoside; 0.1M) and X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-
alactopyranoside; 50 µg/µl). 
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Figure 21. Schematic representation of the pGEM-T Easy expression vector. 
Vector diagram of pGEM-T Easy expression vector showing positions of the multiple 
cloning site. (pGEM-T Easy expression vector map; www.promega.com) 
 
 2.1.16 Oligonucleotide annealment 
 100mM stock solutions of the oligonucleotide adapters were prepared. 5 µl of 
each oligonucleotide were mixed together and boiled at 95ºC for 5 minutes to destroy 
any secondary structures and then cooled down at room temperature to allow the 
primers to anneal. A series of dilutions of the annealed primers were prepared (1:10, 
1:100 and 1:1000) and ligated into a suitably restricted vector. 
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2.1.17 Primer sequences 
Oligonucleotides used for cloning are presented in the following table. 
5’ GGGCCTAAGCTTGAATTCTTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATA 
GGCTTACCCATCATCATCATGGCACCGGGCTTGCGGGTCATGCAC 3’
∆PACrev
5’ TTCGCCGCTAGCTCTAGAAACTCAACCCCTGCAGCCATGTTTGTGTGCGTGTTCAT 
ACTGATATCAGTATTGCTACTGAGTGGTGATGTGGAAATAAGTSCCGGGCCCTTCC 
TGGCCACCGTCGGCG 3’
Str-34f
5’ TTCGCCGCTAGCTCTAGAACCACTGATGATCCTGCCATGCAAGAGAGCACCTGCC 
TCCCTGAGATGATCATGGTAAAGGCTGGAGATGTAGAGCTAAATSCAGGGCCCTTT 
GGCCACCGTCGGCG 3’
Str-14f
5’ ATGATGTCTAGACAGGTCTTCTTCTGAGATGAGTTTTTGTTCCTTGTACAGCTCGT 
CCATGC 3’
CFPr
5’ CATCATGGATCCGTGAGCAAGGGCGAGGAGCTGTTCACC 3’CFPf
5’ATGAT GAAGCTTTTACCGTCTTATTTCCAACTTTGTCC 3’ScFvr
5’ CATCATGGATCCGCCGATGTGCAGGTGGTGGAGTCAGGGGGAGGC 3’ScFvf
5’ ATG ATGGGATCCGGGCCCAGGGTTGGACTCGACGTCTCCCGC 3’Lh135r
5’ CATCATGCTAGCACCATGGGAAAGCCGATCCCAAACCCT 3’Lh135f
5’ GGATCCTCAGCCTGG GTTCATTTCTACATCATGTAT 3’HEPr
5’ CCATGGAA T CCCCTTCTCTCTACCGCATTGATCTT 3’HEPf
5’ ATGATGCCATGGTTACAATTTCCATTCGCCATTCAGGC 3’ApepV5r
5’ CATCATGGGCCCATGACCATGATTACGCCAAGCT 3’ApepV5f
5’ TGATGAGATCTGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCTGA 
GTATTCTATAGTGTCACCTAAATAG 3’
pGEMV5r
5’ GGTTTCTTAGACGTCAGGTG GCACTTTTCGGG 3’pGEMV5f
5’ ATAGAGATTCGGGATTTCGGCGCTCC 3´HERr
5’ GGATCCGGAGCTTGGTCTAGACAGCTGTTGAATTTTGACCTTCTTAAGCTTGCGG
GAGACGTCGAGTCCAACCCCGGGCCCCTGTTGCCCGTCTCACTGGTGAAA 3´
HERf
Primer name Sequence (5’? 3’)
 
 
Table 3. Primers used for cloning. Names and sequences of all the primers used for cloning. S = C or 
G. C being the wild type version and G the mutated version. 
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2.2 Analysis of translation profiles 
   2.2.1 Antibodies 
 Antibodies were used in Western Blotting, Immuno-precipitation and 
Immuno-fluorescence analysis described in the following sections. The primary 
antibodies used in this study are shown in Table 4. 
 The following antibodies were used as secondary antibodies: 
- ELC anti-mouse IgG-peroxidase from sheep (Amersham Biosciences, 
Buckinghamshire, UK) 
- Anti-rabbit IgG peroxidase goat (Sigma-Aldrich company LDT. Dorset, 
UK) 
- Texas red goat anti-mouse (Invitrogen, Ltd, Paisley, UK) 
- Texas red goat anti-rabbit (Invitrogen Ltd, Paisley, UK) 
 
 
Invitrogen Ltd, Paisley, UK
Roche Diagnostics Ltd., Burgess Hill, UK
Kindly provided by Prof. Rick Randall 
(University of St. Andrews)
Kindly provided by Dr. Dario Vignali ( St. Jude 
Faculty, Memphis)
Kindly provided by Dr. Dimitris Xirodimas
(University of Dundee)
β-Galactosidase
GFP, CFP
V5 protein
Anti-β-Galactosidase, Rabbit IgG
fraction
Anti-GFP (mAb)
Anti V5-tag (mAb)
Anti-2A rabbit polyclonal
Anti-2A rabbit polyclonal
Anti-Ub rabbit monoclonal
SourceTarget ProteinAntibody
Kindly provided by Dr. Garry Luke (University of 
St. Andrews)
Ubiquitin
2ATAV
2AFMDV
 
 
Table 4. Primary antibodies and target proteins. 
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 2.2.2 Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 Analysis of protein mixtures was carried out under denaturing (SDS) 
conditions using discontinuous buffer systems similar to that developed by Laemmli 
(1970). SDS-PAGE gels consisted of an upper layer of 4% polyacrylamide stacking 
gel and a lower layer of 12% or 15% polyacrylamide resolving gel. 
 A Hoefer mini-gel apparatus were used to run the gel using a constant current 
of 40mA. Then, the gel was incubated in Coomassie brilliant staining solution (0.2% 
[w/v] Coomassie brilliant blue (R-250), 20% [v/v] methanol, 10% [v/v] acetic acid) to 
stain the proteins. 
 
 2.2.3 Preparation of samples to run on SDS-PAGE 
 Proteins were obtained by preparing a starter culture consisting of the 
inoculation of a  single colony of E.coli, transformed with the plasmid of interest, into 
2 ml LB medium containing the appropriate antibiotic and grown overnight at 37ºC 
with moderate shaking. This starter culture was diluted 1:10 and grown at 37ºC with 
moderate shaking to an A600 of 0.6. Protein expression was induced by adding IPTG 
to a final concentration of 0.5mM. The incubation was continued for 4-6 hours, and 
the culture harvested by centrifugation at 13000rpm for 10 min at 4ºC. The 
supernatant was transferred to a fresh tube and treated with Lysis Buffer (Cell lytic B 
bacterial lysis reagent, protease inhibitors cocktail, Benzonase (240u/µl) (Cell Lytic B 
Kit, Sigma-Aldrich company LDT. Dorset, UK). An equivalent volume of 2x SDS-
PAGE sample loading buffer (2% [w/v] SDS, 20% [v/v] glycerol, 2% [v/v] β-
mercaptoethanol, 0.2% [w/v] bromophenol blue, 100mM Tris, pH 6.8) was added to 
the reactions. 
 Samples were analyzed in SDS-PAGE gels, loading 5 µl of the reaction with 
loading buffer (see 2.2.1). 
 
 2.2.4 Coupled in vitro Transcription/Translation reactions (TNT) 
 Proteins were expressed in vitro using TNT® Coupled Reticulocyte Lysate 
Systems or Wheat Germ Extract systems (Promega Ltd., Southampton, UK) for 
eukaryotic expression. Radiolabelling of the proteins was performed using [35S]-
methionine (10µCi/µl). Reactions were incubated at 30ºC for 90 minutes. 
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 An equivalent volume of 2x SDS-PAGE sample loading buffer (2% [w/v] 
SDS, 20% [v/v] glycerol, 2% [v/v] β-mercaptoethanol, 0.2% [w/v] bromophenol blue, 
100mM Tris, pH 6.8) was added to the reactions.  
 5 µl aliquots of the translation reactions were analyzed by denaturing SDS-
PAGE, loading 5 µl of the reaction with loading buffer (see 2.2.1). 
 
  2.2.5 In vitro Immune precipitation (IP) 
 Proteins expressed in vitro (see 2.2.3) were incubated with an adequate 
antibody for 2 hours at 4ºC. This and subsequent incubations were carried out on 
an orbital shaker. Protein A/G Sepharose beads (Amersham Biosciences, 
Buckinghamshire, UK) were washed three times with PBS to remove the ethanol 
in which they are supplied. The beads were recovered from washes by 
centrifugation at 12,000 x g for 10 seconds. A 50% slurry was prepared by adding 
an equal volume of PBS and stored at 4ºC. 20 µl of this slurry was added to the 
antibody/protein mixture and incubated at 4 ºC for 2 hours. The beads were 
recovered by centrifugation at 12,000 x g for 10 seconds and re-suspended in 2x 
SDS-PAGE sample loading buffer ( 2%[w/v] SDS, 20% [v/v ]glycerol, 2% [v/v] 
β-mecaptoethanol, 0.2% [w/v ] bromophenol blue, 100mM Tris, pH 6.8). Samples 
were boiled at 95ºC for 2 minutes and centrifuged at 12,000 x g for 10 seconds. 
The supernatant was analyzed on SDS-PAGE (see 2.2.1 and 2.2.5).  
 
  2.2.6 Visualization of Radiolabelled Translation products 
  The distribution of radiolabel between the translation products was visualized 
by autoradiography or phosphor-imaging using FUJIX Bio-imaging analyzer. 
 
  2.2.7 Western blot analysis 
 Polypeptides were transferred to PDVF membranes (ImmobilonTM-P 
Transfer membranes, Millipore Corporation, UK), directly after SDS-PAGE 
electrophoresis. The membrane was methanol-activated for 5 minutes, rinsed with 
dH2O and incubated in transfer buffer (2.9g glycine, 5.8g Tris base, 0.37g SDS, 200 
ml methanol in a final volume of 1 litre). 
 A blotting sandwich was prepared as follows: 1 fibre pad, 1 Whatmann 3 MM 
paper, membrane, protein gel, 1 Whatmann 3 MM paper, 1 fibre pad. Both fibre pad 
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and Whatmann 3 MM paper were previously soaked in transfer buffer. The blotting 
apparatus was set at a constant current of 30 mA overnight or 400 mA for 1 hour.  
 Following transfer, the membrane was incubated in blocking buffer (5% (w/v) 
skimmed milk powder, 0.1% (v/v) Tween 20 in PBS) for 1 hour. The membrane was 
rinsed twice with blocking buffer for 10 min. 
 The antibody to be used (previously diluted in blocking buffer depending on 
its efficiency) was incubated with the membrane for 1 hour at room temperature, with 
agitation, followed by three 10 minute washes of the membrane using blocking buffer. 
In order to detect bound primary antibodies, the membrane was incubated with the 
appropriate secondary HRP-conjugated antibody (in blocking buffer) for 45 minutes. 
Then 2 brief washes were carried out using wash buffer (0.1% [v/v] Tween 20 in 
PBS). The membrane was incubated for 15 minutes in wash buffer, and subsequently 
washed twice for 10 min with the same buffer. 
 The bound HRP-conjugated secondary antibodies were visualized by 
enhanced chemiluminescence (ELC plus Western Blotting Detection System, 
Amersham Biosciences, Buckinghamshire, UK). 
 
2.3 Bacterial protein expression and purification 
 Protein purification is essential for the characterisation of the function, 
structure and interactions of the protein of interest. Affinity purification tags can be 
fused to any recombinant protein allowing fast and easy purification. These tags are 
biochemical indicators that are normally small proteins, polypeptides or enzymes 
added to the N- or C- terminus of the protein of interest. They can have a role as an 
aid to solubilization, stabilization and expression of the protein to which they are 
attached. 
 
 2.3.1 Glutathione S-transferase (GST) gene fusion system 
 The GST Gene Fusion System (Amersham Biosciences, Buckinghamshire, 
UK) was used to express, purify and detect fusion protein produced in E.coli BL21 
(DE3) pLys cells (Promega Ltd., Southampton, UK). GST fusion proteins were 
purified from bacterial lysates by affinity chromatography using immobilized 
glutathione. GST fusion proteins were captured by the affinity medium and the fusion 
proteins were eluted under mild, non-denaturing conditions using reduced glutathione 
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after several washes to remove contaminating bacterial proteins. These GST-tagged 
plasmids also include a site-specific protease domain, such as thrombin, which is 
situated upstream of the multiple cloning site. Thus, separation of GST from the 
protein of interest can be achieved.  
 
 2.3.1.1 GST-tagged protein expression 
 For protein expression, transformation of the GST-tagged plasmids of interest 
was performed, using E.coli BL21(DE3) pLys cells (Promega Ltd., Southampton, 
UK), which are cells that allow high-efficiency protein expression of any gene that is 
under the control of a T7 promoter and has a ribosome binding site. 
The vector of interest was transformed in BL21 (DE3) pLysS E.coli competent 
cells (Promega Ltd., Southampton, UK), and, the next morning, a single colony was 
inoculated into 2ml LB medium containing Ampicillin (100 µg/ml) and grown 
overnight at 37ºC with moderate shaking. This starter culture was diluted 1:10 and 
grown at 37ºC with moderate shaking to an A600 of 0.6. Protein expression was 
induced by adding IPTG to a final concentration of 0.5mM and incubating the culture 
for 4-6 hours more. The culture was harvested by centrifugation at 4,000 rpm for 20 
min at 4ºC. The pellet was re-suspended in Lysis Buffer (PBS containing 0.1%  [v/v] 
NP40, 1mM DTT and protease inhibitor cocktail tablet [Complete Mini EDTA-free, 
Roche Diagnostics Ltd., Burgess Hill, Uk]), followed by sonication. The culture was 
then harvested by centrifugation at 18,000rpm for 30 min at 4ºC and the supernatant 
transferred to a fresh tube. 20µl of 50 % slurry of Protein G Sepharose 4 Fast Flow 
(GE Healthcare UK Ltd, Buckinghamshire, England) were added and the tube was 
left rotating for 30 min at 4ºC. The beads/fusion protein complex was washed 5 times 
with PBS containing 0.1% [v/v] NP40. The complex was recovered between washes 
at 12000 rpm for 1 min. The pellet was re-suspended in 2x SDS-PAGE sample 
loading buffer and the solution was dissociated at 100ºC for 2 minutes and analysed 
on SDS-PAGE gel (10 % polyacrylamide, described in section 2.2.1.) 
  
 2.3.2 Polyhistidine gene fusion system (His-tag) 
 A polyhistidine-tag is an amino acid motif in proteins that consists of at least 
six histidine (His) residues, often at the N- or C-terminus of the protein. This 
purification method relies on the affinity of histidine residues for immobilized metal 
such as nickel, which allows specific purification of the proteins. This mechanism is 
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only dependent on the primary structure of proteins, thus it is very efficient for 
purifying recombinant proteins in denaturing conditions.  
 2.3.2.1 His-tagged protein expression 
 2A protein from TMEV virus was inserted into Pehistev vector (a kind gift 
from Dr. Huanting Liu, figure 38) and transformed in BL21 (DE3)pLysS E.coli 
competent cells (Promega Ltd., Southampton, UK). A single colony of E.coli 
transformed with this plasmid was inoculated into 2ml LB medium containing 
Kanamycin (30µg/ml) and grown overnight at 37ºC with moderate shaking. This 
starter culture was diluted 1:10 and grown at 37ºC with moderate shaking to an A600 
of 0.6. Protein expression was induced by adding IPTG to a final concentration of 
0.5mM. Incubation continued for 4-6 hours, and the culture was harvested by 
centrifugation at 5000 rpm for 10 min. Bacterial cells were lysed by re-suspending the 
pellet in 0.5 ml of sample buffer (PBS containing 0.3M NaCl, 10mM imidazol, 
protease inhibitor cocktail tablet [Complete Mini EDTA-free, Roche Diagnostics Ltd., 
Burgess Hill, UK]), followed by sonication. The lysate was centrifuged for 10 min at 
13000 rmp at 4 ºC, and the supernatant transferred to a fresh tube with a 50% slurry of 
Nickel beads inside. The tube was left rotating for an hour at 4ºC and then, washed 3 
times with 0.5ml of washing buffer (PBS containing 0.3 NaCl, 30mM imidazole and 
1mM PMSF). The beads/fusion protein complex was recovered between washes by 
centrifugation at 13000 rpm for 1 min. After washing, 50µl of elution buffer (PBS 
containing 0.3M NaCl, 500nM imidazole, 1mM PMSF) was added to the complex 
and incubated for 2 min. Re-suspension of the pellet in 2x SDS-PAGE sample loading 
buffer was performed after centrifugation of the cells for 1 min at 13000 rpm. The 
sample was dissociated at 100ºC for 2 min and analysed by SDS-PAGE gel (10% 
polyacrylamide, described in section 2.2.1). 
 
 2.3.4 Purification of the His-tagged protein using Immobilised metal affinity columns 
 The bacterial pellet (obtained as explained above) was re-suspended in lysis 
buffer (20mM Tris-HCl pH 8.0, 0.5M NaCl, 0.1% Triton-X-100, 1mM MgCl2, 1 
Complete EDTA-free Protease Inhibitor tablet) and sonicated (3 x 1 minute) on ice. 
 The cell lysate was centrifuged at  20,000 rpm for 30 minutes at 4°C and the 
supernatant filtered (Acrodisc® 0.45mm syringe  filter), and diluted 2 fold with buffer 
A (20mM Tris-HCl pH 8.0, 0.5M  NaCl, 30mM Imidazole, 30mM NaH2PO4).  The 
clear lysate was loaded onto an equilibrated 5 ml HisTrap Chelating Nickel column 
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(GE Healthcare UK Ltd, Buckinghamshire, England) and the His-tagged protein was 
eluted off the column over a 115 ml 30-500mM Imidazole linear gradient. The 
fractions were analysed by SDS-PAGE (see 2.2.1)  
2.3.5 Purification of the GST-tagged protein using Glutathione agarose columns 
   2.3.5.1 Glutathione-Agarose Column 
   Affinity chromatography using Glutathione Agarose allows rapid, mild, non-
denaturing and highly selective purification of glutathione binding enzymes such as 
glutathione-S-transferase. 
 Purification of the protein of interest was achieved by using a 5 ml column 
filled with Glutathione Agarose (Sigma-Aldrich Company LDT. Dorset, UK). The 
entire process was performed at 4˚C to avoid protein degradation. The column was 
regenerated by loading 5 resin volumes of Cleansing Buffer (0.1M borate buffer, pH 
8.5 containing 0.5M NaCl), followed by washes with 5 column volumes of deionized 
water. The column was washed with 5 column volumes of Cleansing buffer 2 (0.1M 
acetate buffer, pH 4.5, containing 0.5M NaCl) and washed again with deionized 
water. After the regeneration process, the column was equilibrated with Equilibration 
buffer (PBS [Phosphate buffered saline: 10mM phosphate buffer pH7.4, 150mM 
NaCl]). 
 The supernatant (with the soluble protein of interest, prepared as explained 
previously) was loaded onto the column under gravity flow. The flowthrough was 
kept for subsequent SDS-analysis, to check the efficiency of binding). 
 Once all the supernatant was loaded, the resin was washed with PBS-T (PBS 
containing 1% [v/v] Triton X-100) until the OD280 was 0. Then the GST-tagged 
protein was eluted from the resin with Elution Buffer (5mM to 10mM reduced 
glutathione in 50mM Tris-HCl, pH 9.5). 
 The fractions containing GST-tagged protein were identified by SDS-PAGE 
analysis and Mass Spectrometry. 
 
   2.3.5.2 Pre-packed Glutathione-Agarose Column 
 Purification of the protein of interest using a 1ml GSTrap™ FF Column (GE 
Healthcare UK Ltd, Buckinghamshire, England). These columns are simple to use and 
bind approx. 10 mg of recombinant GST/ml medium. 
 The pre-packed column was equilibrated with 5-10 column volumes of 
Equilibration Buffer (PBS with 0.5M NaCl). The supernatant containing the protein 
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of interest was loaded onto the column and left re-circulating overnight. The column 
was then washed with Equilibration Buffer until OD280= 0. Elution buffer (5mM to 
10mM reduced glutathione in 50mM Tris-HCl, pH 9.5) was added at this stage and 
3ml fractions collected. The fractions were analysed by SDS-PAGE. 
 
 2.3.6 Ultrafiltration 
Millipore’s Amicon® Ultra-15 centrifugal filter devices (Millipore UK Ltd, 
Watford, England) contain a Millipore Ultracell® regenerated cellulose low binding 
membrane, which provides high concentration factors and excellent sample recoveries 
from dilute protein fractions. The sample was loaded onto the filter device and this 
was spun in a swinging bucket at 4000 x g 15-45 minutes at 4ºC. 
 
 2.3.7 Thrombin protease digestion 
 PGEX vectors, used to purify the protein of interest via Glutathione-Agarose 
column, also have a Thrombin protease recognition site for cleaving the desired 
protein from the fusion product. 
100µg of GST-fusion protein was digested with 1 unit of enzyme in 1x PBS 
[Phosphate buffered saline: 10mM phosphate buffer pH7.4, 150mM NaCl]) and 
incubated at 4˚C overnight. 
 
 2.3.8 Silver staining 
 Silver staining is a sensitive method for detecting proteins in SDS-PAGE gels. 
The gel was incubated in  fresh Fixer ( 10ml glycerol, 100ml methanol, 20ml acetic 
acid, 70ml dH2O) for 20 minutes, then, washed twice with 400ml dH2O.The Staining 
solution (Silver complex (5 ml) [ 0.1g AgNO3 and 0.1g NH4NO3 in a final volume of 
5 ml dH2O], Moderator (5ml) [ 0.5g tungstosilicic acid monohydrate in 5ml of dH2O] 
and Developer (5ml) [ 0.43ml in 5ml dH2O] in a final volume of 30ml dH2O) was 
prepared freshly and mixed with 50ml Accelerator (6.75g Na2CO3 · 10 H2O in 50ml 
dH2O). This mixture was immediately added to the gel and incubated in a clean dish. 
Development was stopped (5% acetic acid) when the bands reached the desired 
intensity in relation to background. 
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2.4 Cell culture 
 2.4.1 Cell lines 
   2.4.1.1 Mammalian cell lines  
 The mammalian cell lines were kindly provided by Dr. Rick Randall 
(University of St. Andrews). 
 - HeLa: cell line derived from cervical cancer cells 
           - BHK:  baby hamster kidney cells.  
 - 293T: human embryo kidney cells (HEK).  
    
   2.4.2 Splitting cells 
 The old medium was poured off and cells washed with PBS to remove the 
remaining residual medium. Trypsin/EDTA (Becton Dickinson, Plymouth, UK), 
which is a buffered salt solution containing 0.5% (w/v) trypsin and 0.2% (w/v) 
EDTA, was added to dissociate adherent cells. The flask was incubated at 37ºC for 5 
minutes and then, 10ml of Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich company LDT. Dorset, UK) supplemented with 10% [v/v] fetal calf serum 
(FCS; Invitrogen Ltd, Paisley, UK) was added to inactivate the trypsin. The cells were 
subsequently dispersed by agitation, transferred to a 15ml tube and centrifuged at 750 
x g for 3 min. The supernatant was removed and the cell pellet re-suspended in 10 ml 
of DMEM supplemented with 10% FCS. 2 ml of cell solution was added.  
 Cells were maintained in 75cm2 flasks at 37ºC in a 5% CO2 humidified 
incubator. 
    
   2.4.3 Mammalian protein expression 
 Transfection is a method that facilitates the introduction of negatively charged 
molecules (phosphate backbone of DNA) into cells with negatively charged 
membranes. It is a non-viral method used to introduce nucleic acids into eukaryotic 
cells using different physical, lipid or chemical methods. Transfection is a very useful 
technique for studying the function of a certain gene in the context of a cell. 
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   2.4.3.1 Transfection reagents 
    2.4.3.1.1 Chemical reagents 
 A cationic polymer associates with the negatively charged nucleic acid leading 
to the formation of a positively charged complex. This DNA/polymer complex will 
associate with the negatively charged cell membrane, which uptakes it by 
endocytosis. 
      
     2.4.3.1.1.1 GeneJuice transfection reagent (Novagen, Nottingham, UK) 
 GeneJuice is a proprietary formulation optimized for maximal transfection 
efficiency and minimal cytotoxicity. It consists of a non-toxic cellular protein and a 
small amount of a novel polyamine. Furthermore, this chemical reagent is compatible 
with both serum-containing and serum-free media. 
 On the day prior to transfection, cells were seeded to achieve a cell density of 
50-80% needed at the time of transfection. A GeneJuice®:DNA ratio of 3:1 was used 
(although different ratios can be used for optimization (see manufacturer´s protocol 
guidelines)). 
 GeneJuice transfection reagent was diluted with serum-free medium (Opti-
MEM® I Reduced Serum Medium (1X), liquid - with GlutaMAX™ I; Invitrogen Ltd, 
Paisley, UK). The reagent was added drop-wise to the medium and mixed thoroughly 
by vortexing. The GeneJuice/serum-free medium mixture was incubated at RT for 5 
minutes. DNA was added to the GeneJuice/serum-free medium mixture and mixed 
gently by pipetting. The mixture was incubated at RT for 5-15 min and then added in 
a drop-wise manner to the cells in complete growth Medium. The dish was gently 
rocked to ensure even distribution. The cells were incubated for 24-48 hours (5% 
CO2). 
     
     2.4.3.1.2 Cationic lipids 
 Liposome-mediated transfection is considered to be relatively more efficient 
in gene transfer than chemical reagents, thus, it is recommendable for certain resistant 
cell types. The DNA is delivered into cells by synthetic cationic lipids. The cationic 
head group of the lipid compound associates with the negatively charged nucleic 
acids, leading to the formation of a positively charged liposome/nucleic acid complex. 
 The complex effectively associates with the negatively charged cell membrane 
inducing very high transfer efficiency via endocytosis or fusion with the plasma 
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membrane (Gao & Huang 1995). Following cellular internalization, the complex will 
be released from the endosomes by an unclear mechanism, and will later appear in the 
nucleus. 
    
     2.4.3.1.2.1 FuGENE 6 transfection reagent (Roche Diagnostics Ltd, Burgess Hill, 
UK) 
 FuGENE 6 is a proprietary blend of lipids that forms a complex with DNA, 
and transports it into animal cells. Transfection can be performed in serum-containing 
media. Cells were seeded one day prior to transfection, so they achieve an appropriate 
density of 50-80% confluency during overnight incubation. Initially a FuGENE 6 : 
DNA ratio of 3:1 was used. Different ratios can be used for optimization (see 
manufacturer´s protocol). 
 First FuGENE 6 reagent was diluted with serum-free medium (Opti-MEM® I 
Reduced Serum Medium (1X), liquid - with GlutaMAX™ I, Invitrogen Ltd, Paisley, 
UK). Serum-free medium was added first, followed by the addition of FuGENE 6 
directly into the medium without allowing contact with the walls of the plastic tubes. 
The solution was mixed, flicking the tube gently, and the mixture was subsequently 
incubated for 5 min at RT. Addition of DNA to the mixture was performed followed 
by incubation of the transfection reagent/DNA complex for 15-45 min at RT. The 
complex was then added to the cells in a drop-wise manner. The wells or flasks were 
swirled to ensure distribution over the entire plate surface, and finally returned to the 
incubator 24-48 hours to allow gene-expression. 
 
   2.4.4 Analyses of protein expressed in mammalian cells 
    2.4.4.1 Lysis of cells and Western Blotting 
 Cells were harvested 48 hours after transfection. The medium was removed 
and the cells washed with PBS 3 times for 3 minutes each. The PBS was removed and 
the cells re-suspended in 2x SDS-PAGE sample loading buffer (2% [w/v] SDS, 20% 
[v/v] glycerol, 2% [v/v] β-mercaptoethanol, 0.2% [w/v] bromophenol blue, 100mM 
Tris, pH 6.8). The re-suspension was transferred to a 1.5 ml tube and sonicated for 5 
seconds. Samples were boiled at 95ºC for 2 minutes, and the supernatant analyzed on 
SDS-PAGE (see 2.2.1).  
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     2.4.4.2 Fixing cells 
 Cells grown in DMEM medium supplemented with 10% FCS on coverslips 
(10mm in diameter, General Scientific Co. Ltd., Redhill, UK) were washed with 
PBS, and subsequently fixed with 4% paraformaldehyde (PFA) for 30 min. The 
fixed cells were washed twice with PBS before mounted using Mowiol mounting 
solution (2.4g Mowiol 4-88 [Calbiochem, San Diego, USA], 6g glycerol, 6ml 
H2O, 0.2M Tris-HCl pH 8.5, 12 ml 1.4-diazabicyclo[2.2.2]octane [DABCO; 
Sigma-Aldrich company LDT. Dorset, UK) supplemented with diamino 
phenylindole (DAPI, 0.5µg/ml; Sigma-Aldrich company Ltd. Dorset, UK) for 
nuclear staining. 
 
    2.4.4.3 Immunofluorescence 
 Cells, grown in DMEM medium supplemented with 10% FCS, were seeded 
onto glass coverslips in a 6-well plate and incubated overnight before being 
transfected (see 2.4.4). After 36-48 hours, cells were fixed with 400µl PFA for 30 
min and washed with PBS before incubation with permeabilization buffer (500ml 
PBS, 10% [w/v] sucrose, 0.5% [v/v] NP40) for 20 min. The cells were blocked for 
15 minutes with blocking buffer (permeabilization buffer containing 30% [v/v] 
goat serum; Sigma-Aldrich company Ltd. Dorset, UK). The proteins of interest 
were detected by incubating the cells with an appropriately diluted primary 
antibody (in blocking buffer 1/500) for at least 45 min. The cells were washed 3 
times with wash buffer (0.1% [v/v] Tween 20 in PBS) for 5 min. The cells were 
then incubated with the fluorochrome-conjugated secondary Antibody (in 
blocking buffer 1/500) in order to detect bound primary antibody. Coverslips were 
kept in the dark to reduce bleaching of fluorescence probe and washed 3 times 
with wash buffer after 30 minutes of incubation. The coverslips were subsequently 
mounted in Mowiol mounting solution (2.4g Mowiol 4-88 [Calbiochem, San 
Diego, USA], 6g glycerol, 6ml H2O, 0.2M Tris pH 8.5, 12ml 1.4-diazabicyclo 
[2.2.2]octane [DABCO; Sigma-Aldrich company Ltd. Dorset, UK) supplemented 
with diamino phenylindole (DAPI, 0.5 micrograms/ml; Sigma-Aldrich company 
Ltd. Dorset, UK). 
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    2.4.4.4 Imaging 
 DeltaVision® microscope system (applied Precision, Marlborough, UK) 
consists of an inverted microscope (Olympus 1x70, Olympus, Tokyo, Japan) with 
a 1.40 NA 100x or 60 x oil immersion objectives and Photometric CH300 CCD 
camera. Images were processed with the softWoRx® Imaging software package 
(applied Precision, Marlborough, UK).  
 
    2.4.4.5 In vivo Immune precipitation (IP) 
 A radioactive mix containing: 1 ml DMEM without met/glu, 30 µCi of [35S]-
methionine (10µCi/µl) and 10 µl 100X glutamine; was added to 25 cm2 flasks 
with transfected cells incubated for 48 hours at 37 ºC. The cells were incubated for 
45-60 minutes at 37 ºC and, then, harvested and lysed in 500 µl chilled IP buffer 
(20mM Tris pH7.8, 650mM NaCl, 5mM EDTA, 0.5% [v/v] NP40, protease 
inhibitor cocktail tablet [Complete Mini EDTA-free, Roche Diagnostics Ltd., 
Burgess Hill, UK]). The cells were kept at -70 ºC for 10 minutes and transferred to 
1.5 ml tubes.  Centrifugation of cells was performed at 13,000 rpm for 30 minutes 
at 4 ºC, and the supernatant transferred to a new 1.5 ml tube. A specific antibody 
was added to the cleared cell lysate and the antibody/lysate mixture incubated at 4 
ºC for 2 hours, rotating constantly. Protein A/G Sepharose beads (Amersham 
Biosciences, Buckinghamshire, UK) were washed three times with PBS to remove 
the ethanol in which they are supplied. The beads were recovered from washes by 
centrifugation at 12,000 x g for 10 seconds. A 50% slurry was prepared by adding 
an equal volume of PBS and stored at 4 ºC. 20 µl of this slurry was added to the 
antibody/lysate mixture and incubated at 4 ºC for 2 hours rotating. The beads were 
recovered by spinning at 12,000 x g for 10 seconds and re-suspended in 2x SDS-
PAGE sample loading buffer ( 2%[w/v] SDS, 20% [v/v] glycerol, 2% [v/v] β-
mecaptoethanol, 0.2% [w/v] bromophenol blue, 100mM Tris, pH 6.8). Samples 
were boiled at 95 ºC for 2 minutes and centrifugated at 12,000 x g for 10 seconds. 
The supernatant was analyzed by SDS-PAGE (see 2.2.1 and 2.2.5).  
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    3. RESULTS 
3.1 Development of a bacterial screen for 2A activity  
  
This work is based on the hypothesis that 2A interacts with the ribosome exit 
tunnel while it is being translated, and is thus, able to stall the ribosome and inhibit 
peptide bond formation. There is consistent data to support this nascent peptide-
ribosome interaction (reviewed by Tenson & Ehrenberg, 2002).  
 After several unsuccessful attempts, a reliable and efficient bacterial screen 
has been successfully developed. It consists of a reporter system that allows the 
detection of 2A activity directly in live cells without the need for Western blots. It is 
based on the construction of a destabilized LacZ reporter (Tobias et al., 1991a; Tobias 
et al., 1991b). This is achieved by the N-terminal fusion of the ubiquitin (Ub) protein 
linked to LacZ by an arginine (Arg; R) residue. Upon co-transformation with the 
ubiquitin proteinase (UBP), the Ub is proteolytically removed from the fusion and the 
Arg becomes the N-terminal residue of the LacZ. This destabilising residue directs 
LacZ to a degradation pathway. The introduction of the FMDV 2A between the 
destabilising Arg and LacZ allows the stabilisation of LacZ if 2A is active and 
removes the N-terminal Arg. 
   
   3.1.1 Construction of the destabilized reporter pHE12 
 The plasmid pUb23R (illustrated in figure 22), was digested with HindIII and 
ApaI, and the large DNA restriction fragment purified by agarose gel electrophoresis, 
and then, religated to create pHE9. A PCR fragment was amplified from pHE9 using 
the oligonucleotide primer forward HERf, which has an N-terminal BamHI restriction 
site and contains also the 2AFMDV sequence and the reverse primer HERr (see table 3 
in section 2.1.17). The PCR product was gel purified and, then, ligated into pcDNA 
3.1/V5-His TOPO®. This vector was doubly restricted with BamHI and ClaI, gel 
purified and ligated into pHE9 vector similarly restricted to produce pHE12. 
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Figure 22: Overview of the cloning strategy utilized for the formation of pHE12. The 
pUb23R fragment was cut with HindIII and ApaI and religated in order to reduce its size. The 
PCR fragment was cloned into pcDNA 3.1/V5-His TOPO® and, then restricted with BamHI and 
ClaI, ligated into pHE9 vector similarly restricted, to produce pHE12. 
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   3.1.2 pJT184 
 A plasmid essential for this novel bacterial screening system is pJT184 (figure 
23), encoding the ubiquitin protease UBP1 (Tobias et al., 1991b). 
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Figure 23: Illustration of pJT184. This plasmid contains the ubiquitin protease UBP1, which
is able to cleave at the C-terminus of ubiquitin, releasing LacI/LacZ protein.  
 
  3.1.3 Testing the system 
There are two versions of the plasmid pUb23, one with an arginine at the N-
erminus of LacI/LacZ (pUb23R) and one with methione (pUb23M). E.coli was co-
ransformed with plasmids pUb23M and pJT184 or plasmids pUb23M and pJT184. 
mpicillin indicator plates, which contain IPTG, and X-Gal were used to grow the 
olonies. In the first co-transformation, the colonies obtained were blue, whereas in 
he second one they were white (Figure 24a). This is because once the LacZ protein is 
leaved away from the ubiquitin by UBP1, its N-terminus is exposed. When this N-
erminus is methionine, LacZ is stable and reacts with X-gal to give blue coloured 
olonies. By contrast, an N-terminal arginine is very unstable, thus LacZ is degraded, 
iving white colonies (Tobias et al., 1991a).  
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Figure 24: Scheme of the bacterial screen system. a) Two control plasmids: pUb23M co-
transformed with UBP1 gives blue colonies, whereas pUb23R co-transformation with UBP1 gives 
white ones. b)  Model of 2A screen system. Different 2As can be cloned into plasmid pHE12 and its 
activity tested through Blue/White screen. 
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In pHE12, the 2A sequence is situated in between the arginine and the N-
terminus of LacZ. It is flanked by BamHI and ApaI, which are unique restriction sites 
in the plasmid. Thus, mutated 2As can be cloned there and their activity tested using 
our Blue/White screening system (Figure 24b). 
  To test the system MC1061 cells (genotype: hsdR2 hsdM+ hsdS+ araD139 
∆(ara-leu)7697 ∆(lac)X74 galE15 galK16 rpsL (StrR) mcrA mcrB1) were used for 
the co-transformations. Additionally aat∆* cells, which derive from MC1061, were 
used as a control. These cells are deficient in the L/F transferase, which is a 
component of the N-end rule pathway necessary for the degradation of proteins 
carrying N-terminal Arg (R) or Lys (L) (Shrader et al., 1993). Thus, pUb23R will be 
stable in these cells and will produce blue colonies (shown in figure 25). 
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Figure 25. Testing the bacterial screen system a) pUb23M co-transformed with pJT184 produces 
blue colonies in MC1061 cells and the mutated strain aat∆* b) pUb23R co-transformed with pJT184 
(UBP1) produces white colonies in MC1061 and blue colonies in aat∆* c1) pHE12 gives the same 
result as pUb23R because wild type FMDV-2A is not active in bacteria. c2) representation of a 
mutated 2A that ‘cleaves’ in bacteria.  
 
 
  
 Western blot analysis using anti-ß-galactosidase antibodies was performed to 
check the presence of the LacZ product in the cell. pUb23M (Ub-M-LacI/Z) and 
pHE12 (Ub-R-2A-LacI/Z) were transformed separately and also, co-transformed with 
pJT184 (UBP1). ß-galactosidase, whose size is 150 kDa, appeared in all the cases 
except when pHE12 was co-transformed with pJT184 (R-2A-LacI/Z), where LacZ is 
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degraded. Because 2A is not active in bacteria, the N-terminal arginine will not be 
cleaved away, and LacZ will therefore be degraded.  
 The results shown in figure 26 are consistent with prior observations seen in 
other types of artificial polyprotein systems, where wild type 2AFMDV is not active in 
prokaryotic systems (Donnelly et al., 1997) 
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Figure 26: Western analysis of the destabilized reporter using anti-β-galactosidase. 
Lane 1: pUb23M (Ub-M-Lacz). Lane 2: Co-transformation of pUb23M with pJT184. Lane 
3: HE12. Lane 4: Co-transformation of HE12 with pJT184 (MC1061 cells). Lane 5: Co-
transformation of HE12 with pJT184 (aat∆* cells), as positive control. pUb23M and HE12 
were transformed in MC1061 cells and show a 150 kDA band, which is β-galactosidase. 
The co-transformation of HE12 with pJT184 in MC1061 cells does not show the LacZ 
band, because is degraded. In contrast, there is LacZ when using aat∆* cells, as a positive 
control. The difference between Ub-M-LacZ and M-Lac is only 8.6 kDa, therefore is 
difficult to see this small difference in size on a protein gel (lanes 1 and 2).  
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 To test that the transformations worked, DNA was purified from MC1061 
cells transformed with pHE12 alone, pHE12 together with pJT184 and pJT184 by 
itself (figure 27).  
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Figure 27: Agarose gel showing the two plasmids involved in the 
co-transformation. HE12 and pJT184 were linearized with the 
restriction enzyme ClaI. Lane 1: Linearized DNA obtained from a co-
transformation with both plasmids was loaded in the gel. Both DNA 
bands are observed. Lane 2: HE12. Lane 3: pJT184.  The positions of 
the size markers (Kb) are shown on the left of the figure. 
 
 
 pUb23M/R and pHE12  expression products were probed by Western blotting, 
using anti-ubiquitin antibodies (figure 28). Recombinant ubiquitin was used as a 
positive control (20ng/µl) and was the only recognized protein. The conjugated 
ubiquitin from pUb23M/R and pHE12 constructs was not recognized, possibly due to 
the Ub-epitope being masked at the C-terminal fusion. 
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Figure 28. Western Blot using anti-ubiquitin antibody. Recombinant
ubiquitin (20ng/µl), kindly provided by Dr. Xirodimas, was used as a positive
control. Unfortunately the antibody only recognizes non-conjugated or non-
fused ubiquitin.   
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   3.1.4 Semi-random Mutagenesis 
 A double-stranded oligonucleotide adapter comprising the 2A sequence with 
‘degeneracy’ built-in to the nucleotides highlighted in red (figure 29) was designed 
(Eurogentec Ltd, Hampshire, UK). The sequence has sticky ends with a 5’ BamHI site 
and a 3’ ApaI site, and the consensus motif is not mutated. The level of spiking is 0.7 
probability of the wild-type nucleotide, 0.3 of incorporating a mutant base. That 
means 4 mutations in total on a 42 nucleotide sequence (figure 31). 
                               
 
 
  
 
 
 
                  R  Q  L  L  N  F  D  L  L  K  L  A  G  D  V  E  S  N  P  
5’GATCCGGAGCTTGGTCTAGACAGCTGTTGAATTTTGACCTTCTTAAGCTTGCGGGAGATGTCGAGTCCAACCCCGGGCC -3’ 
 
 3’-  GCCTCGAACCAGATCTGTCGACAACTTAAAACTGGAAGAATTCGAACGCCCTCTACAGCTCAGGTTGGGGC     -5’ 
 
 
 
Figure 29. Representation of the double-stranded oligonucleotide adapter comprised of the 
2A sequence. The 2A sequence has sticky ends with 5’ BamHI site and a 3’ ApaI site, and the 
consensus motif is not mutated. The mutated nucleotides are highlighted in red. 
 
 The binomial distribution (figure 30) was used to calculate the best level of 
spiking. This distribution is based on two possible outcomes (eg. Mutated or non-mutated 
amino acid in each position of the sequence) and the outcome of one trial does not affect the 
outcome on other trials. 
 
  
 
Figure 30. Binomial formula. X= k, indicates that the outcome X 
occurs k times; n is the number of repeated events; q is the
probability of the second possible outcome and p the probability of 
success in one trial. (http://www.stat.yale. edu/ Courses/ 199798/ 
101/binom.htm) 
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Figure 31: Graph representing the probability of introducing mutations depending
on the length of the sequence. The optimum level of degeneracy was obtained by
calculating the probability of incorporating a mutated nucleotide based on the length of
the sequence. The calculations are based on binomial distribution, where there are two
possible outcomes and the outcome of one trial does not affect the outcome on other
trials. 
  
The oligonucleotide adapters were annealed (as described in section 2.1.16) 
nd then ligated into the pHE12 vector, restricted with BamHI and ApaI, and gel 
urified. 
The mutated clones were transformed into pJM109 cells and grown on Amp-
PTG-X-Gal plates. Potentially active 2As would be selected from blue colonies and 
ested with anti-β-galactosidase and anti-ubiquitin. 
The advantage of this system is that it would offer the possibility to check a 
ery large number of mutated 2As through white/blue colour screening. Furthermore, 
t is a very efficient system because it avoids possible clones with frameshift 
utations or premature stop codons. 
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   3.1.5 Searching for active 2As in prokaryotic systems 
   Thirty different ligations of semi-random mutated 2As within the pHE12 
plasmid were performed, and transformed on Amp-IPTG-XGAL plates. 
Unfortunately, no blue colonies were observed. A positive control was based on the 
substitution of the FMDV-2A with a ribosome binding site (RBS) to create a similar 
situation to that which happens in eukaryotic cells with the FMDV wild type 2A 
(figure 31). 
 
 
t
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Figure 31. Positive control for the bacterial screen system based on the 
substitution of FMDV-2A for a ribosome binding site. This intergenic 
region mimics what an active 2A would do in eukaryotic organisms, thus, 
LacZ is released from the N-terminal arginine (R) and, therefore, blue colonies 
are obtained from the transformation of bacterial cells.  
A number of plasmids prepared from white colonies were analyzed to assess 
he strategy of mutagenesis; check the ratio of mutation: wild-type sequences and, 
hus, the quality of the oligonucleotides (figure 32). 
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Unfortunately, the quality of the oligonucleotides supplied was not as good as 
expected, the majority of mutated 2As showing between 7-10 mutations, much higher 
than the expected average of 4 mutations in a 42 nucleotide sequence. Furthermore, 
some versions with deletions and additions were also obtained showing the poor 
quality of these annealed nucleotides. It should be noted that many other 
oligonucleotides ordered (Eurogentec Ltd, Hampshire, UK) during this period were 
supplied with incorrect sequences resulting from faulty syntheses. 
  
    G    G  A  W    R    L  L  N    D  L  L  K  L  A  G  D V  E     N  P  G  P  
FMDV            GGATCCGGAGCTTGGTCTAGACAGCTGTTGAATTTTGACCTTCTTAAGCTTGCGGGAGACGTCGAGTCCAACCCCGGGCCC 
 
S S SQ F
    G    G  A  W    R    W  L  T  I  H  P    T  L  A  E  D  V  E    N  P  G  P  
HE15.1A         GGATCCGGAGCTTGGTCTAGACAGTGGTTGACTATACACCCTTTTACGCTTGCCGAAGATGTCGAGTCCAACCCCGGGCCC 
S S SQ F
    G    G  A  W    R    Y  M  K  I  D  L  L  G  I  T  E   E  G  E      N P  G   P 
HE15.5A         GGATCCGGAGCTTGGTCTAGACAGTACATGAAAATAGACCTTCTTGGGATTACGGAGGAAGGAGAGTCCAACCCCGGGCCC 
S S SQ
     G  G  A  W  R  E  A  V  N  L  E  L  R  E  I  A  R  T  L  E  N  P  G  P   
HE15.5b         GGATCCGGAGCTTGGTCTAGAGAGGCGGTCAATCTTGAGCTTCGTGAGATTGCGCGTACTCTCGAGTCCAACCCCGGGCCC 
S  S  S  
    G    G  A  W    R  N  V  R  N  L  D  R  V  K  I    A  G  A  E    N  P  G  P  
HE15.7b         GGATCCGGAGCTTGGTCTAGAAACGTAAGGAATCTTGACCGTGTTAAGATTTCCGCAGGTGCCGAGTCCAACCCCGGGCCC 
S S S S
    G    A  W  R  H  H  L  N  D  L  T  L  A  G  D V  E   N  P  G  P  
HE15.8A         GGATCCGGAGCTTGGT AGACACCATTTGAATTTCGACC CTGACGCTGGCGGGAGACGTTGAGT CAACCCCGGGCCC 
S  G S  S  
CT C
F  Q  
AG
    G    G  A  W    R    R  M  N    D    L  K  H  A  A  G D  E     N  P  G  P  
HE15.8b         GGATCCGGAGCTTGGTCTAGACAGCGGATGAATTTTGATCAGCTAAAACATGCGGCAGGAGACGAGTCCAACCCCGGGCCC 
S S SQ F Q
                 G   A  W  R  L  W  N  D  R  K  L  P  G  D  V  E  N  P  G  P   
HE15.10A        GGATCCGGAGCTTGGT AGACAGCTGTGGAATTTTGACCGTTCCAAGCTACCAGGAGATGTCGAGT CAACCCCGGGCCC 
S  G S  S  S  
CT C
Q  F  
    G    G  A  W    R    L  E  D    D  P  L  M  L  G  A  E V  E     N  P  G  P  
HE15.11A        GGATCCGGAGCTTGGTCTAGACAGCTAGAGGATTTTGACCCTCTTATGCTTGGGGCTGAGGTTGAGTCCAACCCCGGGCCC 
S S SQ F
    G    G  A  W    R    L  L  N    D  L  L  K  L  A  G  D V  E     N  P  G  P  
HE15.12A        GGATCCGGAGCTTGGTCTAGACAGCTGTTGAATTTTGACCTTCTTAAGCTTGCGGGAGACGTCGAGTCCAACCCCGGGCCC 
S S SQ F
    G    G  A  W    R    L  M  V    E  H  L  K  L  E  G  D V  E     N  P  G  P  
HE15.12b        GGATCCGGAGCTTGGTCTAGACAGCTGATGGTTTTTGAACATCTTAAGCTTGAGGGAGATGTCGAGTCCAACCCCGGGCCC 
                 
 
S S SQ F
    G    A  W  R  L  L  N  L  *  R  L  *  E  M  V  E  N  P  G  P 
HE15.14b        GGATCCGGAGCTTGGTCTAGACAGCTCTTGAATCTTTAGCGCCTTTAGAGTGAGTCAATGGTAGAGTCCAACCCCGGGCCC 
    G    G  A  W    R  H  L  V  N  Y  V  I  I  D  V  T  A  E    E    N  P  R  P   
HE15.3A         GGATCCGGAGCTTGGTCTAGACATCTGGTGAATTATGTTATTATTGACGTTACGGCTGAGTTCGAGTCCAACCCCAGGCCC 
    G    A  W  R   I  C  I  A          M  R  A      M   T   R  A    
S  G S  S  S  S  
S S S
S  G S  S  S  S  P 
Q  
F
HE15.1b         GGATCCGGAGCTTGGTCTAGAAT-CTGCTCAATTGC--------AATGCGAGCG----ATGTCGAGTCCAACCC-GGGCCC 
    G    G  A  W    R    H  L  I  G  G  L  R  K  I  A  E  D  A  D      P   G  P   S S Q Q
HE15.2A         GGATCCGGAGCTTGGTCTAGACAGCACTTGATTGGTGGGCTTCGGAAGATTGCGGAGGATGCGGA--TCAACCC-GGGCCC 
    G    G  A  W    R  V  L  Y  N    D  L  L  M  L  A    N  I  E    N   P  G     S S SF Q
HE15.2b         GGATCCGGAGCTTGGTCTAGAGTGTTGTATAATTTTGACCTGCTAATGCTCGCGCAAAATATCGAGTCCAACCC-GGGCCC 
    G  G  A  W  R  L  I  N   H  I  L  K  L  A  V  A  L  E  N  P   G     S  S  S S  Q  
HE15.3b         GGATCCGGAGCTTGGTCTAGACAGCTCATTAATTCGCACATTCTTAAGCTCGCGGTAGCTTTGGAGTCCAACCC-GGGCCC 
    G    G  A  W    R  Q  L  L       A    V    L  R  Q  M  *  S  P  T  P  G     S S SF F F
HE15.4A         GGATCCGGAGCTTGGTCTAGACAGCTGTTG-TTTTTTGCCTTCGTAAGTCTGCGGCAGATGTAGAGTCCAACCCCGGGCCC 
    G    A  W   L  D  R  L  L  V  L  L  R  G  M  T  P  G     S  G S  S  S  S  S  P  F  
HE15.7A         GGATCCGGAGCTTGGT-TAGACAGATCGCTTTTATCTGTCTTCTTAAGCTTGCGGGGGATGTCGAGTCCAACCCCGGGCCC 
    G    G  A  W     E    G  R  C    T  Y  L      R  E  M    S  P  T  P  G     S S S S SF F
HE15.9A         GGATCCGGAGCTTGGTCT-GAGAGCGGTCGATGTTTCACATATTTAAGCTTTCGGGAGATGTCGAGTCCAACCCCGGGCCC 
          G    A  W  R  V  L  Y  N  D  L  L  M  L  A  N  I  E  N  P   G     S  G S  S  F  Q  
HE15.10b        GGATCCGGAGCTTGGT TAGAGTGTTGTATAATT ACCTGCTAATGCTCGCGCAAAATATCGAGTCCAACCC-GGGCCC 
    G    G  A  W    R  T  A  G  A    C  H    W  K  R  R  K  G  R  V  Q  P  R  A   
HE15.4b         GGATCCGGAGCTTGGTCTAGGACCGCAGGTGCATCTTGCCATTCGTGGAAGCGAAGGAAAGGTCGAGTCCAACCCCGGGCCC
 
C TTG
S S S S
 
Figure 32. Alignment of various mutated 2A sequences. Some mutated clones were 
sequenced to check the ratio of mutations. The ratio of mutations observed is much higher 
than expected probably due to the poor quality of the oligonucleotides supplied. 
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   3.1.6 Improvement of the bacterial screen system 
    3.1.6.1 pHE29 vector 
 As shown previously, it is difficult to see a difference in size between Ub-M-
LacI/Z and M-LacI/Z on an SDS-PAGE because ubiquitin is only 77 amino acids 
long, equivalent to a protein of 8.6 kDa, and ß-gal is 150 kDa. Therefore, using the α-
peptide, which is only 10.4 kDa, instead of the entire Lac Z protein, the difference in 
size between the reporter protein (with and without Ub) is much better visualized on 
an SDS-PAGE using this system. 
 pGEM3Zf(-) vector (Promega Ltd., Southampton, UK) was used as a template 
to amplify the α-peptide fragment, which is a part of the LacZ gene, used for the 
white/blue screen. The oligonucleotides used were pGEMV5f as a forward primer, 
which has an N-terminal AatII, and the reverse primer pGEMV5r, which contains the 
V5 epitope sequence and a C-terminal BglII (see table 3 in section 2.1.17). 
 The PCR fragment was digested with BglII and AatII and ligated into 
pGEM3ZF(-), which was restricted with BamHI and AatII (figure 33). Thus BamHI 
site was deleted in this new pGEM3ZF(-) vector. A PCR was performed using the 
modified pGEM3ZF(-) vector using the forward primer ApepV5f, which has an N-
terminal ApaI restriction site, and the primer reverse ApepV5r with a C-terminal NcoI 
restriction site (see table 3 in section 2.1.17). 
The PCR fragment was restricted with ApaI and NcoI and ligated into the 
similarly restricted pHE12 vector to give HE29 (figure 33). 
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Figure 33. Strategy for creation of pHE29. The LacZ gene was removed from pHE12 using the ApaI 
and NcoI restriction enzymes. A similarly restricted α-peptide-V5 PCR fragment was ligated into the 
restricted pHE12 to create the new improved reporter, pHE29.  
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    3.1.6.2 Western Blot anti-V5 
  First pGEM3Z-f(-).V5 was tested against anti-V5 in a Western Blot. A 
plasmid consisting of V5-CFP-2A-V5-PAC was used as a positive control. The size 
of α-peptide-V5 fusion protein is ~12 kDa (figure 34).  
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Figure 34. Western blot anti-V5. Lane 1: positive control containing 2 
V5. Lane 2: Negative control, pGEM3Z-f(-). Lane 3: pGEMZ-f(-).V5. The 
size of the proteins recognized by V5 antibodies are shown on the left 
(kDa). 
 
  
To test the “improved” system, transformations of pHE29 with and without pJT184 
were performed in the same cell strains as before (see 3.1.3). Unfortunately, anti-V5 
antibodies did not recognize for pHE29 (figure 35).  
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 Figure 35.  Prokaryotic expression. Artificial polyproteins were expressed in E.coli 
(MC1061 and its mutated version aat∆*) and the cleavage activities assessed by probing a   
Western Blot of total cellular proteins with anti-V5 antibodies.   
 
 
  
 
 One must conclude, therefore, that the V5 epitope on the α-peptide encoded by 
the pHE29 is masked. Mutated 2A were cloned inside pHE29 and co-transformations 
with pJT184 were preformed. Only white colonies were observed. Due to time 
constrictions this work was not pursued further. 
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3.2 Purification of TMEV-2A 
  
 The aim of this part of the project was to purify 2ATMEV protein in order to 
learn more about its structure and its behaviour within the cell. Furthermore, it was 
hoped to produce antibodies against 2ATMEV. Due to time constraints and difficulties 
in the purification process (see below) insufficient material was obtained to proceed 
with 2A crystallization.  
  
 3.2.1 Optimization of bacterial expression systems 
  A construct containing GST-tagged (Glutathione Sepharose 
transferase) 2ATMEV protein (pGEX-2T.2ATMEV, kindly provided by Dr. Garry Luke) 
was transformed in BL21 (DE3) cells and the protein induced with IPTG (figure 36). 
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Thrombin site
 
 
  pGEX-2T.2ATMEV was transformed in BL21(DE3) E.coli cells and the 
colonies were grown overnight. The next morning 9 universals were set up with 10 ml 
of the overnight culture. The cultures were grown at different temperatures and the 
protein induced using various IPTG concentrations to test the optimum conditions for 
GST-tagged 2ATMEV protein induction (figure 37). 
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Figure 36. Schematic illustration of pGEX-2T on the left and SDS-PAGE showing the 
induction and purification of pGEX-2T.2ATMEV on the right. pGEX-2T multiple cloning site 
(MCS) is where 2ATMEV was cloned. As a result pGEX-2T.2ATMEV was obtained and, thereafter, 
transformed in BL21(DE3) E.coli cells. IPTG induction of the cells and purification of GST-2A 
protein were performed. Lane 1, uninduced; lane 2, induced; lane 3, GST-2ATMEV purified with 
Glutathione Sepharose Beads. 
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Figure 37. GST-2A induction with IPTG. Different temperatures of induction and 
different concentrations of IPTG were used during GST-2A protein induction to 
establish the optimum conditions. No differences in protein concentration were 
observed between different conditions. 
 
 
 In a parallel experiment, 2ATMEV was cloned into a His6x-tagged vector and the 
expression of the new plasmid compared to the GST-tagged construct. This was 
influenced by the fact that the Scottish Structural Proteomic Facility (SSPF) in the 
University of St. Andrews works only with His6x-tagged constructs and, therefore, has 
all the high-throughput technologies for protein expression, purification, 
crystallization, structure determination specific for these constructs instead of the 
GST-tagged ones. 
The 2A TMEV sequence was amplified from pcDNA containing the sequence of 
TMEV (GDVII) (provided by Dr. Garry Luke) using the oligonucleotide forward 
primer HEPf, which has an N-terminal NcoI restriction site, and the reverse primer 
HEPr, which has a C-terminal BamHI restriction site (see table 3 in section 2.1.17). 
The PCR fragment was ligated into pcDNA3.1/ V5-His-TOPO® vector and, then, 
doubly restricted with NcoI and BamHI. The NcoI/BamHI product was gel purified 
and ligated into into pEHISTEV (a kind gift from Dr. Huanting, figure 38) similarly 
restricted. 
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Figure 38. His-tagged prokaryotic expression vector. Top: Schematic pEHISTEV 
vector. Bottom: sequence detail of the multicloning site sequence (MCS). 
 
Unfortunately, the resulting His6x-tagged construct (pHE11) did not show any 
significant His6x-2A protein expression (16 kDa) when compared to the GST-tagged 
construct (41 kDa) (figure 39). Therefore, it was discarded and pGEX-2T.2ATMEV was 
used for GST-2A protein induction and purification. 
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Figure 39. Comparison between the GST-tagged 2ATMEV and the His-tagged 2ATMEV IPTG 
induction and purification. Lanes 1-3: GST-tagged 2ATMEV. Lane 1: Uninduced. Lane 2: 
Induced. Lane 3: GST-2ATMEV pull- down with Glutathione Sepharose beads. Lanes 4-6: His-
tagged 2ATMEV. Lane 4: Uninduced. Lane 5: Induced. Lane 6: GST-2ATMEV pull-down with 
Nickel beads. 
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3.2.2 Small scale induction, purification and thrombin digestion trials 
 The construct pGEX-2T.2ATMEV was transformed in BL21 (DE3) E.coli cells 
and, thereafter, a 50 ml culture protein induction with IPTG was performed. The cells 
were, then, lysed and the cleared lysate was loaded into a 5 ml Glutathione-Agarose 
column (Sigma-Aldrich Company Ltd. Dorset, UK). The column was washed with 
PBS-T (PBS containing 1% [v/v] Triton X-100) and the GST-tagged 2ATMEV protein 
eluted with Elution Buffer (5mM to 10mM reduced glutathione in 50mM Tris-HCl, 
pH 9.5). GST-tagged 2ATMEV protein fractions were collected (1.5 ml/fraction) and 
identified by SDS-PAGE analysis (figure 40).  
 
 
1 2 3 4 5 6 7 8 9
25 KDa
37 KDa
 
 
 Figure 40. Small scale GST-tagged 2ATMEV protein purification. The lanes 
are labeled 1-9 corresponding to the different fractions collected.  
 
 All the protein containing fractions (1-9) were pooled and ultra-filtrated 
through a 20 ml Amicon Ultra centrifugal device (Millipore UK Ltd, Watford, 
England) to concentrate the sample (figure 41). 
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Figure 41. GST-tagged 2ATMEV concentration. The 9 
pooled GST-2A fractions were concentrated using a 20 
ml Amicon Ultra centrifugal device. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The concentrated GST-tagged 2ATMEV protein was digested with 1 unit of 
thrombin enzyme (Amersham Biosciences, Buckinghamshire, UK) to cleave the 
2ATMEV away from the GST. To optimize digestion conditions, three experiments 
were set up using either 5 µl, 10 µl or 20 µl GST-tagged 2ATMEV (figure 42). After 
digestion samples were centrifuged at 15,000 rpm for 3 minutes. The supernatants 
were transferred to fresh tubes and, although a pellet was not visible, it was re-
suspended in 5 µl of PBS to make sure there was not insoluble protein present. The 
fact that 2A was found in the precipitate fraction (figure 42, lane 3c) suggests the 
protein is insoluble however; it may be because of the fact that there is more 
concentration of purified protein at the bottom of the tube, rather than being the pellet.  
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Figure 42. Small scale thrombin digestion trial. First lane: GST-2A 
uncleaved. Second lane: Thrombin (37 KDa). The following lanes represent 
GST-2A digested with thrombin using three different starting volumes of GST-
2A protein: 1) 5 µl, 2) 10 µl and 3) 20 µl. s: supernatant, c: centrifuged. The 
digestion was performed at room temperature for 16 hours.  
 
 
  
 GST-2A purification was also performed using Glutathione Sepharose Beads 
(Amersham Biosciences, Buckinghamshire, UK) tested and compared to the 
glutathione agarose column. 
 Another 50 ml small scale protein induction was performed (as explained) and 
the protein purification preformed using Glutathione Sepharose Beads.  Thrombin 
was added to the GST-2A/Beads mixture and incubated by rotating at 16ºC for 16 hrs. 
The mixture was spun down and the supernatant transferred to a fresh tube.   
 The purification was not as clean as the column procedure and most 2A 
protein was observed in the pellet with the Glutathione Sepharose Beads. No 2A band 
was observed in the supernatant. However, this was not due to the possibility of 
insolubility but due to a much diluted sample. Insolubility was discarded when 
Trichloroacetic acid (TCA) precipitation was performed in the supernatant samples 
and 2A protein was observed (figure 43). 
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Figure 43. Thrombin digestion on-beads. GST-2A 
was digested on Beads, the supernatant recovered and 
concentrated with Trichloroacetic acid (TCA). Lane 1: 
Supernatant after thrombin digestion. 2A protein is 
present. Lane 2 and 3: Glutathione sepharose beads 
centrifuged from digested sample. Majority of GST is 
observed on the beads. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The purified samples from the 50 ml glutathione-agarose column (see above) 
were used to test the optimum conditions of thrombin digestion. Two different 
temperatures of incubation were used (4ºC and 16ºC) and samples were taken at 15, 
30, 90, 120 and 240 minutes and overnight. As shown in figure 44 the optimum 
conditions were at 16 ºC overnight.  
Purification using beads was less efficient than the column procedure. 
Although some 2A protein did precipitate with the glutathione sepharose beads, the 
bulk of 2A was recovered from the soluble fraction by TCA precipitation. 
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Figure 44. Small scale GST-2A thrombin digestion trial using different 
conditions. SDS-PAGE above: Coomassie stained; SDS-PAGE below: Silver 
stained. The optimum digestion conditions were 16˚C and overnight. 2A was 
difficult to see due to its small size and small amounts digested. The positions 
of the proteins size markers are indicated. Minor band staining at 25 kDa could 
be 2A dimer. 
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3.2.3 Large scale induction, purification and thrombin digestion  
 Based on the findings of small scale experiments, a large scale experiment was 
set up. GST-2ATMEV protein was induced (4 litres culture) and the tagged protein 
purified (2mg/ml) through 1ml Glutathione-Sepharose column (Invitrogen Ltd, 
Paisley, UK). GST-2A eluted samples were dialyzed (Dialysis tubing size 7; 23.8 mm 
diameter; MW: 12-14 kDa; Medicell International Ltd, London, UK) and digested 
with thrombin (1unit/100µg of protein). The cleavage was not as efficient as 
expected, with a high proportion of the fusion protein not being cleaved by thrombin 
(figure 45). 
 Despite our previous findings cleavage of GST was not as efficient as we 
expected. Failure to separate GST from 2A, allied to the need for larger amounts of 
pure 2A for antibody production, led us to abandon this approach in favour of 
procedure 3.2.4 (see below), whereby GST-2A was purified for anti-GST-2A 
antibody production. 
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Figure 45: Large scale GST-2A purification and digestion with thrombin. a) and b) GST-2A 
purification from 4 litres IPTG induction of E.coli BL21 (DE3) cells. The lanes are labeled 1-19 and   
represent all the fractions collected. Lane 1: GST-2A supernatant before loading onto the column. 
Lane 2: Flow-through from column after sample added. Lane 3:  Flow-through during washes with 
PBS after loading sample. Lanes 4 to 19: Fractions collected during elution with Elution Buffer (5mM 
to 10mM reduced glutathione in 50mM Tris-HCl, pH 9.5). c) GST-2A samples digested with thrombin 
(16 ºC, overnight). Lane 1: GST-2A uncleaved sample after dialysis.  
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3.2.4 Induction of large amounts of protein for TMEV-2A antibody       
production 
 
` 8 litres of E.coli BL21 (DE3) transformed with pGEX-2T, containing 2ATMEV 
(figure 36), were induced with IPTG (0.5mM) and the GST-2A complex purified. 2 
mg/ml of protein complex were digested with thrombin (1u/100µg of protein) 
overnight.   
Eluted fractions are shown in figure 47. The bands were excised and identified 
by MALDI, MALDI-TOF MS and MS/MS methods (Mass spectrometry and 
proteomics facility, Biomolecular Sciences Building, University of St. Andrews) (data 
not shown).  
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Figure 47. SDS-PAGE of GST-2A purified fractions, digested with thrombin eluted 
with glutathione. Lane 1: GST induced form pGEX-5X  Lane 2: uncleaved GST-2A. Lane 
3: Thrombin in PBS (too diluted to be observed (37 kDa). Lane 4: 2A eluted with PBS 
washes, after thrombin cleavage. Lanes 5 to 11: Eluted fractions with Glutathione (to check 
the induction worked).  
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These results indicate 2A forms multimers (dimers, trimers). This may explain 
why 2A was not being eluted through the column and staying attached to the bound 
uncleaved GST-2A on column.  
Due to the difficulties purifying 2A protein from GST-2A, the strategy was 
shifted to obtaining large amounts of induced GST-2A, which was, then, used for 
antibody production (Pentlands Science Park, Penicuik Midlothian). 2mg/ml GST-2A 
was used as immunogen to raise antibodies in sheep. Antibodies were produced not 
only against 2ATMEV but also GST.  GST antibodies were extracted by using 
Glutathione Sepharose Beads, bound to GST. Furthermore, 2ATMEV antibodies were 
tested via ELISA. 
2 litres of E.coli BL21 (DE3) transformed with GST-2A plasmid were induced 
as before and purified (figure 48). 
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Figure 48. SDS-PAGE with GST-2A eluted fractions. 
 
 
 
The eluted fraction number 7, shown in figure 48, was determined to be 2.39 mg/ml 
(figure 49). 
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Figure  49. Measurement of protein concentration and purity. Absorbance at 230nm is 
due to peptide bonds and the absorbance at 280nm is due to light absorption by aromatic 
amino acids, such as, tyrosine, tryptophan and phenylalanine. The concentration of the eluted 
GST-2A fraction number 7 shown in figure 48 was 2.39 mg/ml. 
  
 
Future work will involve testing these 2ATMEV antibodies against artificial 
polyprotein constructs containing this protein, and probing them within the cell.  
Using this new resource we should be able to study 2ATMEV behaviour within 
the cell and resolve a number of interesting questions eg. What happens when 2A is 
cleaved away from the capsid proteins? 
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3.3. Creation of a reporter of stress in the cell using 2AFMDV protein  
  
 The aim of this part of the project was to create an artificial construct as a 
reporter of stress in the cell. This is based on the ability to produce two products from 
a single ORF. The hypothesis tested here is that when cells are not stressed, normal 
levels of eEF2 activity are present resulting in efficient ‘re-initiation’ of the 
translation of sequences downstream of 2A - obtaining a 1:1 ratio of the products up- 
and down-stream of 2A. When cells become stressed, eEF2 becomes phosphorylated, 
elongation rates are reduced and the efficiency of re-initiation of sequences 
downstream of 2A is reduced. This would produce a molar excess of translation 
products up- over those downstream of 2A. The system being tested here is a reporter 
protein (CFP) tagged with a V5 epitope upstream of 2A and a single-chain antibody 
(ScFv binds the V5 epitope) downstream of 2A (an “intrabody”). The rationale being 
that whilst (free) [V5-CFP-2A] is small enough to diffuse through nuclear pores into 
the nucleus, a [V5-CFP-2A]: ScFv complex cannot.  
Analysis of this construct in cells would provide evidence that this type of 
reporter system could be used in cells. The final reporter system would be a V5 
epitope tagged transcriptional transactivator (TTA) linked via 2A to the ScFv ([V5-
TTA-2A-ScFv]). The uncleaved protein (V5-TTA-2A-ScFv) or the cleaved protein 
[V5-TTA-2A] bound to ScFv is too large to diffuse into the nucleus and, thus, is 
localized in the cytoplasm. In contrast, [V5-TTA-2A] not bound to ScFv is small 
enough to diffuse through the nuclear pores, and would be localized both in the 
cytoplasm and inside the nucleus.  
In normal conditions for the cell, [V5-TTA-2A] and scFv are produced in a 1:1 
ratio. However, in stressful conditions the [V5-TTA-2A] product will be produced in 
a higher proportion than the scFv, and will enter the nucleus, since not enough scFv 
will be produced to bind [V5-TTA-2A]. Using stable cell lines expressing luciferase 
under the control of the tetracycline operator system, [V5-TTA-2A] will activate 
luciferase expression and the amount of this luciferase expression will represent the 
level of stress in the cell (see section 4.3). 
 The first step of the project was to test the ability of the singe chain variable 
fragment (scFv) to bind V5 inside the cell. A ‘test’ construct, which has CFP instead 
of TTA, was created (pHE27; figure 50) and used to transfect 293 T cells. The results 
were positive; showing a good binding between V5 and ScFv.  
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 V5-CFP-2A fragment was amplified from Lh135 plasmid (V5-CFP-2A-V5-
∆PAC; kindly provided by Dr. Hughes) using the oligonucleotide primer forward 
Lh135f, which has an N-terminal NheI restriction site, and the reverse primer Lh135r, 
which has a C-terminal BamHI site (see table 3 in section 2.1.17). The PCR product 
was gel purified, restricted with both Nhe I and BamHI enzymes and gel purified 
again.  
 ScFv was amplified from pPDF83 (kindly provided by Dr. de Felipe) using 
the oligonucleotide primer forward ScFvf, which has an N-terminal BamHI restriction 
site, and the reverse primer ScFvr, with a C-terminal HindIII restriction site (see table 
3 in section 2.1.17). The PCR fragment was gel purified, restricted with BamHI and 
HindIII and gel purified again. Lh135 vector was digested with NheI and HindIII and 
gel purified. This restricted plasmid was used as a vector for a triple ligation together 
with V5-CPF-2A and ScFv digested PCR products. This triple ligation led to the 
formation of a new vector, pHE27, which will be used to test the future stress cell 
selector system (figure 50). 
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Figure 50. Overview of the cloning strategy utilized for the formation of HE27 construct.1) and 
3) are the inserts, while 2) is the vector for the performed triple ligation that led to the formation of 
HE27 vector.   
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 3.3.1 Testing pHE27 in vitro 
 Wheat germ in vitro transcription/translation with the pHE27 plasmid 
construct was performed and the obtained products analyzed on SDS-PAGE. As 
expected, three products were observed: full-length protein [V5-CFP-2A-scFv] and 
processed products, [V5-CFP-2A] and [scFv] (figure 51). 
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Figure 51. Translation profile of pHE27. Coupled in
vitro transcription/translation wheat germ extracts were
programmed with the pHE27 plasmid construct and
radiolabelled with [35S]-methionine (10µCi/µl). The full-
length and processed translation products are shown.   
.3.2 Testing pHE27 in cells: Western Blot, Immunofluorescence and 
mmunoprecipitation 
pHE27 vector was transfected into 293T cells, the protein expression assessed 
y probing a Western Blot of total cellular proteins with anti-V5, anti-2AFMDV and 
nti-CFP antibodies. Immunofluorescence and immunoprecipitation was also 
erformed using anti-V5, anti-2AFMDV and anti-CFP antibodies.  
In these experiments Lh135 plasmid was used as a positive control (figure 52) 
nd untransfected cells were used as a negative control. 
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Figure 52. Schematic illustration of pHE27 and pLh135 vectors and their translation products. Both 
vectors, a and c, contain an artificial polyprotein, which is encoded by a single open reading frame. b and 
d show the full-length polyproteins and the processed products of pHE27 and pLh135, respectively. V5: 
small epitope, 14 amino acids long, in the C-terminal of P and V Simian virus 5. CFP: cyan fluorescent 
protein. scFv: single chain variable fragment from anti-V5.  Pac: puromycin-N-acetyltransferase. 
 
 
 
 
 
Several Western Blots were performed after transfection, and revealed the 
expected translation products (figure 53, 54 and 55). 
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Figure 53. Western Blot anti-V5. Artificial polyproteins were expressed in eukaryotic cells 
and probed against anti-V5 antibodies. Lane 1: positive control, pLh135, showing 3 
translation products, the full-length protein, and the two processed ones. Lane 2: Negative 
control. Lane 3: pHE27 vector shows the uncleaved product and the cleaved one, recognized 
by anti-V5 antibody. 
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Figure 54. Western Blot anti-CFP. Artificial polyproteins were expressed in eukaryotic cells 
and probed against anti-CFP antibodies. The full length and processed translation products are 
indicated in each case. Lane 1: negative control. Lane 2: positive control; 2 translation 
products were recognized by the antibody. Lane 3: pHE27; full-length protein and upstream 
processed product were recognized by anti-CFP. 
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Figure 55. Western Blot anti-2A. The full length and processed translation products are indicated 
in each case. Lane 1: positive control, showing two translation products. Lane 2: negative control. 
Lane 3: pHE27; full-length protein and upstream processed product were recognized by anti-2A. 
 
 
 
 
Furthermore, immunofluorescence experiments showed clear cytosolic 
localization of the pHE27 translation products (figure 56). These images suggest ScFv 
binds V5 within the cytoplasm, thus acting as an ‘intrabody’. 
Immunofluorescence using antibodies against V5 and 2A were performed. 
Unfortunately, anti-V5 antibodies did not show any signal, probably due to V5 
epitope being masked in pHE27, and the fluorescence signal obtained from CFP was 
too weak (data not shown). 
Anti-2A antibodies used in cells transfected with pHE30 (positive control 
consisting of [V5-CFP-2A] without scFv) showed [V5-CFP-2A] to be uniformly 
distributed throughout the cell (nucleus + cytoplasm). In contrast, cells infected with 
pHE27, indicated [V5-CFP-2A] was localized in the cytoplasm, and probably 
excluded from the nucleus. NOTE: the weak fluorescence appearing to arise from the 
nucleus can be accounted for by the small amount of cytoplasm above and below the 
nucleus. 
These promising data indicate that further development of this system may 
provide a ‘read-out’ of cellular stress. 
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Figure 56. scFv binds to V5 within the cell. Imunofluorescent images of 293T cells, transfected with 
pHE27 and pHE30, using Texas red anti-2A antibody. Images 1-3: pHE27 shows cytosolic localization. In 
contrast, pHE30 (images 4-6) is localized everywhere in the cell. Black and white pictures are the 
phase/reference images. 
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Immunoprecipitation results from in vivo expression in 293T cells were 
consistent with the cell imaging results shown in figure 56 (figure 57). 
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Figure 57.  In vivo expression and immunoprecipitation using anti-CFP and GST-V 
protein. Above, SDS-PAGE; U: untransfected; T: transfected. Lanes 7-10 are the same as 
lanes 3-6 but 10 µl and 20 µl were added to the gel, respectively. Below, Phosphorimaging 
image of SDS-PAGE gel.  
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In vitro immunoprecipitation (IP) was also performed and confirmed the 
results shown in the immunofluorescence images; scFv was clearly binding V5 within 
the cell (figure 58). 
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Figure 58. Translation in vitro and immunoprecipitation (IP) from these in 
vitro translations. Coupled transcription/translation (TNT) products were 
immunoprecipitated using anti-V5 antibody. The in vitro translation and 
immunoprecipitations were analyzed by SDS-PAGE (4-12%). The first four lanes 
show the in vitro translated products: 1) pGEM3.V as a control, which expressed 
Simian parainfluenza virus 5 V protein (23.8 kDa); 2) pHE27, as shown in figure 
51; 3) plasmids pGEM3.V and pHE27 together; 4) pLh135 as a control. The 3 
lanes on the right showed the results for the immunoprecipitation for 1-3 TNTs.  
 
 
These results confirmed that the scFv binds the V5 protein in vivo (figure 57) 
and also in vitro (figure 58). Immunoprecipitation experiments showed anti-CFP 
antibodies immunopreciptated not only [V5-CFP-2A] but also the scFv protein 
(bound to the V5 epitope; figure 57).  In contrast, in the immunoprecipitation with 
GST-V, no scFv was pulled down: presumably due to the sequestration of the scFv by 
the V5 epitope of [V5-CFP-2A] (figure 57). Immunoprecipitation from the in vitro 
translation reactions was consistent with the in vivo results (figure 58). IP of Lh135 
was not performed because pGEM3.V was used as a control for the IPs and Lh135 as 
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a control for the in vitro translation reactions. No proteins were detected in the IP anti-
V5 against pHE27 translation products (lane 2) since all [V5-CFP-2A] was bound to 
scFv. On the other hand, in the IP of [V5-CFP-2A]:scFv complex and pGEM3.V 
together (figure 58, lane 3) some [V5-CFP-2A-scFv], [V5-CFP-2A] and V protein 
were recognized by the antibody anti-V5, probably because scFv was not only 
binding the full-length and processed product derived from pHE27 but also 
pGEM3.V. Thus, there is some free, unbound, [V5-CFP-2A] from pHE27 and 
pGEM3.V that can be recognized by the antibody. 
 
The immunoprecipitated proteins (figure 58) were determined by probing a 
Western Blot with anti-2A antibodies. [V5-CFP-2A-scFv] full-length (uncleaved) 
protein and processed translation products were identified (figure 59). 
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Figure 59: Western Blot of immuno-precipitations. Immuno-precipitated samples (fig) 
were identified by Western Blot using anti-2A antibodies. Lane 1: Lh135 as positive 
control. Lane 2: Untransfected 293T cells as negative control. Lane 3: HE27. The full-
length and processed translation products are indicated.  
 
 Evidence from co-immunoprecipitation and the cell imaging suggest that this 
strategy may well provide a method to study the effects of stress on the translational 
apparatus of the cell. Future work will involve the creation of the definitive, more 
sensitive, reporter (V5-TTA-2A-scFv), which may allow us to detect stress using 
transcriptional transactivation. 
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3.4 2A-like sequences 
 
 3.4.1 Insect virus 2A-like sequences 
  
Previously identified insect 2A-like sequences (Donnelly et al., 2001a) 
together with newly identified sequences (Luke et al., 2008), were re-cloned in a new 
vector pBiEx-3 (figure 60). This vector contains the Autographa californica nuclear 
polyhedrosis virus (AcNPV) immediate early promoter (IE1), to direct expression in 
insect cells, and the T7 lac promoter for expression in E.coli. 
 The purpose of this study was to test these newly identified insect 2A-like 
sequences (30aa) and longer (30 aa) versions of those previously identified (Luke et 
al., 2008), in a new insect in vitro system (Qiagen Ltd., West Sussex, UK). 
 The 2A-like 30 amino acids long sequences are represented in figure 61. 
 
 
 
 
Figure 60: pBiEx-3 vector (Novagen, Nottingham, UK) contains both insect (IE1) and 
bacterial (T7) promoters. 
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Figure 61. 2A-like amino acid sequences (30 aa long). Infectious flacherie virus (IFV), perina 
nuda picorna-like virus (PnPV), ectropis obliqua picorna-like virus (EoPv), varroa destructor 
virus-1 (VDV-1) cricket paralysis virus (CrPV), providence virus (PrV), bombyx mori cypovirus- 1 
(BmCPV-1) and operophtera brumata cypovirus 18 (OpbuCPV-18) 2A-like sequences are shown. 
The conserved C-terminal motif is highlighted in yellow. 
 
 
Reporter plasmid pSTA1, containing a single ORF encoding green fluorescent 
rotein (GFP), the 30aa version of the insect 2A-like sequences  and β-glucoronidase 
GUS), were restricted with the restriction enzymes  BamHI and XbaI and the large 
ragment purified by agarose gel electrophoresis.  
Cyan fluorescent protein (CFP) was PCR amplified from pMK3 (CFP-2A-
pac; kindly provided by Dr. de Felipe) using the forward oligonucleotide primer 
FPf, which has an N-terminal BamHI restriction site, and the reverse primer CFPr, 
hich contains the human c-Myc epitope tag sequence and a C-terminal XbaI site 
see table 3 in section 2.1.17). The PCR product was doubly restricted with BamHI 
nd XbaI, gel purified, then ligated into pSTA1 similarly restricted. These 10 new 
lasmids (HE241-10) were restricted with BamHI and XhoI, and the small 2.6 Kb 
ragments (CFP-2A-GUS) gel purified.  The purified inserts were ligated into 
imilarly restricted pBiEx-3 vector to give HE251-10 (figure 62).  
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Figure 62. Cloning scheme of HE25 vector. 
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HE251-10 constructs were used to programme insect extract transcription/ 
translation reactions (Insect Direct™ System, Novagen, Nottingham, UK). 
Surprisingly, no translation profiles were obtained (figure 63 a). 
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Figure 63. a) Insect extract transcription/translation reactions. Luciferase as a positive control, 
monomeric protein, 61 kDa. DNA is pIX4 vector. b)Translation profiles of the constructs 
containing 2A-like sequences of insect origin. Coupled transcription/translation wheat germ 
extract reactions were programmed with constructs encoding the 2A-like sequences in the CFP-2A-
GUS artificial polyprotein system. HE32 vector, containing CFP-2AFMDV-GUS profile was included 
for reference. The lanes are labelled with the names of the insect species. The full length translation 
product (CFP-2A-GUS), and processing products ([CFP-2A] and [GUS]) are indicated.  
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To check the integrity of the constructs, the plasmids were used to programme 
wheat germ extract coupled transcription/translation reactions. The radiolabelled 
translation products were separated by 4-12% Bis-Tris SDS-PAGE and visualized by 
autoradiography or phosphorimaging. HE32 (CFP-2AFMDV-GUS) was used as a 
positive control, and showed an expected gel profile with three major translation 
products; full-length polyprotein ([CFP-2AFMDV-GUS]) and the processing products 
([CFP-2AFMDV] and [GUS]) (figure 63 b). 
These data are consistent with Luke et al. (2008). Iflaviruses, Infectious 
flacherie virus (IFV) and Perina nuda picorna-like virus (PnPV), both 2A1 and 2A2, 
showed high cleavage activity. Varroa destructor virus-1 (VDV-1) did not show 
cleavage activity. Its 2A-like sequence does not completely match the conserved 
motif -DxExNPGP- but contain the motif –MDNPNPGP.  
 Cricket paralysis virus (CrPV) showed low cleavage activity together with 
Providence virus 2A2 (PV). In contrast, PV-2A1 and PV-2A3 showed higher cleavage 
activity.  The 2A-like sequences belonging to Cypoviridae, Bombyx mori cypovirus 
type1 (BmCPV-1) and Operophtera brumata cypovirus-18 (OpbuCPV-18) cleavage is 
higher than the observed in CrPV and PV-2A2 but lower than PnPV 2A1 and 2A2. 
 
3.4.2 Strongylocentrotus purpuratus 2A-like sequences 
 Many new 2A-like sequences were found in the genome of the purple sea 
urchin (Strongylocentrotus purpuratus), when probing databases with the conserved 
motif at the C-terminal of 2A (-DxExNPGP-). 
 More than 150 2A-like sequences have been identified within the purple sea 
urchin genome, and analyses show these sequences are distributed between two types 
of cellular sequences: intracellular genes involved in innate immunity and non-LTR 
retrotransposons, similar to Trypanosome 2A-like sequences. 2A is within or close to 
the N-terminus of the single ORF in both groups. 
 Str-14 and Str-34, which are two different Strongylocentrotus purpuratus 2A-
like sequences belonging to the first group of genes (i) and the second one (ii), 
respectively, were cloned into a reporter plasmid (Lh136, kindly provided by Dr. de 
Felipe) and its activity analysed. Reporter plasmid Lh136, containing a single ORF 
encoding cyan fluorescent protein (CFP), 2AFMDV sequence and puromycin-N-
acetyltransferase fragment (∆pac), (kindly provided by Dr. de Felipe) was used as a 
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template to insert the different Strongylocentrotus purpuratus 2A-like (Str) sequences 
using PCR. Primer forward Str-14, which contains the Str 2A sequence and an N-
terminal XbaI restriction site, and reverse primer ∆PACrev, with a C-terminal 
HindIII, were used to amplify Str-14 (figure 64). Furthermore, primer forward Str-34, 
with the same characteristics as Str-14 but with a different Str 2A sequence, and 
∆PACrev, were used to amplify Str-34 (figure 64). There are two versions of forward 
primers, the wild type version and the mutated version (see table 3 in section 2.1.17). 
These two PCR products were doubly restricted with the restriction enzymes XbaI 
and HindIII, gel purified, then ligated into Lh136 similarly restricted (figure 64). 
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TCTAGAACCACTGATGATCCTGCCATGCAAGAGAGCACCTGCCTCCCTGAGATGATCATGGTAAAGGCTGGAGATGTAGAGCTAAATGCAGGGCCC
S  R  T  T  D  D  P  A  M  Q  E  S  T  C  L  P  E  M  I  M  V  K  A  G  D V  E L  N A G  P
TCTAGAACCACTGATGATCCTGCCATGCAAGAGAGCACCTGCCTCCCTGAGATGATCATGGTAAAGGCTGGAGATGTAGAGCTAAATCCAGGGCCC
S  R  T  T  D  D  P  A  M  Q  E  S  T  C  L  P  E  M  I  M  V  K  A  G  D V  E L  N  P  G  P   
Str-14
TCTAGAAACTCAACCCCTGCAGCCATGTTTGTGTGCGTGTTCATACTGATATCAGTATTGCTACTGAGTGGTGATGTGGAAATAAGTGCCGGGCCC
S  R  N  S  T  P  A  A  M  F  V  C  V  F  I  L  I  S  V  L  L  L  S  G  D V  E I  S A G  P
TCTAGAAACTCAACCCCTGCAGCCATGTTTGTGTGCGTGTTCATACTGATATCAGTATTGCTACTGAGTGGTGATGTGGAAATAAGTCCCGGGCCC
S  R  N  S  T  P  A  A  M  F  V  C  V  F  I  L  I  S  V  L  L  L  S  G  D V  E I  S  P  G  P
Str-34
2AFMDV
1
Lh136
6431bp CFP
Pac
XbaI
HindIII
1
Lh136
CFP
Pac
XbaI
HindIII
XbaI+HindIII
∆Pac
Strongylocentrotus purpuratus 2A-Like sequences 
(wt Str-14, mt Str-14, wt Str-34, mt Str-34).
HindIIIXbaI Xba
I+H
indI
II
+ lig
atio
n
PCR
 
 
Figure 64. Strongylocentrotus purpuratus 2A-like (Str) sequences cloning. Lh136 was cut with XbaI 
and HindIII, and the big fragment gel purified and used as a vector for the four different PCR inserts, 
which contain wild type (wt) and mutated (mt) Str-14 and Str-34 2A-like sequences. Wt: C; Mt: G.  
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In vitro coupled transcription/translation wheat germ extract reactions were 
performed and showed Str-14 2A-like sequence to be active whereas Str-34 did not 
show any activity (figure 65). Lack of activity was expected, in the case of Str-34, due 
to the presence of Serine (S) instead of an asparagine (N) in the C-terminal conserved 
motif (–DxExSPGP-). 
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Figure 65. Translation profiles of constructs containing Strongylo-
centrotus purpuratus 2A-like sequences. Coupled transcription/ translation
wheat germ extract reactions were programmed with constructs encoding
2A-like sequences in the CFP-2A-∆Pac artificial polyprotein system. Lh136
was used as a positive control, contains the wild type 2AFMDV. The full-
length translation products (CFP-2A-∆Pac) and the processing products
(CFP-2A and ∆Pac) are indicated. The processed products are absent in the
Str-34 lanes, indicating inactive 2A-like sequences, although extra bands of
~30 kDa and ~15 kDa were observed. 126
3.6 Bioinformatic Analyses 
 
 All the 2A-like sequences found in the database were classified and analyzed 
using Excel. This study focused on the upstream sequence rather than the conserved 
C-terminus motif (-DxExNPGP-). 
The aim of this part of the project was to determine whether the 2A upstream 
sequences follow a pattern among all the different families with 2A-like sequences.  
To be sure we include all the upstream amino acids that might be influencing 
2A’s mechanism of action, the sequences analyzed were 30 amino acids long.  
 Each position of the sequence was analyzed by counting the number of each 
amino acid of each position. The amino acids were grouped in different categories 
depending on the properties of their side-chains. The amino acid classification used 
was the one shown in figure 66, where the hydrophobicity, charge, and size of the 
amino acids were taken into account. 
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Figure 66. Schematic illustration of the amino acids classification. The different tones of green 
represent the level of hydrophobicity, being higher the darker colours.  This colour scheme was used for 
the representation of the data in ‘cones’ and ‘bubbles’ graphs. 
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   3.6.1 Picornaviruses 
 
This analysis includes the 2A sequences within the Picornaviridae. The 
genera and species analyzed are shown in table 5. 
 
 
Number of strainsGenera Species
Aphthovirus
Foot-and-mouth disease virus (FMDV)
Equine rhinitis A virus (ERAV) 
Bovine rhinovirus (BRV-2)
282
7
1
Cardiovirus
Encephalomyocarditis virus (EMCV)
Theiler’s murine encephalomyelitis virus (TMEV)
Theiler’s like virus (TLV)
Saffold virus (SAF-V)
2Equine rhinitis B virus (ERBV) Erbovirus
61Porcine teschovirus (PTV)Teschovirus
14
4
1
2
Seneca virus Seneca valley virus (SVV)
24
Parechovirus Ljungan virus (LV) 2A1 
Unclassified
5
Duck Hepatitis Virus-1 (DHV-1)
1
8Seal picornavirus-1 (SePV-1)Unclassified
 
 
 
Table 5. Picornaviruses analyzed. The table shows the genera, species and number of strains of each 
species analyzed. 
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The sequences analyzed appear to be active. SAF-V, SVV and DHV-1 2A-like 
sequence’s activity have not yet been analyzed. 
The analysis focuses more in the variety of sequences within species and 
between different species, more than the quantity of them. The number of FMDV 
strains is bigger than the rest of species; this is not taken into account in this analysis. 
The amino acids sequences of the 2A protein analyzed in this chapter are 
shown in table 6. Not all of them are shown since there are 281 strains of FMDV, thus 
a maximum of 10 strains per species were selected randomly for representation. 
  First, the 2A amino acid sequences within picornaviruses were analyzed 
altogether and then they were analyzed separately in different genera. FMDV was 
analyzed also in a separate group since the number of strains is quite large. All the 
group analyses were compared to check the variability of amino acids in each 
position, and also the possibility of the existence of a pattern in amino acid 
distribution in all or some of them. Two different graphs were performed to represent 
the data, a cone graph (see figures 67, 69, 71, 73, 75) and a bubble graph (see figures 
68, 70, 72, 74, 76). 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
FMDV-63                    AY593836 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV-64                    AY593831 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV-65                    AY593832 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV-75                    AY593823 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV-76                    AY593824 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV-78                    AY593811 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV-79                    AY593812 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV-83                    AY593828 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV-110                   AF506822 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV-128                   AJ539138 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
ERAV-393/76                L43052   R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
ERAV-Plowright             DQ272127 R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
ERAV-U188                  DQ272128 R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
ERAV-T3                    DQ268580 R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
ERAV-T10                   DQ272577 R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
ERAV-PERV                  X96870   R H K F P T N I N K Q C T N Y A L L K L A G D V E S N P G P
ERAV-PERV-1                DQ272578 R H K F P T N I N K Q C T N Y A L L K L A G D V E S N P G P
BRV2                       EU236594 L R L T G E I V K Q G A T N F E L L Q Q A G D V E T N P G P
ERBV-1-P1436/71            X96871   E A T L S T I L S E G A T N F S L L K L A G D V E L N P G P
ERBV-2-P313/75             AF361253 V A D W E N L L S Q G A T N F D L L K L A G D V E S N P G P
PTV-1-5-D-VIII             AF296106 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1-D 61/96              AY392535 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1-PS 34                AF296105 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1-Sek 549/98           AF296101 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
EMCV (EMC-PV21)           X74312   V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
EMCV (BEL-2887A/91)     AF356822 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
EMCV (pEC9)                DQ288856 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
EMCV (HB1)                 DQ464063 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
EMCV (BJC3)                DQ464062 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
EMCV (EMCV-CBNU)      DQ517424 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
EMCV (EMC-B)               M22457   I F G L Y R I F S T H Y A G Y F S D L L I H D I E T N P G P
MENGO (Rz-pMwt)           DQ294633 V F G L Y H V F E T H Y A G Y F S D L L I H D V E T N P G P
TMEV (GDVII)               X56019   F R E F F K A V R G Y H A D Y Y K Q R L I H D V E M N P G P
TMEV                       M20562   F R E F F K A V R G Y H A D Y Y K Q R L I H D V E M N P G P
TMEV (DA TO)               M20301   F G E F F R A V R A Y H A D Y Y K Q R L I H D V E M N P G P
TMEV (BeAn 8386)           M16020   F G E F F K A V R G Y H A D Y Y R Q R L I H D V E T N P G P
TLV(NGS910) AB090161 F S D F F K H V R E Y H A A Y Y K Q R L M H D V E T N P G P
SAF-V     EF165067 F T D F F K A V R D Y H A S Y Y K Q R L Q H D V E T N P G P
SAF-V     AM922293 F T D F F K A V R D Y H A S Y Y K Q R L Q H D I E A N P G P
LV (174F)                  AF327921 Y F N I M H S D E M D F A G G K F L N Q C G D V E T N P G P
LV (87-012)                AF327920 Y F N I M H S D E M D F A G G K F L N Q C G D V E T N P G P
LV (87-012G)               EF202833 Y F N I M H S D E M D F A G G K F L N Q C G D V E T N P G P
DHV-1 (DRL-62)             DQ219396 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
DHV-1 (R85952)             DQ226541 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
DHV-1 (F)                  EU264072 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
SVV                        DQ641257 R A W C P S M L P F R S Y K Q K M L M Q S G D I E T N P G P
SePV-1                     EU152976 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
SePV-1                     EU142040 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
SePV-1                     EU152979 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
Accession 
number
Species
 
 
 
Table 6. 2A amino acid sequences within picornaviruses. Representation of the species and the 
different strains analyzed. The conserved motif is highlighted in yellow, and the differences in this 
region are shown in red.  
 
 
131
 
 
 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7
6 5
4 3
2 1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 72 3 0 17 0 10 2 0 7 5 1 0 0 24 0 0 8 0 10 1 0 0 0 0 0 0 0 0 3 0
K 1 269 9 185 0 6 9 1 3 284 0 0 0 1 1 23 23 0 344 0 0 0 0 0 0 0 0 0 0 0
H 188 10 1 0 7 9 1 0 0 0 14 7 0 0 0 8 0 0 0 0 0 21 0 0 0 0 0 0 0 0
E 2 0 28 39 1 1 24 0 83 3 0 0 0 0 0 3 0 0 1 0 1 24 0 0 412 61 0 0 0 0
D 6 0 9 0 9 0 1 4 3 2 29 1 0 4 0 276 0 38 0 0 7 0 388 0 0 0 0 0 0 0
Q 0 5 257 5 0 0 0 61 0 2 289 24 0 0 1 0 0 7 4 67 2 0 0 0 0 0 0 1 0 0
N 1 0 6 0 14 1 8 0 28 0 0 0 0 349 23 3 8 0 5 0 0 0 0 0 0 0 412 0 0 0
T 8 2 75 41 0 26 1 4 2 2 0 23 67 0 7 0 0 0 0 24 24 0 0 0 0 23 0 0 0 0
S 6 1 0 4 1 35 3 0 6 24 0 3 7 6 0 67 2 0 0 0 2 0 0 0 0 295 0 0 0 0
C 2 0 8 1 8 3 3 0 0 0 0 7 13 0 1 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0
W 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 32 0 0 0 15 0 7 0 0 0 15 16 1 0 28 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 7 48 0 22 7 0 33 14 0 1 0 3 6 0 343 14 5 0 0 0 0 0 0 0 0 0 0 0 0 0
L 1 2 1 39 51 25 30 3 1 0 0 217 256 0 2 0 353 359 46 320 0 0 0 0 0 3 0 10 0 0
I 1 0 1 5 235 131 15 31 0 0 0 0 19 0 1 0 0 0 0 0 18 0 0 22 0 0 0 0 0 0
M 0 59 0 0 48 7 1 0 0 5 0 10 8 0 0 0 1 0 2 0 1 0 0 1 0 3 0 0 0 0
V 16 0 1 13 2 142 1 13 98 8 0 32 0 0 0 7 0 8 0 0 0 0 0 389 0 0 0 0 0 0
A 69 3 1 13 0 6 268 0 114 13 0 69 27 1 0 3 12 0 0 0 352 0 0 0 0 1 0 0 0 11
G 0 10 14 1 1 2 5 0 66 3 64 0 0 19 5 1 0 0 0 0 0 367 24 0 0 0 0 0 409 0
P 0 0 0 26 13 8 0 281 1 60 0 0 8 8 0 0 0 0 0 0 0 0 0 0 0 26 0 401 0 401
412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412
 
 
 
Figure 67. Analysis of all the 2A-like sequences within the Picornaviridae family. Above, table 
showing the amount of the different amino acids in each position of the 30 amino acids sequence 
analyzed.  Cone graph, below, representing the results from the table. The data set analyzed is shown in 
Appendix 1, sequences 1 to 412. 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 72 3 0 17 0 10 2 0 7 5 1 0 0 24 0 0 8 0 10 1 0 0 0 0 0 0 0 0 3 0
K 1 269 9 185 0 6 9 1 3 284 0 0 0 1 1 23 23 0 344 0 0 0 0 0 0 0 0 0 0 0
H 188 10 1 0 7 9 1 0 0 0 14 7 0 0 0 8 0 0 0 0 0 21 0 0 0 0 0 0 0 0
E 2 0 28 39 1 1 24 0 83 3 0 0 0 0 0 3 0 0 1 0 1 24 0 0 412 61 0 0 0 0
D 6 0 9 0 9 0 1 4 3 2 29 1 0 4 0 276 0 38 0 0 7 0 388 0 0 0 0 0 0 0
Q 0 5 257 5 0 0 0 61 0 2 289 24 0 0 1 0 0 7 4 67 2 0 0 0 0 0 0 1 0 0
N 1 0 6 0 14 1 8 0 28 0 0 0 0 349 23 3 8 0 5 0 0 0 0 0 0 0 412 0 0 0
T 8 2 75 41 0 26 1 4 2 2 0 23 67 0 7 0 0 0 0 24 24 0 0 0 0 23 0 0 0 0
S 6 1 0 4 1 35 3 0 6 24 0 3 7 6 0 67 2 0 0 0 2 0 0 0 0 295 0 0 0 0
C 2 0 8 1 8 3 3 0 0 0 0 7 13 0 1 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0
W 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 32 0 0 0 15 0 7 0 0 0 15 16 1 0 28 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 7 48 0 22 7 0 33 14 0 1 0 3 6 0 343 14 5 0 0 0 0 0 0 0 0 0 0 0 0 0
L 1 2 1 39 51 25 30 3 1 0 0 217 256 0 2 0 353 359 46 320 0 0 0 0 0 3 0 10 0 0
I 1 0 1 5 235 131 15 31 0 0 0 0 19 0 1 0 0 0 0 0 18 0 0 22 0 0 0 0 0 0
M 0 59 0 0 48 7 1 0 0 5 0 10 8 0 0 0 1 0 2 0 1 0 0 1 0 3 0 0 0 0
V 16 0 1 13 2 142 1 13 98 8 0 32 0 0 0 7 0 8 0 0 0 0 0 389 0 0 0 0 0 0
A 69 3 1 13 0 6 268 0 114 13 0 69 27 1 0 3 12 0 0 0 352 0 0 0 0 1 0 0 0 11
G 0 10 14 1 1 2 5 0 66 3 64 0 0 19 5 1 0 0 0 0 0 367 24 0 0 0 0 0 409 0
P 0 0 0 26 13 8 0 281 1 60 0 0 8 8 0 0 0 0 0 0 0 0 0 0 0 26 0 401 0 401
412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412 412
 
 
 
Figure 68. Bubble graph representing the data for all picornavirus 2A-like sequences. Above, table 
showing the amount of the different amino acids in each position of the 30 amino acids sequence 
analyzed. Below, bubble graph; the bubbles represent the amino acids in each position. The size of the 
bubbles is related with the amount of amino acids in each position. The predominant amino acids are 
shown in colour. The data set analyzed is shown in Appendix 1, sequences 1 to 412 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13
12 11 10 9 8 7 6
5 4
3
2 1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 71 1 0 11 0 0 2 0 0 4 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0
K 1 269 8 185 0 0 9 0 3 284 0 0 0 0 0 0 0 0 283 0 0 0 0 0 0 0 0 0 0 0
H 188 10 1 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 0 0 39 0 1 0 0 54 1 0 0 0 0 0 3 0 0 1 0 0 0 0 0 290 0 0 0 0 0
D 0 0 5 0 6 0 0 0 2 0 0 1 0 0 0 275 0 0 0 0 0 0 290 0 0 0 0 0 0 0
Q 0 5 257 5 0 0 0 0 0 1 289 0 0 0 0 0 0 0 4 1 0 0 0 0 0 0 0 1 0 0
N 0 0 2 0 0 0 7 0 8 0 0 0 0 287 0 3 0 0 0 0 0 0 0 0 0 0 290 0 0 0
T 2 0 14 2 0 10 1 4 2 0 0 23 8 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
S 0 0 0 4 0 0 0 0 3 0 0 2 3 3 0 5 0 0 0 0 1 0 0 0 0 284 0 0 0 0
C 0 0 0 0 0 3 3 0 0 0 0 7 13 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 27 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 5 0 7 0 0 0 0 0 0 0 0 1 0 280 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 1 0 1 0 37 0 0 0 1 0 0 217 256 0 2 0 290 290 0 289 0 0 0 0 0 2 0 10 0 0
I 0 0 1 0 234 131 1 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
M 0 0 0 0 0 0 0 0 0 0 0 10 8 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0
V 0 0 1 0 0 142 0 6 98 0 0 24 0 0 0 0 0 0 0 0 0 0 0 289 0 0 0 0 0 0
A 0 0 0 10 0 0 262 0 114 0 0 6 1 0 0 3 0 0 0 0 289 0 0 0 0 0 0 0 0 11
G 0 0 0 1 1 0 5 0 5 0 1 0 0 0 0 1 0 0 0 0 0 290 0 0 0 0 0 0 288 0
P 0 0 0 26 12 0 0 273 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 279 0 279
290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290
 
 
 
 
Figure 69. Analysis of all the 2A-like sequences within aphthoviruses. Above, table showing the 
amount of the different amino acids in each position of the 30 amino acids sequence analyzed.  Cone 
graph, below, representing the results from the table. The data set analyzed is shown in Appendix 1, 
sequences 1 to 290. 
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 30 25 20 15 10 5 1
W
C
S
T
R
K
H
M
I
L
Y
F
P
V
G
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V
G
E
D
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D
Q
N N
S
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 71 1 0 11 0 0 2 0 0 4 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0
K 1 269 8 185 0 0 9 0 3 284 0 0 0 0 0 0 0 0 283 0 0 0 0 0 0 0 0 0 0 0
H 188 10 1 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 0 0 39 0 1 0 0 54 1 0 0 0 0 0 3 0 0 1 0 0 0 0 0 290 0 0 0 0 0
D 0 0 5 0 6 0 0 0 2 0 0 1 0 0 0 275 0 0 0 0 0 0 290 0 0 0 0 0 0 0
Q 0 5 257 5 0 0 0 0 0 1 289 0 0 0 0 0 0 0 4 1 0 0 0 0 0 0 0 1 0 0
N 0 0 2 0 0 0 7 0 8 0 0 0 0 287 0 3 0 0 0 0 0 0 0 0 0 0 290 0 0 0
T 2 0 14 2 0 10 1 4 2 0 0 23 8 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
S 0 0 0 4 0 0 0 0 3 0 0 2 3 3 0 5 0 0 0 0 1 0 0 0 0 284 0 0 0 0
C 0 0 0 0 0 3 3 0 0 0 0 7 13 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 27 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 5 0 7 0 0 0 0 0 0 0 0 1 0 280 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 1 0 1 0 37 0 0 0 1 0 0 217 256 0 2 0 290 290 0 289 0 0 0 0 0 2 0 10 0 0
I 0 0 1 0 234 131 1 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
M 0 0 0 0 0 0 0 0 0 0 0 10 8 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0
V 0 0 1 0 0 142 0 6 98 0 0 24 0 0 0 0 0 0 0 0 0 0 0 289 0 0 0 0 0 0
A 0 0 0 10 0 0 262 0 114 0 0 6 1 0 0 3 0 0 0 0 289 0 0 0 0 0 0 0 0 11
G 0 0 0 1 1 0 5 0 5 0 1 0 0 0 0 1 0 0 0 0 0 290 0 0 0 0 0 0 288 0
P 0 0 0 26 12 0 0 273 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 279 0 279
290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290 290
 
 
 
Figure 70. Bubble graph representing the data for aphthovirus 2A-like sequences. Above, table 
showing the amount of the different amino acids in each position of the 30 amino acids sequence 
analyzed. Below, bubble graph; the bubbles represent the amino acids in each position. The size of 
the bubbles is related with the amount of amino acids in each position. The predominant amino 
acids are shown in colour. The data set analyzed is shown in Appendix 1, sequences 1 to 290.   
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 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8
7 6
5 4
3
2
1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 64 0 0 11 0 0 2 0 0 4 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0
K 1 269 1 185 0 0 9 0 2 277 0 0 0 0 0 0 0 0 276 0 0 0 0 0 0 0 0 0 0 0
H 188 3 1 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 0 0 39 0 0 0 0 54 1 0 0 0 0 0 2 0 0 1 0 0 0 0 0 282 0 0 0 0 0
D 0 0 5 0 6 0 0 0 2 0 0 1 0 0 0 275 0 0 0 0 0 0 282 0 0 0 0 0 0 0
Q 0 5 257 5 0 0 0 0 0 0 282 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 1 0 0
N 0 0 2 0 0 0 0 0 1 0 0 0 0 279 0 3 0 0 0 0 0 0 0 0 0 0 282 0 0 0
T 2 0 14 1 0 3 1 4 2 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
S 0 0 0 4 0 0 0 0 3 0 0 2 3 3 0 0 0 0 0 0 1 0 0 0 0 277 0 0 0 0
C 0 0 0 0 0 3 3 0 0 0 0 0 13 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 5 0 0 0 0 0 0 0 0 0 0 1 0 279 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 0 0 0 0 37 0 0 0 1 0 0 217 256 0 2 0 282 282 0 282 0 0 0 0 0 2 0 10 0 0
I 0 0 1 0 234 131 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
M 0 0 0 0 0 0 0 0 0 0 0 10 8 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0
V 0 0 1 0 0 142 0 5 98 0 0 24 0 0 0 0 0 0 0 0 0 0 0 281 0 0 0 0 0 0
A 0 0 0 10 0 0 262 0 114 0 0 5 1 0 0 1 0 0 0 0 281 0 0 0 0 0 0 0 0 11
G 0 0 0 1 0 0 5 0 5 0 0 0 0 0 0 1 0 0 0 0 0 282 0 0 0 0 0 0 280 0
P 0 0 0 26 5 0 0 273 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 271 0 271
282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282
 
 
Figure 71. Analysis of the 2A-sequences within FMDV strains. Above, table showing the amount of 
the different amino acids in each position of the 30 amino acids sequence analyzed.  Cone graph, below, 
representing the results from the table. The data set analyzed is shown in Appendix 1, sequences 1 to 
282.  
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 64 0 0 11 0 0 2 0 0 4 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0
K 1 269 1 185 0 0 9 0 2 277 0 0 0 0 0 0 0 0 276 0 0 0 0 0 0 0 0 0 0 0
H 188 3 1 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 0 0 39 0 0 0 0 54 1 0 0 0 0 0 2 0 0 1 0 0 0 0 0 282 0 0 0 0 0
D 0 0 5 0 6 0 0 0 2 0 0 1 0 0 0 275 0 0 0 0 0 0 282 0 0 0 0 0 0 0
Q 0 5 257 5 0 0 0 0 0 0 282 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 1 0 0
N 0 0 2 0 0 0 0 0 1 0 0 0 0 279 0 3 0 0 0 0 0 0 0 0 0 0 282 0 0 0
T 2 0 14 1 0 3 1 4 2 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
S 0 0 0 4 0 0 0 0 3 0 0 2 3 3 0 0 0 0 0 0 1 0 0 0 0 277 0 0 0 0
C 0 0 0 0 0 3 3 0 0 0 0 0 13 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 5 0 0 0 0 0 0 0 0 0 0 1 0 279 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 0 0 0 0 37 0 0 0 1 0 0 217 256 0 2 0 282 282 0 282 0 0 0 0 0 2 0 10 0 0
I 0 0 1 0 234 131 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
M 0 0 0 0 0 0 0 0 0 0 0 10 8 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0
V 0 0 1 0 0 142 0 5 98 0 0 24 0 0 0 0 0 0 0 0 0 0 0 281 0 0 0 0 0 0
A 0 0 0 10 0 0 262 0 114 0 0 5 1 0 0 1 0 0 0 0 281 0 0 0 0 0 0 0 0 11
G 0 0 0 1 0 0 5 0 5 0 0 0 0 0 0 1 0 0 0 0 0 282 0 0 0 0 0 0 280 0
P 0 0 0 26 5 0 0 273 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 271 0 271
282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282 282
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Figure 72. Bubble graph representing the data for FMDV 2A sequences. Above, table showing the 
amount of the different amino acids in each position of the 30 amino acids sequence analyzed. Below, 
bubble graph; the bubbles represent the amino acids in each position. The size of the bubbles is related 
with the amount of amino acids in each position. The predominant amino acids are shown in colour. The 
data set analyzed is shown in Appendix 1, sequences 1 to 282. 
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 30 29 28 27 26 25 24 23 22 21 20 19 18 17
16 15
14
13 12
11
10
9
8
7
6
5
4
3
2
1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 0 2 0 0 0 10 0 0 7 0 0 0 0 0 0 0 1 0 7 0 0 0 0 0 0 0 0 0 0 0
K 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0
H 0 0 0 0 0 1 1 0 0 0 14 7 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0
E 0 0 4 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0
D 0 0 3 0 0 0 0 0 0 2 0 0 0 4 0 0 0 14 0 0 0 0 21 0 0 0 0 0 0 0
Q 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 2 0 0 0 0 0 0 0 0 0
N 0 0 0 0 0 0 0 0 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0
T 0 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 17 0 0 0 0
S 0 1 0 0 0 2 0 0 1 0 0 0 0 2 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0
C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 14 0 0 0 0 0 7 14 0 0 21 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 7 14 0 7 7 0 0 14 0 0 0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14 21 0 0 0 0 0 0 0 0 0 0
I 1 0 0 0 0 0 13 0 0 0 0 0 0 0 0 0 0 0 0 0 18 0 0 14 0 0 0 0 0 0
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 3 0 0 0 0
V 13 0 0 0 0 0 1 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0
A 0 0 0 0 0 0 6 0 0 13 0 0 21 1 0 0 12 0 0 0 0 0 0 0 0 1 0 0 0 0
G 0 2 14 0 0 2 0 0 0 3 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0
P 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 21
21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21
 
 
 
 
Figure 73. Analysis of the 2A-sequences within cardioviruses. Above, table showing the amount of 
the different amino acids in each position of the 30 amino acids sequence analyzed.  Cone graph, below, 
representing the results from the table. The data set analyzed is shown in Appendix 1, sequences 354 to 
374.  
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 0 2 0 0 0 10 0 0 7 0 0 0 0 0 0 0 1 0 7 0 0 0 0 0 0 0 0 0 0 0
K 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0
H 0 0 0 0 0 1 1 0 0 0 14 7 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0
E 0 0 4 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0
D 0 0 3 0 0 0 0 0 0 2 0 0 0 4 0 0 0 14 0 0 0 0 21 0 0 0 0 0 0 0
Q 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 2 0 0 0 0 0 0 0 0 0
N 0 0 0 0 0 0 0 0 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0
T 0 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 17 0 0 0 0
S 0 1 0 0 0 2 0 0 1 0 0 0 0 2 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0
C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 14 0 0 0 0 0 7 14 0 0 21 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 7 14 0 7 7 0 0 14 0 0 0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14 21 0 0 0 0 0 0 0 0 0 0
I 1 0 0 0 0 0 13 0 0 0 0 0 0 0 0 0 0 0 0 0 18 0 0 14 0 0 0 0 0 0
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 3 0 0 0 0
V 13 0 0 0 0 0 1 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0
A 0 0 0 0 0 0 6 0 0 13 0 0 21 1 0 0 12 0 0 0 0 0 0 0 0 1 0 0 0 0
G 0 2 14 0 0 2 0 0 0 3 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0
P 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 21
21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21
 
 
Figure 74. Bubble graph representing the data for cardiovirus 2A-like sequences. 
Above, table showing the amount of the different amino acids in each position of the 30 
amino acids sequence analyzed. Below, bubble graph; the bubbles represent the amino acids 
in each position. The size of the bubbles is related with the amount of amino acids in each 
position. The predominant amino acids are shown in colour. The data set analyzed is shown 
in Appendix 1, sequences 354 to 374. 
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 30 29 28 27 26 25 24
23 22 21
20 19 18
17 16
15 14
13
12
11
10
9
8
7
6
5
4
3
2
1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 0 0 0 6 0 0 0 0 0 1 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0
K 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 59 0 0 0 0 0 0 0 0 0 0 0
H 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 61 61 0 0 0 0
D 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 61 0 0 0 0 0 0 0
Q 0 0 0 0 0 0 0 61 0 0 0 0 0 0 0 0 0 0 0 60 0 0 0 0 0 0 0 0 0 0
N 1 0 0 0 0 0 0 0 0 0 0 0 0 60 0 0 0 0 0 0 0 0 0 0 0 0 61 0 0 0
T 6 0 60 39 0 15 0 0 0 0 0 0 57 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
S 0 0 0 0 0 32 0 0 0 0 0 0 3 1 0 61 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 0 0 0 0 0 33 0 0 0 0 0 0 0 61 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 0 2 0 0 14 1 21 0 0 0 0 0 0 0 0 0 61 61 0 0 0 0 0 0 0 0 0 0 0 0
I 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0
M 0 59 0 0 44 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
V 2 0 0 13 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 54 0 0 0 0 0 0
A 45 0 1 3 0 6 0 0 0 0 0 61 1 0 0 0 0 0 0 0 61 0 0 0 0 0 0 0 0 0
G 0 0 0 0 0 0 0 0 61 0 61 0 0 0 0 0 0 0 0 0 0 61 0 0 0 0 0 0 61 0
P 0 0 0 0 0 0 0 0 0 60 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 61 0 61
61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61
 
 
 
Figure 75. Analysis of all the 2A-like sequences within teschoviruses. Above, table showing the 
amount of the different amino acids in each position of the 30 amino acids sequence analyzed.  Cone 
graph, below, representing the results from the table. The data set analyzed is shown in Appendix 1, 
sequences 293 to 353.  
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 0 0 0 6 0 0 0 0 0 1 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0
K 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 59 0 0 0 0 0 0 0 0 0 0 0
H 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 61 61 0 0 0 0
D 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 61 0 0 0 0 0 0 0
Q 0 0 0 0 0 0 0 61 0 0 0 0 0 0 0 0 0 0 0 60 0 0 0 0 0 0 0 0 0 0
N 1 0 0 0 0 0 0 0 0 0 0 0 0 60 0 0 0 0 0 0 0 0 0 0 0 0 61 0 0 0
T 6 0 60 39 0 15 0 0 0 0 0 0 57 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
S 0 0 0 0 0 32 0 0 0 0 0 0 3 1 0 61 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 0 0 0 0 0 33 0 0 0 0 0 0 0 61 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 0 2 0 0 14 1 21 0 0 0 0 0 0 0 0 0 61 61 0 0 0 0 0 0 0 0 0 0 0 0
I 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0
M 0 59 0 0 44 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
V 2 0 0 13 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 54 0 0 0 0 0 0
A 45 0 1 3 0 6 0 0 0 0 0 61 1 0 0 0 0 0 0 0 61 0 0 0 0 0 0 0 0 0
G 0 0 0 0 0 0 0 0 61 0 61 0 0 0 0 0 0 0 0 0 0 61 0 0 0 0 0 0 61 0
P 0 0 0 0 0 0 0 0 0 60 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 61 0 61
61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61
 
 
 
Figure 76. Bubble graph representing the data for teschovirus 2A-like sequences. Above, table 
showing the amount of the different amino acids in each position of the 30 amino acids sequence 
analyzed. Below, bubble graph; the bubbles represent the amino acids in each position. The size of the 
bubbles is related with the amount of amino acids in each position. The predominant amino acids are 
shown in colour. The data set analyzed is shown in Appendix 1, sequences 293 to 353. 
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There is a clear pattern in all picornaviruses 2A-like sequences (figures 67, 
68). There is conservation from position 1 to 15 and it is notable that tryptophan is 
never observed in this region. This could be due to its bulky aromatic side chain, 
although phenylalanine is observed in the majority of sequences at position 16, 
although. tyrosine and asparagine are also observed in this position. 
Greater heterogeneity is observed from position 15 to 30: charged amino acids 
are predominant in the middle of the sequence whilst hydrophobic residues being 
more common at the N-terminus. Positions 27, 29 and 30 mostly are occupied by the 
hydrophilic residues, histidine and lysine.  There is a large predominance of leucine 
residues in positions 11, 13, 14, 15, 18 and 19, whereas position 12 is a lysine in most 
sequences.  
Aphthovirus 2A sequences are the most conserved (figures 69, 70), together 
with teschovirus 2A-like sequences (figures 75, 76). This is probably due to the 
presence of 3Cpro cleavage site. Position 19 and 20 in FMDV comprise a consensus 
sequence, which is the cleavage site for 3Cpro or more efficiently 3CDpro, to separate 
2A from 1D (Ryan et al., 1989).  This conserved amino acid pair is mostly glutamine 
and leucine at position 19 and 20, respectively (figures 71, 72). Conservation at these 
positions is also observed in teschoviruses (figures 75, 76), where the cleavage site is 
completely conserved at a glutamine/glycine (Q/G) pair (see section 4.5 for 
discussion).  
In contrast, cardiovirus 2A-like sequences are more heterogeneous. These 
sequences do not present any consensus motif at position 19, 20 since they are longer 
(~150aa) than tescho- and aphthoviruses (~19aa) and the C-terminal portion of 
cardiovirus 2A is not proteolytically cleaved from the remainder of 2A.  
Tryptophan seems to be avoided in this part of the sequence too. It is only 
present in two cases:  SVV (position 28) and ERBV-2 (position 27).  
 It is also remarkable the periodicity of aliphatic residues along 2A’s upstream 
sequence, mostly leucine and valine, which is consistent with the suggestions about 
2A’s structural model being in a helical conformation (Donnelly et al., 1997; Hahn & 
Palmenberg, 2001).  
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3.6.2 Mammalian 2A-like sequences 
 
Analysis on the mammalian 2A-like sequences shows a similar pattern to that 
observed in picornaviruses although with a higher range of heterogeneity. Neutral 
non-polar residues are predominant along the sequence, some of them being bulky 
aromatic residues, which are not found in picornaviruses (except phenylalanine at 
position 16). Phenylalanine is found in positions 18 and 27, whereas position 20 has, 
mostly, tyrosine. Moreover, tryptophan is also observed in a minority of sequences. 
The C-terminal motif (-DxExNPGP-) is highly conserved except in ADRV-N 
where there is a point mutation at the D8?C (table 8).  
The mammalian 2A-like amino acid sequences analyzed are shown in table 8, 
and the analyses, in figures 77 and 78. 
 
 
 Number of strainsGenera Species
New adult diarrhoea virus (ADRV-N)
Bovine rotavirus C (BoRV)
Porcine rotavirus C (PoRV)
Human rotavirus C (HuRV). 
Seneca virus Seneca valley virus (SVV) 1
8Seal picornavirus-1 (SePV-1)Unclassified
Reoviridae Cypovirus
Family
Picornaviridae
3
1
1
4
 
 
 
Table 7. Classification of mammalian 2A-like sequences. The table shows the families, genera, 
species and number of strains analysed. 
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  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
SVV                        DQ641257 R A W C P S M L P F R S Y K Q K M L M Q S G D I E T N P G
SePV-1                     EU152976 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G
SePV-1                     EU142040 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G
SePV-1                     EU152979 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G
SePV-1                     EU152978 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G
SePV-1                     EU152975 C G C F C P L P N V Y V P P T H N V L L D G D V E S N P G
SePV-1                     EU152974 C G C F C P L P N V Y V P P T H N V L L E G D V E S N P G
SePV-1                     EU152980 S G C F C P L P N V Y V P P I H N V L L D G D V E S N P G
SePV-1                     EU152977 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P R
ADRV-N                     AY632079 F F D S V W V Y H L A N S S W V R D L T R E C I E S N P G
ADRV-N (J19)            DQ113901 F F D S V W V Y H L A N S S W V R D L T R E C I E S N P G
ADRV-N (B219)        DQ168032 F F D S I W V Y H L A N S S W V R D L T R E C I E S N P G
Human-C (V508) AY941781 G V G Y P L I V A N S K F Q I D K I L I S G D I E L N P G
Human-C (V966) AY941782 G V G Y P L I V A N S K F Q I D K I L I S G D I E L N P G
Human-C (Bristol) AJ132203 G A G Y P L I V A N S K F Q I D K I L I S G D I E L N P G
Human-C (V460) AY941780 G T G Y P L I V A N S K F Q I D K I L I S G D I E L N P G
Bovine-C (Shintoku) L12390   G I G N P L I V A N S K F Q I D R I L I S G D I E L N P G
Porcine-C (Cowden) M69115   G N G N P L I V A N A K F Q I D K I L I S G D V E L N P G
Accession 
number
Species
 
                       
Table 8. Table showing the mammalian 2A-like sequences analyzed. The conserved amino acids 
at the C-terminal motif are highlighted in yellow, and the differences in the region are shown in 
red. 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17
16 15 14 13 12
11 10 9
8
7 6
5
4
3
2
1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 4 0 0 0 3 0 0 0 0 0 0 0 1 0
K 0 0 0 0 0 0 0 0 0 0 0 6 0 1 0 1 5 0 0 0 0 0 0 0 0 0 0 0 0 0
H 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 0 0 18 0 0 0 0 0
D 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 6 0 3 0 0 7 0 15 0 0 0 0 0 0 0
Q 0 0 0 0 0 0 0 0 0 0 0 0 0 6 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
N 0 1 0 2 0 0 0 0 8 6 0 3 0 0 0 0 8 0 0 0 0 0 0 0 0 0 18 0 0 0
T 0 1 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 3 0 0 0 0 0 1 0 0 0 0
S 6 0 0 3 0 1 0 0 0 0 5 1 3 3 0 0 0 0 0 0 7 0 0 0 0 11 0 0 0 0
C 2 0 8 1 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0
W 0 0 1 0 0 3 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 4 0 0 0 3 0 0 8 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 3 3 0 8 0 0 0 0 0 1 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 0 0 0 0 0 6 8 1 0 3 0 0 0 0 0 0 0 1 17 8 0 0 0 0 0 6 0 0 0 0
I 0 1 0 0 1 0 6 0 0 0 0 0 0 0 7 0 0 6 0 6 0 0 0 9 0 0 0 0 0 0
M 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0
V 0 2 0 0 2 0 3 6 0 8 0 8 0 0 0 3 0 8 0 0 0 0 0 9 0 0 0 0 0 0
A 0 2 0 0 0 0 0 0 6 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
G 6 8 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 15 0 0 0 0 0 0 17 0
P 0 0 0 0 7 8 0 8 1 0 0 0 8 8 0 0 0 0 0 0 0 0 0 0 0 0 0 18 0 18
18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18
 
 
Figure 77. Analisys of all the 2A-like sequences within Mammalian viruses. Above, table showing the 
amount of the different amino acids in each position of the 30 amino acids sequence analyzed.  Cone 
graph, below, representing the results from the table. The data set analyzed is shown in Appendix 1, 
sequences 404 to 421 
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  30 25 20 15 10 5 1
W
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F
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V
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E
D
E
D
Q
N N
S
A
V
G
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 4 0 0 0 3 0 0 0 0 0 0 0 1 0
K 0 0 0 0 0 0 0 0 0 0 0 6 0 1 0 1 5 0 0 0 0 0 0 0 0 0 0 0 0 0
H 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 0 0 18 0 0 0 0 0
D 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 6 0 3 0 0 7 0 15 0 0 0 0 0 0 0
Q 0 0 0 0 0 0 0 0 0 0 0 0 0 6 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
N 0 1 0 2 0 0 0 0 8 6 0 3 0 0 0 0 8 0 0 0 0 0 0 0 0 0 18 0 0 0
T 0 1 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 3 0 0 0 0 0 1 0 0 0 0
S 6 0 0 3 0 1 0 0 0 0 5 1 3 3 0 0 0 0 0 0 7 0 0 0 0 11 0 0 0 0
C 2 0 8 1 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0
W 0 0 1 0 0 3 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 4 0 0 0 3 0 0 8 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 3 3 0 8 0 0 0 0 0 1 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 0 0 0 0 0 6 8 1 0 3 0 0 0 0 0 0 0 1 17 8 0 0 0 0 0 6 0 0 0 0
I 0 1 0 0 1 0 6 0 0 0 0 0 0 0 7 0 0 6 0 6 0 0 0 9 0 0 0 0 0 0
M 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0
V 0 2 0 0 2 0 3 6 0 8 0 8 0 0 0 3 0 8 0 0 0 0 0 9 0 0 0 0 0 0
A 0 2 0 0 0 0 0 0 6 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
G 6 8 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 15 0 0 0 0 0 0 17 0
P 0 0 0 0 7 8 0 8 1 0 0 0 8 8 0 0 0 0 0 0 0 0 0 0 0 0 0 18 0 18
18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18
 
 
 
Figure 78. Bubble graph representing the data for 2A-like sequences within mammalian viruses. 
Above, table showing the amount of the different amino acids in each position of the 30 amino acids 
sequence analyzed. Below, bubble graph; the bubbles represent the amino acids in each position. The 
size of the bubbles is related with the amount of amino acids in each position. The predominant amino 
acids are shown in colour. The data set analyzed is shown in Appendix 1, sequences 404 to 421 
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3.6.3 Insect 2A-like sequences 
  
The analysis on the insect 2A-like sequences showed a similar pattern to that 
observed in picornaviruses, but with a much higher heterogeneity of residues in the 
upstream region, from position 10 to 30. Notable is the tract of amino acids with a 
preponderance of longer, aliphatic, sidechains (leucine, aspartate, glutamine, 
glutamate, lysine) observed in positions 11 to 14. 
The sequences analyzed are represented in table 8, and the analysis in figures 
79 and 80. 
 
 
 
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
EoPV-2A1 AY365064 G Q R T T E Q I V T A Q G W A P D L T Q D G D V E S N P G P
EoPV-2A2 AY365064 T R G G L Q R Q N I I G G G Q R D L T Q D G D I E S N P G P
EoPV-2A1 AY341824 G Q R T T E Q I V T A Q G W A P D L T Q D G D V E S N P G P
EoPV-2A2 AY341824 T R G G L Q R Q N I I G G G Q R D L T Q D G D I E S N P G P
PnPV-2A1 AF323747 G Q R T T E Q I V T A Q G W V P D L T V D G D V E S N P G P
PnPV-2A2 AF323747 T R G G L R R Q N I I G G G Q K D L T Q D G D I E S N P G P
IFV AB000906 P S I G N V A R T L T R A E I E D E L I R A G I E S N P G P
ABPV (U.K.) AF150629 T G F L N K L Y H C G S W T D I L L L L S G D V E T N P G P
ABPV (Poland-1) AF486073 T G F L N K L Y H C G S W T D I L L L L S G D V E T N P G P
ABPV (Hungary-1) AF486072 T G F L N K L Y H C G S W T D I L L L W S G D V E T N P G P
KBV AY275710 I G F L N K L Y K C G T W E S V L N L L A G D I E L N P G P
IAPV EF219380 I G F L N K L Y R C G D W D S I L L L L S G D I E E N P G P
CrPV AF218039 L V S S N D E C R A F L R K R T Q L L M S G D V E S N P G P
DCV (EB) AF014388 Q G I G K K N P K Q E A A R Q M L L L L S G D V E T N P G P
TaV AF062037 R G P R P Q N L G V R A E G R G S L L T C G D V E E N P G P
TaV AF282930 R G P R P Q N L G V R A E G R G S L L T C G D V E E N P G P
EeV AF461742 R R L P E S A Q L P Q G A G R G S L V T C G D V E E N P G P
PrV-2A1 AF548354 L E M K E S N S G Y V V G G R G S L L T C G D V E S N P G P
PrV-2A2 AF548354 N S D D E E P E Y P R G D P I E D L T D D G D I E K N P G P
PrV-2A3 AF548354 T L M G N I M T L A G S G G R G S L L T A G D V E K N P G P
D. punctatus CPV1 AY163248 M T A F D F Q Q A V F R S N Y D L L K L C G D V E S N P G P
D. punctatus CPV1 AY185594 M T A F D F Q Q A V F R S N Y D L L K L C G D V E S N P G P
L. dispar CPV1     AF389466 M T A F D F Q Q A V F R S N Y D L L K L C G D V E S N P G P
B. mori      AF433660 R T A F D F Q Q D V F R S N Y D L L K L C G D I E S N P G P
B. mori CPV1-H  AB035733 R T A F D F Q Q D V F R S N Y D L L K L C G D I E S N P G P
B. mori CPV1-I      AB035732 R T A F D F Q Q D V F R S N Y D L L K L C G D I E S N P G P
O. brumata CPV18 DQ192245 I H A N D Y Q M A V F K S N Y D L L K L C G D V E S N P G P
Accession 
number
Species
 
Table 8.  Representation  of all  the insect 2A-like sequences analysed. The conserved C-terminal 
motif is highlighted in yellow. 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 6 4 3 2 0 1 3 1 2 0 3 7 1 1 6 2 0 0 0 0 1 0 0 0 0 0 0 0 0 0
K 0 0 0 1 1 6 0 0 2 0 0 1 0 1 0 1 0 0 7 0 0 0 0 0 0 2 0 0 0 0
H 0 1 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 1 0 0 3 4 1 1 0 0 1 0 2 2 0 2 0 1 0 0 0 0 0 0 27 4 0 0 0 0
D 0 0 1 1 7 1 0 0 3 0 0 1 1 1 3 7 8 0 0 1 7 0 26 0 0 0 0 0 0 0
Q 1 3 0 0 0 4 10 10 0 1 1 3 0 0 4 0 1 0 0 5 0 0 0 0 0 0 0 0 0 0
N 1 0 0 1 8 0 4 0 3 0 0 0 0 7 0 0 0 1 0 0 0 0 0 0 0 0 27 0 0 0
T 7 6 0 3 3 0 0 1 1 3 1 1 0 3 0 1 0 0 7 5 0 0 0 0 0 4 0 0 0 0
S 0 2 1 1 0 2 0 1 0 0 0 4 7 0 2 0 5 0 0 0 6 0 0 0 0 16 0 0 0 0
C 0 0 0 0 0 0 0 1 0 5 0 0 0 0 0 0 0 0 0 0 11 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 5 3 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 0 1 0 5 1 1 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 0 5 6 0 6 0 0 0 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 2 1 1 5 3 0 5 2 2 1 0 1 0 0 0 0 13 25 12 12 0 0 0 0 0 1 0 0 0 0
I 3 0 2 0 0 1 0 3 0 3 3 0 0 0 2 4 0 0 0 1 0 0 0 10 0 0 0 0 0 0
M 3 0 2 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0
V 0 1 0 0 0 1 0 0 3 9 1 1 0 0 1 1 0 0 1 1 0 0 0 17 0 0 0 0 0 0
A 0 0 7 0 0 0 2 0 4 2 3 3 3 0 2 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0
G 3 8 3 6 0 0 0 0 3 0 6 5 8 8 0 5 0 0 0 0 0 26 1 0 0 0 0 0 27 0
P 1 0 2 1 2 0 1 1 0 2 0 0 0 1 0 3 0 0 0 0 0 0 0 0 0 0 0 27 0 27
27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27
 
 
Figure 79. Analisys of all the 2A-like sequences within insect viruses. Above, table showing the amount 
of the different amino acids in each position of the 30 amino acids sequence analyzed.  Cone graph, below, 
representing the results from the table. The data set analyzed is shown in Appendix 1, sequences 422 
to 448. 
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 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 6 4 3 2 0 1 3 1 2 0 3 7 1 1 6 2 0 0 0 0 1 0 0 0 0 0 0 0 0 0
K 0 0 0 1 1 6 0 0 2 0 0 1 0 1 0 1 0 0 7 0 0 0 0 0 0 2 0 0 0 0
H 0 1 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 1 0 0 3 4 1 1 0 0 1 0 2 2 0 2 0 1 0 0 0 0 0 0 27 4 0 0 0 0
D 0 0 1 1 7 1 0 0 3 0 0 1 1 1 3 7 8 0 0 1 7 0 26 0 0 0 0 0 0 0
Q 1 3 0 0 0 4 10 10 0 1 1 3 0 0 4 0 1 0 0 5 0 0 0 0 0 0 0 0 0 0
N 1 0 0 1 8 0 4 0 3 0 0 0 0 7 0 0 0 1 0 0 0 0 0 0 0 0 27 0 0 0
T 7 6 0 3 3 0 0 1 1 3 1 1 0 3 0 1 0 0 7 5 0 0 0 0 0 4 0 0 0 0
S 0 2 1 1 0 2 0 1 0 0 0 4 7 0 2 0 5 0 0 0 6 0 0 0 0 16 0 0 0 0
C 0 0 0 0 0 0 0 1 0 5 0 0 0 0 0 0 0 0 0 0 11 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 5 3 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 0 1 0 5 1 1 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 0 5 6 0 6 0 0 0 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 2 1 1 5 3 0 5 2 2 1 0 1 0 0 0 0 13 25 12 12 0 0 0 0 0 1 0 0 0 0
I 3 0 2 0 0 1 0 3 0 3 3 0 0 0 2 4 0 0 0 1 0 0 0 10 0 0 0 0 0 0
M 3 0 2 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0
V 0 1 0 0 0 1 0 0 3 9 1 1 0 0 1 1 0 0 1 1 0 0 0 17 0 0 0 0 0 0
A 0 0 7 0 0 0 2 0 4 2 3 3 3 0 2 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0
G 3 8 3 6 0 0 0 0 3 0 6 5 8 8 0 5 0 0 0 0 0 26 1 0 0 0 0 0 27 0
P 1 0 2 1 2 0 1 1 0 2 0 0 0 1 0 3 0 0 0 0 0 0 0 0 0 0 0 27 0 27
27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27
30 25 20 15 10 5 1 
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Figure 80. Bubble graph representing the data for insect 2A-like sequences. Above, table showing 
the amount of the different amino acids in each position of the 30 amino acids sequence analyzed. The 
bubbles represent the amino acids in each position. The size of the bubbles is related with the amount of 
amino acids in each position. The predominant amino acids are shown in colour. The data set analyzed 
is shown in Appendix 1, sequences 422 to 448. 
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3.6.4 Trypanosomal 2A-like sequences 
 
The sequences analyzed belong to T.cruzi (14 strains), T.brucei (3 strains), 
T.congolense (37 strains) and T.vivax (83 strains). The 2A-like sequences are 
represented in table 9. Not all are shown since the number of strains in some cases 
is very high:  a maximum of 17 strains are represented in the table. 
Trypanosomal 2A-like sequences show a similar pattern observed in 
picornaviruses although their C-terminal motif is not totally conserved and point 
mutations are present in a wide range of these 2A-like sequences (see table 9). 
Charged amino acids predominate at positions 16, 17, 19 and 23. A majority of 
neutral residues are found in the other positions, some of them being aromatic 
(tyrosine, tryptophan and phenylalanine) similar to that previously observed in 
insect 2A-like sequences.  
The tract of leucine residues (positions 12 to 15) is commonly flanked by a 
pair of basic residues at the N-terminal side, and a neutral residue (S) at the C-
terminal side, like in insect 2A-like sequences (C). This neutral residue is mostly 
followed by a glycine in both cases. 
It should be borne in mind that these non-LTR elements were active when 
transposed, but in many cases have accumulated mutations throughout evolution 
and become inactive. Indeed, the ‘age’ of such elements may be assessed by the 
accumulations of such mutations. 
 
The analyses are shown in figures 81 and 82.  
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 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
T.brucei CAA29181 R S L G T C K R A I S S I I R T K M L V S G D V E E N P G P
T.brucei CAD21861 R S L G T C Q R A I S S I I R T K M L L S G D V E E N P G P
T.brucei CAD21860 R S L G T C Q R A I S S I I R T K M L L S G D V E E N P G P
T.congo 354h04.q1k_6 I L P C T C G R A T L D A R R I L L L V S G D I E R N P G P
T.congo 335b10.q1k_3 I L P C T C G R A T L D A R R I L L L V S G D I E R N P G P
T.congo 432g10.q1k_7 I L P C T C G C A T L D A R R I L L L V S G D V E R N P G P
T.congo 400g12.q1k_4 I L P C T C G R T T L D A R R I L L L V S G D I E R N P G P
T.congo 876g11.p1k_3 I L P C T C G R T T L D A R R I L L L V S G D I E R N P G P
T.congo 1381h11.q1k_4 I V P C T C G R T T L D A R R I L L L V S G D I E R N P G P
T.congo 1071g10.p1k_14 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
T.congo 1294e07.p1k_3 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
T.congo 1473f10.p1k_5 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
T.congo 1305b04.p1k_2 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
T.congo 530f06.q1kbw_10 I L P C T C I C P T L E A R R L L V L V S G G I E R N P R P
T.congo 1463e05.p1k_0 A L S C V C G H G N S L L C R L L L F L S G D V E Y N P G S
T.congo 800b12.p1k_3 A L S C V C G H G N S L L C R L L L F L S G N V E Y N P G S
T.congo 47d01.q1k_6 A L S C V C G H G N S L L C R L L L F L S G N V E Y N P G S
T.congo 987a11.q1k_0 A L S C V C G H G N S L L C R L L L F L S G N V E Y N P G S
T.congo 1423d04.p1k_0 T L S C T C G S A L P K A L G P L L L L S R V E D H N P G P
T.congo 1182h09.q1k_0 F T C T C W R G R A L L C R P F L M P L S G D V G Q N P E P
T.cruzi AAA67559 Q P Y T Y C L R A L C D A Q R Q K L L L I G D I E Q N P G P
T.cruzi CAB41692 Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A R R Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A Q Q Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V R D A Q R Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A P Q Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I G Q N P G P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q N Q A P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q N P S P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q H P G P
T.cruzi Q R Y T Y R L R A V C D A R R Q K L L L S G D I E Q H P G P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L N G D I E Q H P G P
T.cruzi Q R Y T Y R L R A V Y D A Q R Q K L L L S G D I E Q H P G P
T.vivax 638g08.p1k_1 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
T.vivax 262a12.p1k_4 M L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
T.vivax 1734a06.p1k_4 M L P C A C G R A T L D A R R L T L L V S G D V E R D P G P
T.vivax 720g04.q1k_0 I L P C T C E R A T L D A R R L L L L I S G D V E R N P G P
T.vivax 814g01.p1k_9 T L P F A R W H I A L D M R R P L L L I S G D V D S K P G P
T.vivax 1814e03.p1k_1 L L P C T C G R A T L D A W R L L L L I C G G V G R N P G P
T.vivax 346a10.p1k_3 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
T.vivax 1198e11.p1k_1 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
T.vivax 104g02.p1k_0 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
T.vivax 961a05.q1k_2 I L P C T C G R A A L D A Q W R L L L I F V D A E R N P G P
T.vivax 1278c04.p1k_6 I L P C T C G R A A L D A Q W R L L L I F V D A E R N P G P
T.vivax 856h07.q1k_12 I L P C T R G R A M L S A R W L L L L I S G G V E R K P G P
T.vivax 1858e01.q1k_5 I L P F T C G R A A L D A W R L L L L I G G G V G R N P G P
T.vivax 158a04.q1k_12 I L P C L C V H A A S D A R W L L L L I S G D V E R R P C P
T.vivax 1890c02.p1k_12 M L L C T S G R A M L R A R W L L L L I S G D V E R D S G P
T.vivax 1013b08.p1k_5 S Q V R W S N G A E K K V Q R L L L L S G G D V E R N P G P
Accession 
numberSpecies
 
 
Table 9. Trypanosome 2A-like sequences. The C-terminal motif is highlighted in yellow and the 
differences in this region in red. Sequences without an accession number were taken from Heras et 
al., 2006. 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 3 17 0 7 1 27 3 110 1 13 1 6 1 84 110 11 0 0 2 0 5 7 0 0 0 91 1 0 1 0
K 1 0 1 0 0 0 1 0 0 0 2 4 0 0 0 1 22 0 0 0 0 0 0 0 6 0 4 0 0 0
H 0 1 4 0 0 0 0 8 0 0 0 0 13 0 0 1 0 0 0 0 0 0 0 0 0 3 4 0 0 0
E 0 1 0 0 0 1 3 0 0 1 0 6 1 0 0 0 0 0 0 0 0 1 0 3 115 3 0 0 1 0
D 0 0 0 0 0 0 0 0 0 0 0 97 0 0 0 0 0 0 0 0 2 0 114 0 4 0 8 0 0 0
Q 14 1 0 0 0 0 7 0 0 0 5 0 0 16 2 18 0 0 0 0 1 0 0 0 0 15 0 1 0 0
N 1 0 0 2 5 0 1 0 0 4 0 0 0 0 0 0 0 0 0 0 3 0 4 0 0 0 116 0 0 1
T 5 2 0 16 100 0 0 0 4 60 0 0 2 0 0 5 1 0 0 1 1 0 4 0 0 0 1 0 0 1
S 13 14 8 10 0 14 1 5 0 0 11 4 0 0 0 0 0 0 0 1 106 0 0 0 0 3 0 2 1 4
C 0 0 1 87 2 91 0 9 1 1 12 12 1 4 0 13 0 0 0 0 7 0 0 0 0 2 0 0 1 0
W 0 0 0 0 1 1 1 0 0 0 0 0 0 2 8 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
Y 1 0 14 1 14 0 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 4 0 0 0 0
F 1 2 1 4 0 1 0 0 0 0 0 0 0 0 0 5 0 1 17 0 2 0 0 0 0 0 0 0 0 0
L 13 96 20 2 1 0 27 0 1 9 89 5 5 11 0 59 95 128 109 29 0 0 0 0 0 13 0 0 0 0
I 69 0 0 0 0 0 1 0 1 3 0 0 3 3 0 17 0 0 0 70 4 0 0 24 0 0 2 0 0 0
M 9 0 0 0 1 0 0 0 0 7 0 0 1 0 0 0 0 4 0 0 0 0 0 0 0 0 1 0 0 0
V 2 2 1 0 5 1 1 0 12 16 13 0 7 13 0 0 0 3 1 30 0 17 3 107 0 0 0 0 1 0
A 5 0 5 0 7 0 0 2 112 20 0 1 103 1 1 1 13 1 0 4 0 0 1 3 0 3 0 1 2 2
G 0 0 0 3 0 1 91 2 4 2 0 2 0 0 14 0 0 0 0 0 6 112 11 0 12 0 0 0 129 0
P 0 1 82 5 0 0 0 0 1 1 3 0 0 3 2 6 6 0 8 1 0 0 0 0 0 0 0 133 0 129
137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137
 
 
Figure 81. Analisys of all the 2A-like sequences within Trypanosomes. Above, table showing the 
amount of the different amino acids in each position of the 30 amino acids sequence analyzed.  Cone 
graph, below, representing the results from the table. . The data set analyzed is shown in Appendix 1, 
sequences 449 to 585. 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 3 17 0 7 1 27 3 110 1 13 1 6 1 84 110 11 0 0 2 0 5 7 0 0 0 91 1 0 1 0
K 1 0 1 0 0 0 1 0 0 0 2 4 0 0 0 1 22 0 0 0 0 0 0 0 6 0 4 0 0 0
H 0 1 4 0 0 0 0 8 0 0 0 0 13 0 0 1 0 0 0 0 0 0 0 0 0 3 4 0 0 0
E 0 1 0 0 0 1 3 0 0 1 0 6 1 0 0 0 0 0 0 0 0 1 0 3 115 3 0 0 1 0
D 0 0 0 0 0 0 0 0 0 0 0 97 0 0 0 0 0 0 0 0 2 0 114 0 4 0 8 0 0 0
Q 14 1 0 0 0 0 7 0 0 0 5 0 0 16 2 18 0 0 0 0 1 0 0 0 0 15 0 1 0 0
N 1 0 0 2 5 0 1 0 0 4 0 0 0 0 0 0 0 0 0 0 3 0 4 0 0 0 116 0 0 1
T 5 2 0 16 100 0 0 0 4 60 0 0 2 0 0 5 1 0 0 1 1 0 4 0 0 0 1 0 0 1
S 13 14 8 10 0 14 1 5 0 0 11 4 0 0 0 0 0 0 0 1 106 0 0 0 0 3 0 2 1 4
C 0 0 1 87 2 91 0 9 1 1 12 12 1 4 0 13 0 0 0 0 7 0 0 0 0 2 0 0 1 0
W 0 0 0 0 1 1 1 0 0 0 0 0 0 2 8 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
Y 1 0 14 1 14 0 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 4 0 0 0 0
F 1 2 1 4 0 1 0 0 0 0 0 0 0 0 0 5 0 1 17 0 2 0 0 0 0 0 0 0 0 0
L 13 96 20 2 1 0 27 0 1 9 89 5 5 11 0 59 95 128 109 29 0 0 0 0 0 13 0 0 0 0
I 69 0 0 0 0 0 1 0 1 3 0 0 3 3 0 17 0 0 0 70 4 0 0 24 0 0 2 0 0 0
M 9 0 0 0 1 0 0 0 0 7 0 0 1 0 0 0 0 4 0 0 0 0 0 0 0 0 1 0 0 0
V 2 2 1 0 5 1 1 0 12 16 13 0 7 13 0 0 0 3 1 30 0 17 3 107 0 0 0 0 1 0
A 5 0 5 0 7 0 0 2 112 20 0 1 103 1 1 1 13 1 0 4 0 0 1 3 0 3 0 1 2 2
G 0 0 0 3 0 1 91 2 4 2 0 2 0 0 14 0 0 0 0 0 6 112 11 0 12 0 0 0 129 0
P 0 1 82 5 0 0 0 0 1 1 3 0 0 3 2 6 6 0 8 1 0 0 0 0 0 0 0 133 0 129
137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137 137
 
 
 
 
Figure 82. Bubble graph representing the data for trypanosomal 2A-like sequences. Above, table 
showing the amount of the different amino acids in each position of the 30 amino acids sequence 
analyzed. Below, bubble graph; the bubbles represent the amino acids in each position. The size of the 
bubbles is related with the amount of amino acids in each position. The predominant amino acids are 
shown in colour. The data set analyzed is shown in Appendix 1, sequences 449 to 585.   
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3.6.5 Strongylocentrotus purpuratus 2A-like sequences 
 
  The analyses were divided in two groups of 2A-like sequences: 
CATERPILLER sequences and non-LTR retrotransposons. Both groups show a 
pattern similar than picornavirus 2A sequences being the C-terminal motif more 
conserved in CATERPILLER 2As than non-LTR retrotransposons. A remarkable 
difference between the two types of 2A-like sequences should be noted; this is the 
distribution of amino acids surrounding the patch of leucine residues, which is 
observed in both cases (also observed in insect 2A-like sequences). Non-LTR 2A-like 
sequences comprise a patch of leucine residues at positions 11 to 14, flanked by 
neutral residues. In contrast, CATERPILLER 2A-like sequences, which have the tract 
of leucine residues at positions 12 to 15, possess a basic residue (K) and an acidic 
residue (E) at positions 11 and 16, respectively. This is consistent with their recently 
observed function as signal sequences (see discussion, section 4.4.2) 
The results of the analyses are represented in Tables 10 and 11 and figures 83, 84, 
85, 86. 
 
3.6.5.1 CATERPILLER sequences 
 
 
  
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
STR-20 XP_001196456 S K T D L I S G Q F P P L S E L L L L K S G D V E L N P G P
STR-50 GLEAN3_03186 S K T D L I S G Q I P H L S E L L L M K S G D V E L N P G P
STR-65 GLEAN3_09160 S K T E L M S G Q I P P L S E L L L L K S G D V E L N P G P
STR-70 GLEAN3_22394 S K T D L I S G Q I P S L S E L L L L K S G D V E L N P G P
STR-76 GLEAN3_03448 S K T D L I S G Q I P P L S K L L L L K S G D V E L N P G P
STR-81 GLEAN3_21478 S K T D L I S G Q I P P L S E L L L L K S G D V E L N P G P
STR-83 GLEAN3_22780 S K T D L I S G Q I P P L S E L L L M K S G D V E L N P G P
STR-100 GLEAN3_15340 S K T D L I S G Q I P P L S E L L L L K S G D V E L N P G P
STR-111 GLEAN3_20436 S K T D L I S G Q F P P L S E L L L L K S G D V E L N P G P
STR-127 GLEAN3_23550 S K T D L I S G Q I P P L S E L L L L K S G D V E L N P G P
STR-147 GLEAN3_11433 S K T D L I S G Q I P P L S E L L L L K S G D V E L N P G P
STR-23 XP_001198729 L H P A I L C S A S L C F R P Y L L L M A G D V E P N P G P
STR-35 XP_001200466 N S S C V L N I R S T S H L A I L L L L S G Q V E P N P G P
STR-54 GLEAN3_25204 S Q N I D V L S Q Q P Y L T E L L L V K A G D V E L N P G P
STR-60 GLEAN3_09111 Q N L D F N L Y L L M I L L M I L L M R S G D V E T N P G P
STR-67 GLEAN3_08283 P Q Q D L Q G F C L L Y L L M I L L M R S G D V E T N P G P
STR-82 GLEAN3_25914 T T D D P V V Q E S T C L P E M I L V K A G D V E Q N P G P
STR-106 GLEAN3_23532 L H P A I L C S A S L C F R P Y L L L M A G D V E P N P G P
STR-110 GLEAN3_06203 Q D L D V K E A D K P H I T Q S L I L K A G D V E S N P G P
STR-136 GLEAN3_20380 G A V D V V L S Q Q P Y L T E L L L V K A G D V E L N P G P
STR-143 GLEAN3_22449 S R P I L Y Y S N T T A S F Q L S T L L S G D I E P N P G P
Accession 
number
Species
 
 
Table 10. CATERPILLER 2A-like sequences analyzed within Strongylocentrotus purpuratus. 
C-terminal conserved motif is shown in yellow. 
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 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11
10 9 8 7
6 5
4
3
2
1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 0 1 0 0 0 0 0 0 1 0 0 0 0 2 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0
K 0 11 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 15 0 0 0 0 0 0 0 0 0 0
H 0 2 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 0 0 1 0 0 1 0 1 0 0 0 0 0 13 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0
D 0 1 1 15 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 20 0 0 0 0 0 0 0
Q 2 2 1 0 0 1 0 1 13 2 0 0 0 0 2 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0
N 1 1 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0
T 1 1 11 0 0 0 0 0 0 1 3 0 0 3 0 0 0 1 0 0 0 0 0 0 0 2 0 0 0 0
S 13 1 1 0 0 0 11 5 0 4 0 2 1 11 0 1 1 0 0 0 15 0 0 0 0 1 0 0 0 0
C 0 0 0 1 0 0 2 0 1 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 0 1 1 1 0 0 0 3 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 0 0 0 1 0 0 1 0 2 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 2 0 2 0 13 3 3 0 1 2 3 0 16 3 0 14 19 19 14 2 0 0 0 0 0 13 0 0 0 0
I 0 0 0 2 2 10 0 1 0 9 0 1 1 0 0 3 1 1 0 0 0 0 0 1 0 0 0 0 0 0
M 0 0 0 0 0 1 0 0 0 0 1 0 0 0 2 1 0 0 4 2 0 0 0 0 0 0 0 0 0 0
V 0 0 1 0 3 3 1 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 20 0 0 0 0 0 0
A 0 1 0 2 0 0 0 1 2 0 0 1 0 0 1 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0
G 1 0 0 0 0 0 1 11 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 21 0
P 1 0 3 0 1 0 0 0 0 0 14 9 0 1 2 0 0 0 0 0 0 0 0 0 0 4 0 21 0 21
21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21
 
Figure 83. Analisys of the CATERPILLER 2A-like sequences within Strongylocentrotus purpuratus. 
Above, table showing the amount of the different amino acids in each position of the 30 amino acids 
sequence analyzed.  Cone graph, below, representing the results from the table. . The data set analyzed is 
shown in Appendix 1, sequences 586 to 606.  
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 0 1 0 0 0 0 0 0 1 0 0 0 0 2 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0
K 0 11 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 15 0 0 0 0 0 0 0 0 0 0
H 0 2 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E 0 0 0 1 0 0 1 0 1 0 0 0 0 0 13 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0
D 0 1 1 15 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 20 0 0 0 0 0 0 0
Q 2 2 1 0 0 1 0 1 13 2 0 0 0 0 2 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0
N 1 1 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0
T 1 1 11 0 0 0 0 0 0 1 3 0 0 3 0 0 0 1 0 0 0 0 0 0 0 2 0 0 0 0
S 13 1 1 0 0 0 11 5 0 4 0 2 1 11 0 1 1 0 0 0 15 0 0 0 0 1 0 0 0 0
C 0 0 0 1 0 0 2 0 1 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 0 1 1 1 0 0 0 3 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 0 0 0 1 0 0 1 0 2 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 2 0 2 0 13 3 3 0 1 2 3 0 16 3 0 14 19 19 14 2 0 0 0 0 0 13 0 0 0 0
I 0 0 0 2 2 10 0 1 0 9 0 1 1 0 0 3 1 1 0 0 0 0 0 1 0 0 0 0 0 0
M 0 0 0 0 0 1 0 0 0 0 1 0 0 0 2 1 0 0 4 2 0 0 0 0 0 0 0 0 0 0
V 0 0 1 0 3 3 1 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 20 0 0 0 0 0 0
A 0 1 0 2 0 0 0 1 2 0 0 1 0 0 1 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0
G 1 0 0 0 0 0 1 11 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 21 0
P 1 0 3 0 1 0 0 0 0 0 14 9 0 1 2 0 0 0 0 0 0 0 0 0 0 4 0 21 0 21
21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21
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Figure 84. Bubble graph representing the data for CATERPILLER 2A-like sequences within 
Strongylocentrotus purpuratus. Above, table showing the amount of the different amino acids in each 
position of the 30 amino acids sequence analyzed.  Bubble graph, below; the bubbles represent the 
amino acids in each position. The size of the bubbles is related with the amount of amino acids in each 
position. The predominant amino acids are shown in colour. . The data set analyzed is shown in 
Appendix 1, sequences 586 to 606. 
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 3.6.5.2 Non-LTR sequences 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
STR-1 XP_797143 N S T P A A M F V C A F I L I S V L L L S G D V E I N P G P
STR-34 XP_001196844 N S T P A A M F V C V F I L I S V L L L S G D V E I S P G P
STR-24 XP_001196407 S Q R D L S C S Q P R T I I L G L I M C A G D V Q P N P G P
STR-25 XP_001186348 S Q R D L S C S Q P R T I I L G L I M C A G D V Q P N P G P
STR-32 XP_001185404 N S S C V L N I R S T S H L A I L L L L S G Q V E P N P G P
STR-35 XP_001200466 N S S C V L N I R S T S H L A I L L L L S G Q V E P N P G P
STR-164 XR_025775 N S S C V L N I R S T S H L A I L L L L S G Q V E P N P G P
STR-27 XP_001185149 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
STR-28 XP_001179204 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
STR-29 XP_791376 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
STR-30 XP_001199602 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
STR-31 XP_001200060 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
STR-33 XP_001184905 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
STR-36 XP_001180489 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
STR-163 XP_001192137 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P D P
STR-116/160 XR_026225 T T C Q C K A L S V M Y L T L L L L T N A S D I E L N P G P
STR-40/141 GLEAN3_18025 K S C I S Y Y S N S T A C F N I E I M C C G D V K S N P G P
STR-55 GLEAN3_24854 G A R I S Y H P N T T A T F Q L R L L V S G D V N P N P G P
STR-61 GLEAN3_22393 G A R I R Y Y N N S S A T F Q T I L M T C G D V D P N P G P
STR-89 GLEAN3_19055 G R R I Q Y Y N N S I S T F R S E L L R C G D V E S N P G P
STR-38 XP_793501 K T R I P Y S V N S N A S F Q L E L L H A G D V H P N P G P
STR-51 GLEAN3_22449 S R P I L Y Y S N T T A S F Q L S T L L S G D I E P N P G P
STR-69 GLEAN3_27016 C R R I A Y Y S N S D C T F R L E L L K S G D I Q S N P G P
STR-133 GLEAN3_00868 K R R I P Y N P N S T A S F Q L E L L H A G D V H P N P G P
Accession 
number
Species
 
Table 11. Non-LTR 2A-like sequences analyzed within Strongylocentrotus purpuratus. The C-terminal 
conserved amino acids are highlighted in yellow, and the differences in this region are shown in red. 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11
10 9 8 7
6 5
4
3
2
1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 0 4 8 0 1 0 8 0 3 0 2 0 0 0 2 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0
K 3 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0
H 0 0 0 0 0 0 1 0 0 0 0 0 11 0 0 0 0 0 0 2 0 0 0 0 2 0 0 0 0 0
E 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 16 0 0 0 0 0
D 0 0 0 2 8 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 13 0 1 0 0 0 1 0
Q 0 2 0 1 1 0 0 0 2 0 0 0 0 0 5 0 0 0 0 0 0 0 11 0 3 0 0 0 0 0
N 5 0 0 0 0 0 4 2 8 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 23 0 0 0
T 1 2 2 0 0 0 0 0 8 2 7 2 4 1 8 1 0 1 1 1 0 0 0 0 0 8 0 0 0 0
S 3 6 3 0 2 2 1 13 1 17 1 12 3 0 0 3 1 0 0 0 16 1 0 0 0 3 1 0 0 0
C 1 8 2 3 1 0 2 0 0 2 0 1 1 0 0 0 0 0 0 3 3 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 0 8 5 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 0 0 0 0 8 0 2 0 0 0 2 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 8 0 0 8 3 3 0 1 0 0 8 0 1 13 3 6 14 20 19 14 0 0 0 0 0 1 0 0 0 0
I 0 0 0 8 0 0 0 3 0 0 1 0 4 2 2 12 1 3 0 0 0 0 0 3 0 2 0 0 0 0
M 0 0 0 0 0 0 2 0 0 0 1 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0
V 0 0 0 0 3 0 0 1 2 1 1 0 0 0 0 0 2 0 0 1 0 0 0 21 0 0 0 0 0 0
A 0 2 0 0 3 2 1 0 0 0 1 6 0 0 3 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0
G 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 23 0 0 0 0 0 0 23 0
P 0 0 9 2 2 0 0 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10 0 24 0 24
24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24
 
 
Figure 85. Analisys of the non-LTR 2A-like sequences within Strongylocentrotus purpuratus. Above, 
table showing the amount of the different amino acids in each position of the 30 amino acids sequence 
analyzed.  Cone graph, below, representing the results from the table. The data set analyzed is shown in 
Appendix 1, sequences 607 to 630. 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 0 4 8 0 1 0 8 0 3 0 2 0 0 0 2 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0
K 3 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0
H 0 0 0 0 0 0 1 0 0 0 0 0 11 0 0 0 0 0 0 2 0 0 0 0 2 0 0 0 0 0
E 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 16 0 0 0 0 0
D 0 0 0 2 8 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 13 0 1 0 0 0 1 0
Q 0 2 0 1 1 0 0 0 2 0 0 0 0 0 5 0 0 0 0 0 0 0 11 0 3 0 0 0 0 0
N 5 0 0 0 0 0 4 2 8 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 23 0 0 0
T 1 2 2 0 0 0 0 0 8 2 7 2 4 1 8 1 0 1 1 1 0 0 0 0 0 8 0 0 0 0
S 3 6 3 0 2 2 1 13 1 17 1 12 3 0 0 3 1 0 0 0 16 1 0 0 0 3 1 0 0 0
C 1 8 2 3 1 0 2 0 0 2 0 1 1 0 0 0 0 0 0 3 3 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 0 8 5 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 0 0 0 0 0 8 0 2 0 0 0 2 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L 8 0 0 8 3 3 0 1 0 0 8 0 1 13 3 6 14 20 19 14 0 0 0 0 0 1 0 0 0 0
I 0 0 0 8 0 0 0 3 0 0 1 0 4 2 2 12 1 3 0 0 0 0 0 3 0 2 0 0 0 0
M 0 0 0 0 0 0 2 0 0 0 1 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0
V 0 0 0 0 3 0 0 1 2 1 1 0 0 0 0 0 2 0 0 1 0 0 0 21 0 0 0 0 0 0
A 0 2 0 0 3 2 1 0 0 0 1 6 0 0 3 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0
G 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 23 0 0 0 0 0 0 23 0
P 0 0 9 2 2 0 0 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10 0 24 0 24
24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24
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Figure 86. Bubble graph representing the data for non-LTR 2A-like sequences within 
Strongylocentrotus purpuratus. Above, table showing the amount of the different amino acids in each 
position of the 30 amino acids sequence analyzed. Below, bubble graph; the bubbles represent the amino 
acids in each position. The size of the bubbles is related with the amount of amino acids in each 
position. The predominant amino acids are shown in colour. The data set analyzed is shown in Appendix 
1, sequences 607 to 630. 
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3.6.6 Non-LTR 2A-like sequences 
 
 All the non-LTR 2A-like sequences within Trypanosomes and 
Strongylocentrotus purpuratus were analyzed together. The distribution of amino 
acids is very similar in both cases, with a tract of leucine residues at positions 12 to 
15.  This hydrophobic tract is very commonly flanked at its N-terminus by a pair of 
basic residues and at the C-terminus by either serine or cystine (hydroxyl or 
sulphydryl groups). The majority of the residues present are neutral, polar or non-
polar, except in positions 12, 17 and 23, where arginine predominates. 
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R
K
H
E
D
Q
N
T
S
C
W
Y
F
L
I
M
V
A
G
P
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 3 21 8 7 2 27 11 110 4 13 3 6 1 84 112 11 1 0 2 1 5 7 0 0 0 91 1 0 1 0
K 4 0 1 0 0 1 1 0 0 0 2 4 0 0 0 1 22 0 0 1 0 0 0 0 7 0 4 0 0 0
H 0 1 4 0 0 0 1 8 0 0 0 0 24 0 0 1 0 0 0 2 0 0 0 0 2 3 4 0 0 0
E 0 1 0 0 0 1 3 0 0 1 0 6 1 0 0 0 5 0 0 0 0 1 0 3 131 3 0 0 1 0
D 0 0 0 2 8 0 0 0 0 0 1 97 0 0 0 0 0 0 0 0 2 0 127 0 5 0 8 0 1 0
Q 14 3 0 1 1 0 7 0 2 0 5 0 0 16 7 18 0 0 0 0 1 0 11 0 3 15 0 1 0 0
N 6 0 0 2 5 0 5 2 8 4 1 0 0 0 1 0 0 0 0 1 3 0 4 0 1 0 139 0 0 1
T 6 4 2 16 100 0 0 0 12 62 7 2 6 1 8 6 1 1 1 2 1 0 4 0 0 8 1 0 0 1
S 16 20 11 10 2 16 2 18 1 17 12 16 3 0 0 3 1 0 0 1 122 1 0 0 0 6 1 2 1 4
C 1 8 3 90 3 91 2 9 1 3 12 13 2 4 0 13 0 0 0 3 10 0 0 0 0 2 0 0 1 0
W 0 0 0 0 1 1 1 0 0 0 0 0 0 2 8 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
Y 1 0 14 1 14 8 5 1 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 4 0 0 0 0
F 1 2 1 4 0 9 0 2 0 0 0 2 0 8 0 5 0 1 17 0 2 0 0 0 0 0 0 0 0 0
L 21 96 20 10 4 3 27 1 1 9 97 5 6 24 3 65 109 148 128 43 0 0 0 0 0 14 0 0 0 0
I 69 0 0 8 0 0 1 3 1 3 1 0 7 5 2 29 1 3 0 70 4 0 0 27 0 2 2 0 0 0
M 9 0 0 0 1 0 2 0 0 7 1 0 1 0 0 0 0 4 4 0 0 0 0 0 0 0 1 0 0 0
V 2 2 1 0 8 1 1 1 14 17 14 0 7 13 0 0 2 3 1 31 0 17 3 128 0 0 0 0 1 0
A 5 2 5 0 10 2 1 2 112 20 1 7 103 1 4 1 13 1 0 4 5 0 1 3 0 3 0 1 2 2
G 3 0 0 3 0 1 91 2 4 2 0 2 0 0 14 2 0 0 0 0 6 135 11 0 12 0 0 0 152 0
P 0 1 91 7 2 0 0 2 1 3 3 0 0 3 2 6 6 0 8 1 0 0 0 0 0 10 0 157 0 153
161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161
 
Figure 87. Analisys of all the non-LTR 2A-like sequences within Trypanosomes and 
Strongylocentrotus purpuratus. Above, table showing the amount of the different amino acids in each 
position of the 30 amino acids sequence analyzed.  Cone graph, below, representing the results from the 
table. The data set analyzed is shown in Appendix 1, sequences from 449 to 585 and from 607 to 630.  
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30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
R 3 21 8 7 2 27 11 110 4 13 3 6 1 84 112 11 1 0 2 1 5 7 0 0 0 91 1 0 1 0
K 4 0 1 0 0 1 1 0 0 0 2 4 0 0 0 1 22 0 0 1 0 0 0 0 7 0 4 0 0 0
H 0 1 4 0 0 0 1 8 0 0 0 0 24 0 0 1 0 0 0 2 0 0 0 0 2 3 4 0 0 0
E 0 1 0 0 0 1 3 0 0 1 0 6 1 0 0 0 5 0 0 0 0 1 0 3 131 3 0 0 1 0
D 0 0 0 2 8 0 0 0 0 0 1 97 0 0 0 0 0 0 0 0 2 0 127 0 5 0 8 0 1 0
Q 14 3 0 1 1 0 7 0 2 0 5 0 0 16 7 18 0 0 0 0 1 0 11 0 3 15 0 1 0 0
N 6 0 0 2 5 0 5 2 8 4 1 0 0 0 1 0 0 0 0 1 3 0 4 0 1 0 139 0 0 1
T 6 4 2 16 100 0 0 0 12 62 7 2 6 1 8 6 1 1 1 2 1 0 4 0 0 8 1 0 0 1
S 16 20 11 10 2 16 2 18 1 17 12 16 3 0 0 3 1 0 0 1 122 1 0 0 0 6 1 2 1 4
C 1 8 3 90 3 91 2 9 1 3 12 13 2 4 0 13 0 0 0 3 10 0 0 0 0 2 0 0 1 0
W 0 0 0 0 1 1 1 0 0 0 0 0 0 2 8 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
Y 1 0 14 1 14 8 5 1 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 4 0 0 0 0
F 1 2 1 4 0 9 0 2 0 0 0 2 0 8 0 5 0 1 17 0 2 0 0 0 0 0 0 0 0 0
L 21 96 20 10 4 3 27 1 1 9 97 5 6 24 3 65 109 148 128 43 0 0 0 0 0 14 0 0 0 0
I 69 0 0 8 0 0 1 3 1 3 1 0 7 5 2 29 1 3 0 70 4 0 0 27 0 2 2 0 0 0
M 9 0 0 0 1 0 2 0 0 7 1 0 1 0 0 0 0 4 4 0 0 0 0 0 0 0 1 0 0 0
V 2 2 1 0 8 1 1 1 14 17 14 0 7 13 0 0 2 3 1 31 0 17 3 128 0 0 0 0 1 0
A 5 2 5 0 10 2 1 2 112 20 1 7 103 1 4 1 13 1 0 4 5 0 1 3 0 3 0 1 2 2
G 3 0 0 3 0 1 91 2 4 2 0 2 0 0 14 2 0 0 0 0 6 135 11 0 12 0 0 0 152 0
P 0 1 91 7 2 0 0 2 1 3 3 0 0 3 2 6 6 0 8 1 0 0 0 0 0 10 0 157 0 153
161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161 161
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Figure 88. Bubble graph representing the data for all the non-LTR 2A-like sequences within 
Trypanosomes and Strongylocentrotus purpuratus. Above, table showing the amount of the different 
amino acids in each position of the 30 amino acids sequence analyzed. Below, bubble graph; the bubbles 
represent the amino acids in each position. The size of the bubbles is related with the amount of amino 
acids in each position. The predominant amino acids are shown in colour. The data set analyzed is 
shown in Appendix 1, sequences from 449 to 585 and from 607 to 630. 
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4. DISCUSSION 
 
 
4.1 Development of a bacterial screen for 2A activity  
  
This work is based on the observation that some nascent peptides may regulate 
translation by interacting with the ribosome exit tunnel during translation. This has 
not only been observed in eukaryotic systems (Delbecq, et al., 2000; Bachursky et al., 
1994) but also in prokaryotic organisms (Harrod & Lovett, 1994; Nakatogawa and Ito, 
2002). Some examples of nascent peptides that interact with the ribosome exit tunnel 
are presented in table 12 (adapted from Tenson and Ehrenberg, 2002). 
These findings repudiate earlier assumptions of the ribosome exit tunnel being 
a ‘neutral’ path that does not interact with nascent peptides during translation. It is 
now clear that the ribosome plays an active role in sequence-specific gating of nascent 
peptides and in responding to cellular signals. These interactions not only affect 
protein elongation but also peptide termination (Lovett & Rogers, 1996). The 
molecular mechanisms of such interactions and of the ribosome response are currently 
unknown. Recent studies have, however, revealed elements of the tunnel which might 
be involved in ‘sensing’ the nascent-peptide sequence. In the case of prokaryotes, at 
approximately one-third of the tunnel length from the peptidyltransferase centre 
(PTC), the nascent peptide reaches a constriction formed by the tunnel walls formed 
by the extensions of two ribosomal proteins, L22 and L4, which are exposed in the 
lumen from opposite walls of the tunnel. In prokaryotes, this region seems to be the 
most crucial, whereas, in eukaryotes, other segments of the tunnel might also be 
involved in the ribosomal response (Rospert, 2004; Johnson, 2005).   
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Nascent peptides causing ribosome stalling
Gene Organism Active sequence Co-effector
Cat / cmlA eubacteria VKTD/KNAD                              chloramphenicol
ermC eubacteria SFVI                                            erythromycin                          
tnaC eubacteria KWFNID                                      tryptophan
secM eubacteria FXXXXWIXXXXGIRAGP            membrane trasnlocation
(SecA)
CPA1                          yeast                      NSQYTCQDYISDHIWKTS          arginine
arg fungi                      PSXFTSQDYXSDHLWXAX         arginine
AdoMet mammals                MAGDIS            spermidne
Gene 60                    bacteriophage T4       KYKLQNNVRRSIKSSSM          No co-effector
Other active nascent peptides
Gene Organism Active sequence Co-effector
ß-Tubulin eukaryotes                  MREI             unknown
Export signal             universal                          Signal recognition 
particle (SRP)
                        
Adapted from Tenson & Ehrenberg, 2002 
  
  
Table 12. Examples of Active Nascent peptides  
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The motif FxxxxWIxxxxGIRAGP (x being any amino acid) was shown to 
induce elongation arrest in E. coli while SecM protein was being synthesized 
(Nakatogawa and Ito, 2002). This sequence also hindered translation elongation in E. 
coli when present in the unrelated sequence of LacZα protein (Nakatogawa and Ito, 
2002), demonstrating that its action is independent of the sequence context around 
this motif.  The proline (P), tryptophan (W) and isoleucine (I) were identified to be 
the main residues involved in ribosome stalling. P incorporation in the nascent chain 
allows W and I to reach the L22 ß-hairpin protein, triggering its rearrangement and 
thus inducing elongation arrest of the nascent peptide (Berisio et al., 2003). 
Consistent with these studies are the findings made by Gong and Yanofsky 
(2002) on the E. coli tryptophanase (tnaC) operon, which stalls the ribosome at the 
last sense codon of tnaC in the presence of a high concentration of tryptophan. The 
model put forward by Gong and Yanofsky postulates that specific interactions of the 
nascent peptide with the exit tunnel generate a tryptophan-binding site at, or near, the 
A-site in the large ribosomal subunit. Binding of tryptophan at this site might hinder 
functions of the PTC, thus, preventing termination and release of the nascent tnaC 
peptide from the tRNA. Mutational analyses have revealed P24, the C-terminal 
proline, K11 and W12 to be involved in the ribosome stalling. K11 could be cross-
linked to A750 in the loop of the helix 35 of 23S rRNA, which is located at the PTC 
and contains the peptidyl bond synthesis activity at the central loop in domain V 
(Nissen et al., 2000). In contrast,W12 may interact with L22 once the P24 is being 
translated, suggesting the importance of the position of W and also the spacing 
between P and W, which seems to be crucial for elongation arrest of the nascent 
peptide. Mutations near the tip of the ß-hairpin of protein L22 alter the stalling effects 
(Berisio et al., 2003). All these findings suggest that the exact position of the nascent 
peptide in the tunnel might depend on the peptide sequence.  Therefore, having the 
right residues at the right positions on 2A sequence, we may be able to create the right 
interactions between the 2A oligopeptide and the prokaryotic ribosomal exit tunnel, 
which would lead to the ‘ribosome skipping’  mechanism observed in eukaryotes. 
A remarkable point is that in both tnaC and SecM, stalling occurs at the 
proline, underscoring the importance of the C-terminal P residue, which, in the stalled 
complex resides in the peptidyl-transferase active site and is still linked to the tRNA 
moiety. Furthermore, in both tnaC and SecM nascent peptides, a tryptophan residue, 
located 11 and 10 amino acids from the C-terminal proline, in tnaC and SecM, 
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respectively, is crucial for stalling. Mutations in the loop of helix 35 of 23S rRNA or 
in the tip of the L22 ß-hairpin, abolish ribosome stalling at both nascent peptides. 
However, a mutation at A2058, which is also located in the tunnel, has a profound 
effect on the ribosome response to SecM, but it does not greatly affect the tryptophan-
induced stalling (Mankin, 2006). Potentially, different placement of SecM and tnaC in 
the exit tunnel might explain the involvement of different rRNA and protein positions 
in the ribosome stalling. It must also be mentioned that these two nascent peptides 
stalling action leads to different outcomes. Sec M stalling interferes in elongation of 
translation, whereas tnaC stalls at the last sense codon and fails to terminate 
translation (Mankin, 2006).   
It is an interesting fact that the W residue is not present in any region of the 
FMDV 2A oligopeptide or the majority of Eukaryotic 2A-like sequences, excepting 
some insect and trypanosome 2A-like sequences, where the W is in a minority of 
these sequences (see section 4.5, Bionformatic analysis). This suggests that W is 
disfavoured residue for these nascent peptide-ribosome interactions: it may, however, 
play a role in these interactions in some insect ribosomes or at least does not hamper 
2A mechanism of action. It should be remarked that eukaryotic ribosomes are not 
only different from prokaryotic ribosomes but also present distinctive features among 
different origins (insect, trypanosomes, mammals, yeast, etc).  
Could the fact that FMDV 2A does not comprise W residues in the sequence 
disfavour the interaction of 2A nascent peptide with the prokaryotic ribosome exit 
tunnel? It could that be one of the reasons for lack of 2A activity in prokaryotic 
systems, having seen these two striking examples of two sequences (SecM, tnaC) 
containing W in conserved positions, and being able to stall prokaryotic ribosomes?  
A good approach to test the effect of W residues in the interaction between 2A 
and the ribosome would be to change several amino acids from the upstream 2A 
region, for W residues to see the effect in 2A’s activity and compare it between 
eukaryotic and prokaryotic systems. However, having the right interactions may not 
be the only important factor involved in 2A’s activity. Other factors that seem to be 
involved are also discussed here. 
 
 
 
 166
 4.1.1 Predicted model of 2A oligopeptide within the ribosome 
 
2A oligopeptide predicted model structure shows 2A forming an N-terminal α-
helix with a tight-turn at its C-terminus (Ryan et al., 1999). This is consistent with 
previous studies, where analysis searching for sterically allowed conformations within 
the ribosome exit tunnel predicted a unique solution: the α-helical conformation. The 
α-helix possesses a required rigidity for pushing the nascent peptide through the 
ribosome during translocation and it is also geometrically the most suitable 
conformation, being the most self-saturated structure with hydrogen bonds and, 
thermodynamically, the most stable single-stranded structure, universal for any amino 
acid sequence (Lim & Spirin, 1986). 
The mechanism by which ribosomes function as molecular machines is one of 
the paramount unsolved problems of molecular biology. Advancements toward 
ribosome structure at high levels of resolution hold great promise of providing a 
structural basis of understanding the details of the reactions that are involved. A 
tunnel, in the large ribosomal subunit, was first detected in Bacillus 
stearothermophilus ribosomes (Yonath et al., 1987). The tunnel was estimated to have 
a diameter of about 24Ǻ and a length of 100-120Ǻ, starting from a point at the region 
in which the PTC has been located (Yonath et al., 1987), and predicted to be able to 
accommodate 40 amino acids (Hardesty & Krammer, 2001). The PTC is located at 
the interface side of the 30 and 50 S ribosomal subunits close to the base of the central 
protuberance (5S RNA) (Oakes et al., 1990).  
These findings are consistent with the 2A structural model, where the length 
of the proposed helical region of 2A sequence (~15aa) is some 27Ǻ, which could be 
entirely accommodated within the exit tunnel of the ribosome.  
The upstream region of 2A and 2A-like sequences form an essential 
interaction within the ribosome exit tunnel creating an environment that promotes 2A 
‘ribosome skipping’ activity. The C-terminal –NPG- residues of 2A could play a role 
in the reorientation of the peptidyl tRNA-glycine substrate to disfavour peptide 
formation and then stimulate hydrolysis of the linkage between the nascent peptide 
and its tRNA when the A site is occupied by prolyl-tRNA. 
The upstream helical part of 2A interacts with the exit pore and this promotes 
specific orientation of the base of the helix (the tight-turn) within the PTC of the 
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ribosome. Thus the NPG portion with its tight turn structure reorients the peptide-
tRNA ester linkage promoting an unusual conformation: one different to that required 
for peptide bond formation. The ester bond between the nascent peptide and its tRNA 
is hydrolysed and the protein released. Therefore, not only the –DxExNPGP- motif is 
required for a 2A-like sequence to be active, but also the upstream region is critical 
for the functionality of the 2A protein. This model represents another modus operandi 
of viruses in their way to modify the host cell´s translation process for their own ends. 
Suboptimal functioning of 2A could be due to the loss of interactions between 
the nascent peptide and the ribosome since the length of some tested 2As is not 
optimum. These interactions are at specific positions within the ribosome and re-
orient the tight-turn (NPG) at the base of the helix, preventing the peptide bond 
formation. If the upstream sequence does not have the appropriate composition to 
allow these nascent peptide-ribosome interactions, then 2A’s action will not be 
optimal, and that is why uncleaved protein has been obtained in past experiments 
using sub-optimal lengths of 2As (Donnelly et al., 2001a). Increasing the length of the 
FMDV-2A and 2A-like sequences, by extending it N-terminally including regions of 
the 1D protein, improves the efficiency of 2A ‘cleavage’ (Donnelly et al., 2001b; 
Luke et al., 2008)  
 
Having the correct conformation of 2A is an essential factor for ‘ribosome 
skipping’ to occur but other factors must also be taken into account, such as the 
release factors, which have been recently found to be an integral part in this 
‘cleavage’ event (Doronina et al. 2008). It should be pointed out that prokaryotic and 
eukaryotic ribosomes present different features - discussed below. 
 
 
   4.1.2 Involvement of the Release factors in 2A’s mechanism of action. 
 
Our model predicts that peptidyl(2A)-tRNA occupies the P site of the 
ribosome and prolyl-tRNA in the A site – but that the peptide bond cannot be formed. 
The orientation of the ester linkage (electrophilic centre) of the peptidyl-tRNA in the 
P-site preventing it from attack by the nucleophile. Normally, once the aminoacyl-
tRNA binds into the A site the ribosome undergoes specific conformation changes, 
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changing the orientation of the α-amino group from the A site aa-tRNA and the 
carbonyl carbon from the P site peptidyl-tRNA thus allowing peptide bond formation 
and hydrolysis of the peptydil-tRNA (Nissen et al., 2000). This suggests that this 
change of conformation of the ribosome, once the A site is filled, makes the peptidyl-
tRNA susceptible to hydrolysis. The first suggestions about 2A’s mechanism of action 
mentioned the possibility of the C-terminal –NPG- residues, which form a tight turn, 
promoting a specific 2A peptidyl-tRNA substrate orientation that disfavours peptide 
bond formation and enhances hydrolysis of the peptidyl-tRNA ester bond (Ryan et al., 
1999). In this case the A site is not empty but occupied by a prolyl-tRNA, which will 
form the N-terminal of the protein downstream 2A. The first hypothesis suggested 
that hydrolysis of the ester bond between the nascent peptide and the tRNA was 
mediated by the ribosome or that 2A may act itself as a hydrolytic element, activating 
a water molecule (Ryan et al., 1999). However, the recent findings of the involvement 
of the release factors in 2A’s action add a new insight in the model of 2A’s 
mechanism of action, where eRF1 and eRF3 promote hydrolysis of the 2A peptidyl-
tRNA ester linkage.  
    
The new model predicts that (i) due to there is no peptide bond formation 
between 2A peptidyl-tRNA and prolyl-tRNA, eventually the latter dissociates, 
allowing ingress of eRF1/eRF3 into the A site, which promotes hydrolysis of 2A 
peptidyl-tRNA ester linkage. Thus, the upstream (in the case of FMDV – the capsid 
proteins) domain plus the C-terminal 2A are released. Subsequently the release factors 
egress the A site and there is ingress of prolyl-tRNA. Two outcomes are possible at 
this stage, the dissociation of the unstable translation complex and, thus, termination 
of translation or translocation of prolyl-tRNA into the P site followed by ingress of 
the next aminoacyl-tRNA into the A site, thus, synthesis of the downstream protein 
domains. In the case of FMDV, the replication proteins. 
  
 The mechanism of translation termination has been widely studied, and it still 
remains uncertain how the three stop codons (UAA, UGA, and UAG) are recognized 
and how the process of termination and ribosome dissociation occurs. The release 
factors (RFs) are responsible for the recognition of these three stop codons and the 
hydrolysis of the nascent peptide. There are two types of RFs, codon specific class I 
and codon non-specific class II. Prokaryotes have two class I RFs, RF1, specific for 
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UAG and/or UAA, and RF2, specific for UGA and/or UAA) whereas eukaryotes have 
only one class I factor (eRF1) that recognizes all three stop codons. Class II factors 
RF3 and eRF3, which are GTPases, are present in prokaryotes and eukaryotes, 
respectively. RF3 is not, however, present in small-genome bacteria or Archaea. eRF3 
function is not yet understood but is essential for cell growth, in contrast with RF3, 
which is not necessary in cell growth but is known to recycle class-I RFs. 
In response to a stop codon in the ribosomal A-site, formation of a quaternary 
complex comprising the ribosome, eRF1, GTP and eRF3 triggers GTP hydrolysis and 
enhances the rate of peptidyl release (Frolova et al., 1994). Unlike eRF3, RF3 is non-
essential and does not form stable complexes with the RF1 and RF2, implying these 
latter RFs can function in the absence of RF3 (Grentzmann et al., 1994). RF3 may 
stimulate termination efficiency by ejecting the class I release factors (RF1/2) from 
the A site following peptidyl-tRNA hydrolysis (Freistroffer et al., 1997). The way 
eRF3 acts is still unclear but some observations suggest that it might act as a complex 
with eRF1 (Zhouravleva et al., 1995). However, some contradictory studies have 
shown eRF1 alone having peptidyl-release activity in vitro (Bertram et al., 2001). It 
may, therefore, be unnecessary to form an eRF1-eRF3 complex in order to terminate 
translation, although it remains possible that eRF3 may still have affinity for 
ribosome-eRF1-stop codon complex.   
 Termination of translation is induced by recognition of the stop codon in the 
mRNA by class I RFs, which promotes hydrolysis of the ester bond between the 
nascent peptide and the tRNA on the P site of the ribosome. The release of the nascent 
peptide is followed by the disassembly of the post-termination complex. This is 
achieved by the ribosome recycling factor (RRF) and the elongation factor EF-G in 
prokaryotes (reviewed by Nakamura and Ito, 2003). Eukaryotes do not encode a RRF 
homologue, and their mechanism of ribosomal recycling is unknown. Recent studies 
in eukaryotic recycling have shown that the initiation factors eIF3, eIF1, eIF1A, and 
eIF3j, a loosely associated subunit of eIF3, can promote recycling of eukaryotic post-
translation complexes. eIF3 is the principal factor that promotes splitting of 
posttermination ribosomes into 60S subunits and tRNA- and mRNA-bound 40S 
subunits. Its activity is enhanced by eIFs 3j, 1, and 1A. eIF1 also mediates release of P 
site tRNA, whereas eIF3j ensures subsequent dissociation of mRNA (Pisarev et al., 
2007). 
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   4.1.3 Eukaryotic and prokaryotic release factors 
 
Eukaryotic and bacterial RFs exhibit little conservation when their sequences 
are aligned. However, RF1 and RF2 share highly conserved regions in their primary 
sequences. Further, they all contain Gly-Gly-Gln (GGQ motif), which is essential for 
peptidyl-tRNA hydrolysis (Frolova et al., 1999). It was shown that the tripeptides 
Pro-Ala-Thr (-PAT-) in RF1 and Ser-Pro-Phe (-SPF-) in RF2 are responsible for RF 
specificity. Hence, the first and third amino acids of these tripeptides ‘anticodons’ 
discriminate the second and third purine bases, respectively (Ito et al., 2000).  
The human eRF1 and Escherichia coli RF2 crystal structures were solved at 
high resolution (Song et al., 2000; Vestergaard et al., 2001) and revealed substantial 
structural differences. This is remarkable since they carry out similar tasks, although 
in different organisms. eRF3 and RF3 show limited sequence similarity to one another 
at the amino acid level, and while the eRF3 C-terminal domain shows most sequence 
similarity to eukaryotic elongation factor eEF-1 (which brings aminoacyl tRNA to the  
A-site), RF3 is most similar to prokaryotic elongation factor EF-G (the ribosome 
translocase), implying their precise functions may differ (Bertram et al., 2001).  
Much more detailed biochemical evidence is required before the mechanism 
of eukaryote termination is elucidated. It may be possible that eRF3 enhances 
peptidyl-release.  Interestingly, the recent determination of the genome sequence from 
the ciliated protozoan Tetrahymena thermophila showed it encodes an eRF1 protein 
highly homologous at the amino acid level to other more complex eukaryotic and 
archaeal release factors (Karamyshev et al., 1999). 
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 4.1.4 TmRNA rescue system versus Release factors function in 2A’s 
mechanism of action? 
Transfer-messenger RNA (tmRNA), also known as ssrA and 10Sa RNA, is a 
unique hybrid between tRNA and mRNA that is present in prokaryotes, which 
recycles 70S ribosomes stalled on problematic mRNA  and also contributes to the 
degradation of incompletely synthesized peptides (reviewed by Gillet & Felden, 
2001). A complex of alanyl-tmRNA, SmpB protein, and EF-Tu·GTP binds stalled 
ribosomes; the nascent peptide is transferred to the alanine on the tmRNA, and 
translation switches from the original message to a short tmRNA ORF that encodes a 
degradation tag. Translation of the ORF and normal termination releases the tagged 
polypeptide for degradation and permits disassembly and recycling of ribosomal 
subunits for new rounds of protein synthesis. Archaea and eukaryotic cells lack 
tmRNA (illustrated in figure 89, adapted from Dulebohn et al., 2007).  
In eukaryotes deadenylated mRNA is degraded by the exosome, although the 
fate of the ribosome on a truncated mRNA (and the associated polypeptide) remains 
to be elucidated (reviewed by Moore & Sauer, 2007).  
Recently, a novel mRNA decay pathway called No-Go decay (NGD) has been 
identified in Saccharomyces cerevisiae. This pathway releases ribosomes stalled in 
translation due to the presence of a stable stem-loop within the mRNA and this 
complex triggers direct endonucleolytic cleavage of aberrant mRNA. It involves a 
protein called Dom34, which is related to eRF1, and physically interacts with another 
protein Hbs1 that is itself related to eRF3 (Clement & Lykke-Andersen, 2006).  The 
crystal structure of Dom34 has been resolved revealing two domains structurally 
homologous to eRF1 (Graille et al., 2008). This could mean that they both interact 
with the ribosome in similar ways as they both trigger ribosome release by catalysing 
chemical bond hydrolysis.  
 The similarities of these two factors reinforce the new 2A’s model mechanism 
of action, where a stalled ribosome is recognized and released by eRF1 (eRF3). 
Therefore, suggesting that these eukaryotic release factors may also be part of a 
ribosome rescue system similar to that observed in prokaryotes (tmRNA) and, 
recently, in yeast. 
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From Dulebohn et al., 2007 
 
 
Figure 89. TmRNA-mediated protein tagging and ribosome rescue. A ribosome stalls on an 
incomplete or untranslatable message, leading to (a) the recruitment of aminoacylated tmRNA to the 
ribosomal A site and (b) transfer of the nascent chain to the alanine-charged tRNA-like domain of 
tmRNA. A message-switching event (c) then replaces the faulty mRNA with an open reading frame 
within tmRNA (d), which is translated until a stop codon is reached (e) and the tagged protein is 
released and degraded by C-terminal specific proteases (f). 
 
It could well be, therefore, that viruses employing 2A as part of their 
replication strategy have utilised aspects of general mechanism that has evolved in 
eukaryotes to release ribosomes stalled on truncated mRNAs. In the case of 2A, in the 
middle of an ORF, this event occurs not at a stop codon but in the midst of the ORF 
such that translation can either (i) terminate, or, (ii) essentially pseudo re-initiate to 
synthesise the downstream sequences 
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4.2 Purification of TMEV-2A  
 
 2A is only 18aa long in aphthoviruses whereas in cardioviruses 2A is ~150aa. 
In spite of this difference, their C-terminal regions are similar and posses the same 
self-cleaving activity (Donnelly et al., 1997). 
The high level of cleavage activity of the C-terminal region in cardioviruses, 
without the need of the upstream sequence raises interesting questions, Why do 
cardioviruses posses a 2A region of 150aa whilst those of aphthoviruses are a mere 
18aa? What is the function of the remaining -85% of the cardiovirus 2A sequence?  
 
The role of the upstream sequences has been previously highlighted (Ryan et 
al., 1991) and several experiments have been performed to determine the influence of 
these upstream sequences on aphthovirus and cardiovirus 2A activity (Donnelly et al., 
1997). It is most improbable that the only function of cardiovirus 2A is to enhance the 
C-terminal region’s cleavage activity to 100% since FMDV 2A can achieve that with 
a total length of 30-55 aa. Furthermore, previous studies demonstrated that deletions 
of two-third of the N-terminal region of cardiovirus 2A had no effect on the cleavage 
of 2A/2B junction (Palmenberg et al., 1992).  
 
Another role, other than the separation between the capsid and replicative 
domains, could be invoked, similar to that shown for the 2Apro. The 2Apro in 
enteroviruses and rhinoviruses not only cleaves the polyprotein at its N-terminus, 
separating the capsid precursor from the replicative domain, but also  mediates host 
cell shut off by cleaving eIF4GI (Zamora et al., 2002). In FMDV this activity is found 
not in the 2A region but in the N-terminal protease unique to aphthoviruses, Lpro 
(Lloyd et al., 1988). Therefore, FMDV 2A’s sole activity appears to be separating the 
capsid protein precursor form the replicative domain whilst the longer 2A found in 
cardioviruses may have an additional role other than the primary cleavage of 2A/2B.  
Such a function could be cis-acting in capsid protein processing, encapsidation or, 
trans-acting, in replication once it is cleaved from 1D. 
 
Not much is known about the biological functions of cardiovirus 2A. EMCV 
2A has been found to have non-specific RNA-binding properties and to be associated 
with ribosomes isolated from infected cells (Medvedkina et al., 1974).  
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Recent studies reported EMCV-dependent changes in 4EBP1 phosphorylation 
patterns and a link between these changes and the presence of cardiovirus 2A (Svitkin 
et al., 1998). 4EBP1 is a regulator of eIF4E availability and direct competitor of 
eIF4G-eIF4E interactions. In BHK cells infected with EMCV 2A the mammalian 
target of rapamycin (mTOR) protein kinase pathway is activated, leading to 
dephosphorylation of 4EBP1, inactivating 4E. Deletions within EMCV 2A abrogated 
host protein shutoff and, additionally were partially defective in viral protein 
processing (Svitkin et al., 1998). 
More recent studies in HeLa cells infected with EMCV show EMCV 2A 
tightly associated with some of the free 40S ribosome subunits, but not present in the 
80S pool which accumulated after infection. Expression of 2A protein in cells in the 
absence of infection was able to modulate the cellular translational environment to 
increase the ratio of internal ribosome entry site-dependent translation to cap-
dependent translation of a reporter construct.  These results provide further evidence 
for a role of 2A protein in the mechanism of cardiovirus induced host translational 
shutoff although the mechanism by which 2A affects this response remains elusive 
(Groppo & Palmenberg, 2007).  
 
Important goals for future work must include studies on the localization of 
TMEV 2A within the cell. The production of antibodies against TMEV 2A will, 
therefore, be very useful to resolve the yet unknown localization of 2A once it is 
separated from 1D, and to provide an insight into its possible role in the inhibition of 
host´s cells protein synthesis (reported for EMCV 2A). Bacterial expression will 
allow another important goal to be achieved: the resolution the atomic structure of 2A 
by nuclear magnetic resonance (NMR) spectroscopy.   
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4.3 Creation of a reporter of cellular stress using 2AFMDV protein  
 
Protein synthesis consumes a large amount of energy in the cell, with the 
highest proportion used in peptide-chain elongation. Therefore, under conditions of 
temporary increased energy demand or reduced energy supply, the cell has regulatory 
mechanisms to reduce the rate of protein synthesis allowing energy to be diverted to 
other processes, such as maintaining the plasma membrane potential and ion 
gradients.  
The elongation cycle of protein synthesis starts with the ribosome bound to the 
mRNA with peptidyl-tRNA in the P site, and aminoacyl-tRNA binding to the A site 
in a codon-dependent manner. This reaction requires an elongation factor (EF-Tu and 
eEF-1 in prokaryotes and eukaryotes, respectively) and GTP, which together form a 
high-affinity ternary complex with the A-site aminoacyl-tRNA. Codon recognition 
triggers GTP hydrolysis followed by release of the aminoacyl-tRNA from the 
elongation factor-GDP complex. The aminoacyl-tRNA is accommodated in the PTC 
where transpeptidation occurs. A second elongation factor (EF-G and eEF-2 in 
prokaryotes and eukaryotes, respectively) catalyses the translocation of the peptidyl-
tRNA from the A site to the P site, with hydrolysis of GTP.  The deacylated tRNA is 
then transferred from the P site to the E site, from where it dissociates. Thus, 
translocation restores the initial state of the ribosome, which then enters the next 
elongation cycle unless a stop codon in the A site cause termination (reviewed by 
Rodnina et al., 2000).  
 Under environmental stress, such as temperature changes or viral infections, 
the cell can regulate these factors by phosphorylation. EF-2 is a monomeric protein 
with a mass of ~93 kDa, which binds guanine nucleotides and is active when bound to 
GTP. Phosphorylation of eEF-2 inhibits its activity by preventing it binding to the 
ribosome (Carlberg et al., 1990). eEF-2 is phosphorylated in a Ca+2/calmodulin-
dependent manner (Ryazanov, 1987) by the Ca+2/calmodulin-dependent kinase III, 
which is known as eEF-2 kinase (Nairn & Palfrey, 1987). The activity of this kinase is 
also regulated by cAMP-dependent protein kinase (PKA), which is activated under 
cellular conditions of increased energy demand (Mitsui et al., 1993). Different types 
of cellular stress (osmotic, oxidative or heat stress) has been shown to cause inhibition 
of peptide synthesis at different levels (initiation, elongation and termination). For 
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instance, phosphorylation of eEF-2 occurs with oxidative stress of the cell (Patel et 
al., 2002). As said before, translation elongation is expensive in terms of metabolic 
energy, thus, may be inhibited when the cellular energy supply is restricted, for 
instance under stressing conditions, such as, viral infection leading to the activation of 
stress signaling pathways within the cell (reviewed by Browne & Proud, 2002). 
  eEF-2 levels have an effect on the outcome of translation products produced 
upstream and downstream of the 2A oligopeptide. Following release of the nascent 
peptide by eRF1/3, deacylated tRNA is present in the P site. The model proposes that 
these release factors leave the A site allowing prolyl-tRNA to bind. For continued 
synthesis of downstream sequences to occur, the deacylated tRNA needs to be 
translocated from the P to E site concomitant with proly-tRNA translocated from the 
A to P site. eEF-2 is responsible for this translocation reaction, thus if its activity is 
inhibited, further elongation cannot occur:  ribosomes dissociate and termination 
occurs (Ryan et al., 1999). This is consistent with the previous observations of Svitkin 
and Agol (1983) where a ‘translational barrier’ prevented the synthesis of translation 
products downstream of EMCV 2A. These translational studies of cardiovirus RNA 
were made in Krebs-2 cell-free extracts, which were found to have low levels of 
active eEF-2. When eEF-2- was added to the cellular extracts, enhancement of the 
translation of the downstream of 2A was achieved. This may be because, as with 
FMDV 2A, eEF-2 promotes translocation of the prolyl-tRNA from the A to the P site 
thus allowing synthesis of the downstream products.  
 As previously mentioned, one of the innate responses of cellular stress is the 
phosporylation of eEF-2, to inhibit the level of translation. Viruses may have adapted 
to this situation, taking advantage in a very subtle manner. Therefore, the effects of 
eEF-2 levels on 2A-mechanism may be favouring the virus production, when in the 
latter stages of infection (increased stress) only the capsid proteins are produced. This 
would allow the generation of the large excess of capsid proteins (60 copies per viral 
genome) required for encapsidation, avoiding the further production of the replicative 
proteins. Indeed, preliminary data indicate that whilst the level of eEF2 remains 
constant through TMEV infection, the proportion of phosphorylated eEF2 increases 
throughout infection (M. Ryan, pers. comm.) 
 The creation of the construct [V5-TTA-2A-scFv] (TTA: transcriptional 
transactivator) from pHE27 may open up a new approach in the use of 2A 
oligopeptide, which had already been widely used to co-express genes of interest with 
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reporter proteins in biotechnology and gene therapy (Percy et al., 1994; Chaplin et al., 
1999; de Felipe et al., 1999; reviewed by Szymczak & Vignali, et al., 2005). 
This artificial reporter may allow us to detect the level of stress in the cell. As 
explained above one of the cellular outcomes in stressful conditions is the 
phosphorylation of eEF-2, thus, inhibiting translocation. In normal conditions, the 
translation of [V5-TTA-2A-scFv] leads to two products: [V5-TTA-2A] and [scFv] in 
equimolar quantities. The downstream product [scFv] will bind the V5 from the 
upstream protein, and, therefore the complex is too big to pass through the nuclear 
pore and stays in the cytoplasm. In contrast, when the cell is stressed and, thus, 
translocation is repressed, there will be an excess of the upstream product compared 
to the downstream one. This will, consequently, allow the free [V5-TTA-2A] protein 
to pass through the nuclear pore since it is not bound to [scFv]. TTA activates gene 
expression, thus, this will be used in cell lines expressing luciferase under the control 
of tetracyline, where the amount of expressed luciferase will represent the levels of 
stress in the cell.  
  This system will allow us to measure stress in the cell in a range of conditions 
of stress: temperature, pH, osmolarity, nutrient limitation, infection etc. This artificial 
reporter will also be a very useful tool for cell biology and biotechnology and will 
shed important new light on the cellular stress studies not only in animals but in 
plants. 
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4.4 2A-like sequences 
 
First identified and characterized in picornaviruses, 2A-like sequences are 
found in other mammalian viruses and a wide range of insect viruses. These naturally 
occurring 2A-like sequences have been recognized by database searches and, then 
analyzed with the intention to provide insights into the role of this oligopeptide and to 
determine the requisites of the N-terminal region.  
 
    4.4.1 Insect virus 2A-like sequences 
 
 Many insect 2A-like sequences have been identified and analyzed in the past 
12 years. First analyses of 2A were performed using the “short” 2A version (18 aa) 
(Donnelly et al., 2001a) – the length of the first 2A sequence characterised. Later 
studies on FMDV 2A demonstrated that residues located upstream of 2A, located 
within the 1D capsid protein domain influenced 2A by enhancing the cleavage 
activity (Donnelly et al., 1997). Thus, recent experiments on insect 2A-like sequences 
have been performed using longer 2A versions (30aa), including upstream sequences 
(Luke et al., 2008). The results obtained with the longer versions show a clear 
improvement on 2A cleavage activity in the majority of species compared to the 
previous results using the shorter 2A version (18aa). 
 A first approach here was to compare 2A activity between two different in 
vitro systems: the wheat germ extract system and a new insect in vitro system (Qiagen 
Ltd., West Sussex, UK). Although translation profiles were routinely obtained using 
other in vitro translation systems, unfortunately (other than the positive control 
supplied by the manufacturer) no translation products were obtained using the insect 
translation system. The results obtained using the wheat germ extract systems were 
consistent with those seen in previous experiments (Luke et al., 2008).  Infectious 
flacherie virus (IFV), Varroa destructor virus 1(VDV-1) and Perina nuda picorna-
like virus (PnPV) belong to an unassigned genera of Iflaviruses, which are positive 
single stranded RNA viruses. IFV, which causes flacherie disease in the silkworm 
Bombyx mori, has the same genome arrangement as picornaviruses (see figure 18), 2A 
is situated in between the N-terminal structural protein domain and the replicative 
domain at the C-terminus of the polyprotein (Isawa, et al., 1998). In IFV 2A-like 
sequence the –DxExNPGP- motif is not conserved, but differs from the consensus by 
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a single change, a glycine residue instead of an aspartate, -GxExNPGP-. It is, 
however, still active. It is likely that IFV 2A-like sequence has the same role as in 
picornaviruses, to separate the capsid protein from the replicative proteins during 
translation. Interestingly, when this glycine residue was mutated to be the canonical –
DxExNPGP- motif, the sequence showed no cleavage activity (Donnelly et al., 
2001a). This suggests that the 2A sequence requirements to be active are more 
complex than having the –DxExNPGP- motif alone. The upstream sequence of 2A 
may also have a major influence in the efficiency of cleavage. VDV has also the same 
genome structure than picornaviruses, although 2A consensus motif is not conserved, 
nor is this 2A-like sequence active. The –NPGP- motif is present but the upstream 
sequence is different (–MDNPNPGP-). 
The rest of the insect viruses analyzed have a genome organization that is very 
different from picornaviruses. Perina nuda picorna-like virus (PnPV) has two 2A-like 
sequences: the first 2A is in the same position as picornaviruses, flanked by the capsid 
and replicative protein domains, whilst the second 2A lies between the structural VP2 
and VP4 proteins (figure 18). Both 2As are highly active. Phylogenetic studies of 2A 
show that IFV is much more distantly related to the other members of the family with 
active 2As. There are two possible explanations; one where 2A would be acquired at 
early stage in evolution accompanied by divergence of 2A between IFV and 
PnPV/EoPV (acquisition of a second 2A in PnPV/EoPV and loss of 2A from the other 
lineages), or 2A would be acquired independently, one in the PnPv lineage and 
another one in the IFV lineage (Luke et al., 2008). 
 Cricket paralysis virus (CrPV), which belongs to the Dicistroviridae family, 
has a monopartite and bicistronic genome. This genome encodes two large non-
overlapping ORFs with viral non-structural and structural polyprotein precursors 
encoded by the upstream and downstream ORFs, respectively (figure 18). Each ORF 
is preceded by an internal ribosome entry site (IRES), which control translation of the 
two different ORFs independently. It was observed that the downstream IRES was 
more active than the upstream IRES, providing a mechanistic explanation for the 
previously observed increased expression of viral structural proteins relative to the 
non-structural protein in infected cells. This genome organization and the utility of 
IRES elements of different strengths could be an economical strategy for gene 
expression (Wilson et al., 2000). The 2A-like sequence is located in the N-terminal 
region of the replicative ORF1 and is able to mediate cleavage. However, 2A-like 
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sequence is less active in CrPV than the other members of the family, drosophila C 
virus (DCV) and acute bee paralysis virus (ABPV), where 2A is highly active 
(Donnelly et al., 2001a). Nevertheless, all were capable of mediating cleavage and 
this translational model of 2A activity would predict that the translation of the 
replicative proteins (ORF1) would result in a ‘primary’ N-terminal cleavage product 
of 96aa (DCV) and 166aa (CrPV and ABPV) (Donnelly et al., 2001a).  
Studies where 2As were aligned using ClustalX 1.81, showed clusters that do 
not necessarily corresponded to the same clusters formed when the RNA-dependent 
RNA-polymerase (RdRp) sequences were aligned. Whilst 2A appears to have been 
acquired at a relatively early stage in picornavirus evolution, the reverse seems to be 
the case in the dicistroviruses (Luke et al., 2008). 
Providence virus (PrV), a member of the family Tetraviridae, infects midgut 
cell line derived from the corn earworm (Helicoverpa zea). The virus possesses a 
bicistronic genome with two N-terminal overlapping ORFs (ORF1 and ORF2) 
encoding the non-structural proteins and a third C-terminal ORF (ORF3), which 
encodes the structural proteins (Pringle et al., 2003). Three 2As can be found in its 
genome; 2A1, within ORF1 and 2A2-2A3 in ORF3 (figure 18). PrV 2A2 shows lower 
cleavage activity than 2A1 and 2A3. Appreciable levels of uncleaved polyprotein can 
be observed in in vitro experiment using PrV 2A2, similar to CrPV 2A (figure 63). 
Currently no data is available from PrV and CrPV infected cells. The tetraviruses 
could not be included in the polymerase based phylogenetic analysis since the 
domains in the polymerase of these viruses are ‘shuffled’ compared to all other 
positive stranded RNA virus polymerases. 
 The 2A-like sequences found in Bombyx mori cypovirus type1 (BmCPV-1) 
and Operopthera brumata cypovirus-18 (OpbuCPV-18), members of Reoviridae, are 
highly active and located in the segment 5 of its genome, encoding non-structural 
proteins. This family contains a segmented genome of 10 to 12 segments of linear 
double stranded RNA. Similar to dicistroviruses, 2A acquisition appears to have 
occurred at a relatively late stage in the evolution of this family (Luke et al., 2008). 
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    4.4.2 Strongylocentrotus purpuratus 2A-like sequences 
 
 Active 2A-like sequences have been found not only in a wide range of RNA 
viruses but also in trypanosomal sequences, such as in Trypanosoma cruzi (L1Tc) and 
T. brucei (igni), where 2A is associated with non-LTR retrotransposons (Donnelly et 
al., 2001a; Heras et al., 2006). 2A-like sequences have been also found in cellular 
genes such as the carbamyl-phosphate synthetase I (CPS1) protein of North American 
bullfrog Rana catesbeiana (with a histidine instead of an aspartic acid in the C-
terminal conserved sequence (-HPEANPGP-), the Mod (mdg4) 59.0 modifier protein 
of Drosophila melanogaster, the mouse mu opioid receptor variant F (MOR-1F) and 
the α-glucuronidase enzyme of the hyperthermophilic bacterium Thermatoga 
maritima. All of them were analyzed and found to be inactive (Hughes, 2003). It 
seemed, therefore, that this method of controlling protein biogenesis was limited to 
viruses or retroelements. 
 The recent discovery of new cellular 2A-like sequences in the purple sea 
urchin genome, Strongylocentrotus purpuratus (Sea Urchin Genome Sequencing 
Consortium, 2006) gives us insight into the role of these 2A-like sequences. Some of 
these sequences have been analyzed and found to be active. More than 100 sequences 
have been found in the genome and have been subsequently classified in two major 
groups. The first group of 2A-like sequences is found in the genes encoding 
intracellular proteins involved in innate immunity: nucleotide-binding oligomerization 
domain/leucine-rich repeat family (NOD-LRR), NACHT domain/leucine-rich repeat 
(NACHT-LRR family) or ‘CATERPILLER’ (CARD, transcription enhancer, R 
(purine)-binding, pyrin, lots of LRRs) genes (Lich & Ting, 2007). CATERPILLER 
proteins have been recently discovered and form the second important family 
involved in inflammatory responses to pathogens, together with the mammalians toll-
like receptor (TLR) family. They have not only been found in animals but also in the 
plant kingdom, in great numbers (~100 genes). They are greatly expanded in 
Strongylocentrotus purpuratus (~200 genes) and, surprisingly, 2A is found in ~50% 
of them, where it is located at the N-terminus of the ORF. The 2A sequence is mainly 
followed by a DEATH domain (DD; mediating protein:protein interactions), followed 
by a NATCH domain (predicted ATP/GTPase activity with similarity to apoptopic 
proteinase activating factor-1), then LRR (thought to bind variously pathogen 
proteins, lipids or carbohydrates) (figure 19).  
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The second major group of 2A-like sequences is associated with non-LTR 
retrotransposons and are also found forming or close the N-terminus of the single 
ORF. The non-LTR sequences downstream of 2A correspond to ORF2 of these 
elements (figure 19). Bioinformatic analyses of the sequences show three groups of 
non-LTR retrotransposons, all clustering within the chicken repeat (CR) 1 lineage of 
these elements, in contrast with L1Tc and ingi of trypanosomes. The first group of 
retroelements (~17 genes) are more similar to the Bf CR1 retroelement, the second 
group (~4 genes) most similar to ReO_6 and the third (~4 genes) most similar to 
Maui. The role of 2A within these elements remains unclear; it may form a genomic 
site favourable for their transposition. 
Most of the 2A sequences analyzed so far appear to be active, and, as 
previously shown in a wide range of RNA viruses, 2A may also be playing a role in 
the regulation of the synthesis of these novel cellular polyproteins. Furthermore, it has 
been recently observed that CATERPILLAR 2A-like sequences act as signal 
sequences (personal communication, Dr. Ryan). Two artificial constructs, consisting 
of [CATERPILLAR 2A-Cherry fluorescent protein] and a point mutated form of the 
CATERPILLAR 2A were assembled. In vitro translation analyses showed the 
expected products, with ~90% ‘cleavage’. When the wild-type 2A plasmid construct 
was transfected into HeLa cells (2A cleaving at its own C-terminus), Cherry 
fluorescent protein was localized in the cytosol. In contrast, the mutated, inactive, 2A 
resulted in the cherry fluorescent protein being localized to the ER and Golgi. Thus, 
2A when is at the N-terminus of the Cherry protein (‘uncleaved’), it acts as a signal 
sequence: is recognized by SRP and translocated into the ER co-translationally. If 2A 
mediates ‘cleavage’, then the downstream protein (lacking a signal) is located in the 
cytoplasm. Recently, the intriguing possibility of dual localization of membrane-
targeted single translation products has emerged. Sorting of a protein to a membrane-
sealed organelle involves targeting to the organelle, interaction with its surface 
receptors and translocation through the membrane by specific import machineries 
(post-translational import). Therefore dual distribution of a single translation product 
must reflect competition and/or promiscuity in one or more of these sorting steps. The 
cell uses different ‘tricks’ to achieve dual localization, such as competition between 
two signals on the same polypeptide, one ambiguous signal that is recognized by two 
organelles, inaccessibility of a signal by folding or protein binding, among others. If 
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the signal is hidden, this may lead to the retention of the protein in the cytosol 
(reviewed by Karniely and Pines, 2005) 
 
The Strongylocentrotus CATERPILLAR 2A-like sequences represent another 
case of dual protein targeting, where 2A protein acts as an N-terminal ‘self-cleaving’ 
signal for the CATERPILLER protein. Presumably the proportions of the secreted / 
cytosolic forms of the protein depend upon the ‘cleavage’ activity of each particular 
2A-like sequence. This range of 2A-like sequences is currently being investigated.  
 
     
    4.4.2 2A-like sequences within Dicistroviridae 
 
The N-terminal peptide upstream of the 2A-like sequences within DCV, 
ABPV and CrPV of the Dicistroviridae is reported to be involved in the shut off of 
the innate immune system during infection (personal communication, Professor 
Martin Ryan). These proteins inhibit the formation of the RNA-induced silencing 
complex (RISC). Small interfering double-stranded RNAs (siRNAs) are part of the 
RISC formed as part of the innate immune response. This complex cleaves one of the 
strands of siRNA, leaving the other strand as a guide to bind complementary (target) 
mRNA sequences, which are then cleaved by Argonaute endonucleases and then,  
degraded (reviewed by Sioud, 2007). 
Interestingly, other 2A-like sequences have also been observed in the genome 
of type C rotaviruses and Penaeid shrimp infectious myonecrosis virus (IMNV) as a 
‘linker’ between these dsRNA binding motifs and various proteins (Luke et al, 2008). 
In Rotaviruses the dsRNA binding motif is at the C-terminus of 2A (figure 90), and 
shares homology with the interferon-induced, double stranded RNA-dependent 
protein kinase (PKR) (Langland, et al., 1994). PKR, like many components of the 
innate immune system, depend on dsRNA for its activation. One of the virus 
strategies to repress the immune response consists in the ability to sequester dsRNAs, 
and thus, inhibit the activation of these effector proteins. 
IMNV presents the dsRNA binding motif at the N-terminus of 2A1 (figure 90). 
This protein arrangement is also the case for many other 2A-like sequences, such as 
non-LTR sequences in Trypanosomes. The function of these short proteins upstream 
of the 2A-like sequences of trypanosome non-LTRS is not known, but it may be 
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considered that, by analogy with Dicistroviruses, suppression of the formation of the 
RISC may promote transposition. 
2A may, therefore, represent a method of adding – ‘bolting-on’ - an extra-
function to these viral genomes, which seems to have a common theme in the 
inhibition of the cellular innate immune response. 
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333aa 69aa 
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'2A-Like' Sequences      2A1   -WDPTYIEISDCMLPPPDLTSCGDVESNPG P-
2A2 -RDVRYIEKPFDKEEHTDILLSGDVEENPG P-
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Figure 90. 2A-like sequences within dsRNA binding motifs. a) Type C Rotavirus Protein NSP3, 
segment 6. The segment is divided in three different parts, the ssRNA binding region, the eIF-4G 
region and the dsRNA binding fragment at the C-terminus of the 2A-like sequence represented in red. 
b) Penaeid shrimp infectious myonecrosis virus genome. The replicative domains are shown in green, 
and the structural domain in blue. The 2A-like sequences are represented in red and the dsRNA 
binding motifs are indicated 
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4.5 Bioinformatic Analyses  
 
 The 2A-like sequences found in the database searches containing the 2A motif 
are variable in the content upstream of the conserved motif. The analyses made, 
comparing this region between different species and different families has provided 
more knowledge about this region of 2A: those residues which are variable or 
conserved amongst different families of viruses.  
 As discussed in section 4.1 it is known that the ribosome exit tunnel is not 
neutral and interactions exist between the tunnel and nascent peptides. This tunnel is 
known to be able to accommodate approximately 40 amino acids in a helical 
conformation. This is consistent with the proposed and mapped interaction of 2A with 
the exit tunnel being ~30aa long (see section 4.1). 
 
 
   4.5.1 Picornaviruses  
  
2A upstream sequences present a very similar pattern within picornaviruses. In 
spite of the fact that the range of amino acids is not conserved, there is a higher 
presence of hydrophobic amino acids at the N-terminus of the sequence except from 
the more upstream positions 27, 29 and 30, where there is a prominence of 
hydrophilic, positively charged, amino acids (table 13).   
Tryptophan is avoided in all 2A sequences except SVV and ERBV-2. ERBV 
has been tested and is active (Donnelly et al., 2001a), whereas SVV has yet to be 
tested. 
 The similarities and differences between sequences and reasons for the 
presence of certain conserved residues on the N-terminal sequence will be discussed 
below. 
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 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
FMDV-63                    AY593836 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
ERAV-393/76                L43052   R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
BRV2                       EU236594 L R L T G E I V K Q G A T N F E L L Q Q A G D V E T N P G P
ERBV-1-P1436/71            X96871   E A T L S T I L S E G A T N F S L L K L A G D V E L N P G P
ERBV-2-P313/75             AF361253 V A D W E N L L S Q G A T N F D L L K L A G D V E S N P G P
PTV-1-Sek 549/98           AF296101 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
EMCV (EMC-PV21)           X74312   V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
TMEV (GDVII)               X56019   F R E F F K A V R G Y H A D Y Y K Q R L I H D V E M N P G P
SAF-V     EF165067 F T D F F K A V R D Y H A S Y Y K Q R L Q H D V E T N P G P
LV (174F)                  AF327921 Y F N I M H S D E M D F A G G K F L N Q C G D V E T N P G P
DHV-1 (DRL-62)             DQ219396 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
SVV                        DQ641257 R A W C P S M L P F R S Y K Q K M L M Q S G D I E T N P G P
SePV-1                     EU152976 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
Accession 
number
Species
 
Table 13. Picornaviral 2A sequences. Only one strain per species is shown. The conserved motif is in 
yellow and the tryptophan residues in orange. Differences at the conserved motif are shown in red. 
 
During processing of the P1-2A precursor, 2A is cleaved from 1D by the 3Cpro 
r more efficiently by 3CDpro (Ryan et al., 1989). This provides an additional 
onstraint on the 2A sequence: specifically the need to form a suitable substrate for 
Cpro.  
In comparison with other picornavirus 3C proteinases, FMDV 3Cpro cleaves a 
ide range of amino acid pairs (Ryan et al., 2004).  The primary cleavage of P1-2A 
ccurs mostly at the Q/L site, and in some cases, at the Q/M, Q/T, Q/V, Q/S and Q/C, 
hereas in PTV the cleavage site between P1-2A is completely conserved at a Q/G 
air (Zell et al., 2001). The presence of this cleavage site presents a constraint in the 
osition 19-20 and the 2-3 residues surrounding the 1D/2A cleavage site in FMDV. 
his is not the case in cardioviruses, since 2A is not 19 amino acids in length but 
150 amino acids. This constraint is also observed in other viruses in which 2A is 
roteolytically trimmed from 1D; BRV, ERBV (position 20-21) and PTV (position 
2-23). It is known that 3Cpro recognizes a short sequence of four or more residues 
reviewed by Ryan & Flint, 1997). The constrains are, therefore, on a longer tract (5-6 
a) than just the amino acid pair where the cleavage occurs (see table 14). 
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 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
FMDV    AY593836 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AY593831 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AY593832 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AY593823 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AY593824 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AY593811 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AY593812 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AY593828 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AF506822 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AJ539138 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AJ539139 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AJ539140 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    AJ539141 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    DQ296518 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    DQ296517 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    DQ296514 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    DQ296511 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    DQ296507 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
FMDV    DQ296506 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
FMDV    AY593814 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
FMDV    AY593815 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
FMDV    AY593816 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
FMDV    AY593817 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
FMDV    AY593799 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
FMDV    AY304994 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
FMDV    AY593800 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
FMDV    AY593798 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
FMDV    X88856   R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
FMDV    DQ989309 R K Q E I I A P E K Q M M N F D L L K L A G D V E S N P G P
FMDV    DQ989308 R K Q E I I A P E K Q M M N F D L L K L A G D V E S N P G P
FMDV    DQ989304 R K Q E I I A P E K Q D L N L D L L K L A G D V E S N P G P
FMDV    DQ989303 R K Q E I I A P E K Q V L N L D L L K L A G D V E S N P G P
FMDV    DQ119643 H K Q K I V A P A K Q S L N F D L L R L A G D V E S N P G P
ERAV     L43052   R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
BRV2      EU236594 L R L T G E I V K Q G A T N F E L L Q Q A G D V E T N P G P
ERBV-1  X96871   E A T L S T I L S E G A T N F S L L K L A G D V E L N P G P
ERBV-2  AF361253 V A D W E N L L S Q G A T N F D L L K L A G D V E S N P G P
PTV-1     AF296106 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1     AY392535 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1     AF296105 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1     AF296101 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1     AY392553 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1-    AF231769 A M T T L S Y Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1-    AB038528 A M T T L S Y Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1    Q355222  A M T T L S Y Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1     AJ011380 A M T V M A F Q G P G A T N F S L L K Q A G D V E E N P G P
PTV-1     AY392552 A M T V M A F Q G P G A T N F S L L K Q A G D V E E N P G P
EMCV    AY392555 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
TMEV    AF231768 F R E F F K A V R G Y H A D Y Y K Q R L I H D V E M N P G P
TLV AF296097 F S D F F K H V R E Y H A A Y Y K Q R L M H D V E T N P G P
SAF-V    AF296103 F T D F F K A V R D Y H A S Y Y K Q R L Q H D V E T N P G P
Accession 
number
Species
 
 
Table 14. Aphthoviruses, teschoviruses and cardioviruses different strains (not all shown). The 
conserved motif is highlighted in yellow. The different 3Cpro cleavage sites that separate P1 from 2A are 
shown in purple. Not shown in cardioviruses, since 2A is longer, thus 3Cpro cleavage site is upstream the 30 
amino acids showed in the figure. 
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Molecular modelling studies of FMDV 2A (cited in Ryan et al., 1999) 
revealed a predicted structure wherein an amphipathic α-helix is stabilized by a 
number of side-chain/side-chain interactions (figure 91). Therefore, there are 
interactions not only between side chains and the ribosomal exit tunnel but also 
between the side chains within 2A protein. One of these interactions might occur 
across the 1D/2A 3Cpro cleavage site (-Q/Xaa) between the capsid protein 1D C-
terminal K and an N residue (figure 91). 
This α-helix is characterized by consecutive main chain i?i+4 hydrogen 
bonds between each amide hydrogen and a carbonyl oxygen from the adjacent helical 
turn (Pauling and Corey, 1951).  
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H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
 
 
 
Figure 91. FMDV 2A sequence, including the C-terminus o 1D. Side-chain interactions are shown in 
blue. 
 
 
 
4.5.2 Trypanosomes, insects and mammalian 2A-like sequences 
 
2A-like sequences, in T. cruzi and T. brucei, are located at the N-terminus of 
apurinic/apyrimidinic-endonuclease (APE) domain and repeated sequence TRS-1, 
respectively. T. congolense and T. vivax 2A-like sequences are also situated at the 
N-terminus of the APE domain.  
It should be noted that these repeated elements may no longer be active and, 
thus, may have accumulated mutations. The high rate of mutations present in the C-
terminal motif is shown in table 15 and 16. Using translation systems in vitro, both 
types of trypanosome 2A-like sequences were shown to mediate cleavage (Heras et 
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al., 2006). Alignments of the last 19 residues of T.cruzi 2A-like sequences, showed 
a high degree of amino acid conservation maintaining identity of 93.7 %. 72.5 % of 
them maintained the consensus motif (-DxExNPGP-), whereas 27.5 % contained 
point mutations at the consensus motif, the 20% being N4?H (-DxExHPGP) 
(figure 92). The presence of this H residue at this position in a high percentage of 
sequences suggests that it may provide a selective advantage and a functional role.      
In the bioinformatics analysis only one type of each sequence with point 
mutation is represented, taking into account the variability but not the 
predominance of each type of sequence. 
2A sequences with this N4?H point mutation are active in trypanosomes but, 
like FMDV, they are less active reducing the efficiency of cleavage to 30% in 
FMDV (Donnelly et al., 2001a) and to 23.9% in trypanosomes (Heras et al., 2006). 
Further experiments, where a point mutation N4?Q was introduced into the 
sequence, showed only 10.91% activity, confirming the significance of this N4 
residue in the cleavage activity. These studies suggested that this 2A-like sequence 
may play a role in regulation of L1Tc translation. Similar results were obtained for 
FMDV 2A, where this N4?Q mutations was introduced and showed 10% of 
cleavage activity (Donnelly et al., 2001a). This suggests that L1Tc 2A has similar 
mechanism of action than FMDV 2A. However, it must be taken into account that 
the experiments were made in heterologous ribosomes and translation systems. 
From these earlier studies of L1Tc 2A the conclusion made was that this sequence 
plays a role in determining the ratio of the cleavage products, where the sequence 
with the conserved motive mediates molar excess of the upstream over the 
downstream product. In contrast, the N4?H point mutated sequence showed 
equimolar ratios of translation products, which was also obtained when the length 
of the sequence was increased up to 58 residues (Heras et al., 2006). These results 
are consistent with the results obtained for FMDV 2A, where the addition of 
residues located upstream of the consensus motif favours hydrolysis of the tRNA-
peptide ester linkage together with ‘pseudo-reinitiation’ instead of ‘pseudo-
termination’ (Donnelly et al., 2001b). 
 
 
 190
 CDAQRQKLLLSGDIEQNPG P
DIEQNPG  P
DIEQNPG P
DIEQNPG P
DIEQNPG P
DI NPG P
DIEQN P
DIEQNP P
DIEQ PG P
DIEQ PG P
DIEQ PG P
DIEQ PG P
57.5
CDARRQKLLLSG 5.0
CDAQQQKLLLSG 5.0
RDAQRQKLLLSG 2.5
CDAQRQKPLLSG 2.5
CDAQRQKLLLSG GQ 2.5
CDAQRQKLLLSG QA 2.5
CDAQRQKLLLSG S 2.5
CDAQRQKLLLSG H 12.5
CDARRQKLLLSG H 2.5
CDAQRQKLLLNG H 2.5
YDAQRQKLLLSG H 2.5
72.5%
20%
Active
Active
27.5 %
Cleavage activity (%)
1)
2)
3)
4)
5)
6)
7)
8)
9)
10)
11)
12)
 
 
Figure 92. 2A-like T.cruzi sequences contained in L1Tc elements. Sequences were grouped 
considering the point mutations they contain (shown in green). The percentage (%) of elements that 
contain each type of 2A-like sequence are shown, being 75.5% sequences with conserved motif, 
27.5% sequences with mutations at the conserved motif, and 20% sequences with the mutation 
N17?H and tested to be active. Sequences 7, 8 and 9 have not been analyzed (adapted from Heras et 
al., 2006). 
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 FMDV-63     AY593836 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
T.cruzi AAA67559 Q P Y T Y C L R A L C D A Q R Q K L L L I G D I E Q N P G P
T.cruzi CAB41692 Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A R R Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A Q Q Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V R D A Q R Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A P Q Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I G Q N P G P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q N P G P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q N Q A P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q N P S P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q H P G P
T.cruzi Q R Y T Y R L R A V C D A R R Q K L L L S G D I E Q H P G P
T.cruzi Q R Y T Y R L R A V C D A Q R Q K L L L N G D I E Q H P G P
T.cruzi Q R Y T Y R L R A V Y D A Q R Q K L L L S G D I E Q H P G P
T.vivax 936e06.q1k_21 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
T.vivax 1768f01.q1k_0 M L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
T.vivax 1768f01.q1k_7 M L P C A C G R A T L D A R R L T L L V S G D V E R D P G P
T.vivax 302f07.p1k_20 I L P C T C E R A T L D A R R L L L L I S G D V E R N P G P
T.vivax 1681d10.q1k_7 T L P F A R W H I A L D M R R P L L L I S G D V D S K P G P
T.vivax 1664g12.q1k_4 L L P C T C G R A T L D A W R L L L L I C G G V G R N P G P
T.vivax 1768f01.q1k_0 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
T.vivax 1768f01.q1k_7 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
T.vivax 563c09.q1k_9 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
T.vivax 696d02.p1k_1 I L P C T C G R A A L D A Q W R L L L I F V D A E R N P G P
T.vivax 395e02.q1k_1 I L P C T C G R A A L D A Q W R L L L I F V D A E R N P G P
T.vivax 938f02.q1k_5 I L P C T R G R A M L S A R W L L L L I S G G V E R K P G P
T.vivax 733e05.p1k_4 I L P F T C G R A A L D A W R L L L L I G G G V G R N P G P
T.vivax 73h08.q1k_2 I L P C L C V H A A S D A R W L L L L I S G D V E R R P C P
T.vivax 390g10.p1k_23 M L L C T S G R A M L R A R W L L L L I S G D V E R D S G P
T.vivax 892h02.p1k_5 S Q V R W S N G A E K K V Q R L L L L S G G D V E R N P G P
Accession 
number
Species 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
 
Table 15. Comparison between FMDV 2A and Trypanosome (T. vivax and T. cruzi) 2A-like 
sequences. T. cruzi 2A-like sequences without accession numbers are taken from Heras et al., 2006. The 
conserved motif is highlighted in yellow and the differences in red. 
  
The T. congolense and T. vivax 2A-like sequences analyzed showed a high 
level of heterogeneity compared to FMDV 2A. Interestingly, some of the sequences 
contain a tryptophan (W) residue, which is never present in any picornavirus 2A 
sequences, except ERBV-2 and SVV (table 16). However, most of the sequences with 
W, do not have the consensus motif conserved and they may be inactive, which would 
be consistent with the fact that a bulky residue like tryptophan apparently does not 
favour the correct 2A conformation inside the ribosome. This is still unclear yet, since 
these sequences have not been tested.  
It is interesting to note that where tryptophan do occur, the i+4 residue is very 
frequently leucine, or a residue with an aliphatic, hydrophobic, side chain (table 16). 
This is also observed in insect and mammalian 2A-like sequences (tables 17 and 18).  
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The fact that eukaryotic ribosomes from different origins are slightly different 
must also be taken into account. It has been reported using cryo-electron microscopy, 
that the overall structure of the T. cruzi 80S ribosome shows the phylogenetically 
conserved eukaryotic rRNA core structure, having well-defined small (40S) and large 
(60S) subunits, but also together with some distinctive structural features. It was also 
observed that the 60S ribosomal subunit from T.cruzi presents a shape that is similar 
to those from bacteria (Gao et al., 2005). 
  
 
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
FMDV-63 AY593836 H K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
T.congo 354h04.q1k_6 I L P C T C G R A T L D A R R I L L L V S G D I E R N P G P
T.congo 335b10.q1k_3 I L P C T C G C A T L D A R R I L L L V S G D V E R N P G P
T.congo 432g10.q1k_7 I L P C T C G R T T L D A R R I L L L V S G D I E R N P G P
T.congo 400g12.q1k_4 I L P C T C G R T T L D A R R I L L L V S G D I E R N P G P
T.congo 876g11.p1k_3 I V P C T C G R T T L D A R R I L L L V S G D I E R N P G P
T.congo 1381h11.q1k_4 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
T.congo 1071g10.p1k_14 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
T.congo 1294e07.p1k_3 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
T.congo 1473f10.p1k_5 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
T.congo 1305b04.p1k_2 I L P C T C I C P T L E A R R L L V L V S G G I E R N P R P
T.congo 530f06.q1kbw_10 A L S C V C G H G N S L L C R L L L F L S G D V E Y N P G S
T.congo 1463e05.p1k_0 A L S C V C G H G N S L L C R L L L F L S G N V E Y N P G S
T.congo 800b12.p1k_3 A L S C V C G H G N S L L C R L L L F L S G N V E Y N P G S
T.congo 47d01.q1k_6 A L S C V C G H G N S L L C R L L L F L S G N V E Y N P G S
T.congo 987a11.q1k_0 T L S C T C G S A L P K A L G P L L L L S R V E D H N P G P
T.congo 1423d04.p1k_0 F T C T C W R G R A L L C R P F L M P L S G D V G Q N P E P
T.congo 245e02.p1k_7 T V P P N R Q C A L Q E A L R K K L L L C G D V E S N P W N
T.vivax 1198e11.p1k_1 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
T.vivax 961a05.q1k_2 M L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
T.vivax 1875a05.p1k_16 M L P C A C G R A T L D A R R L T L L V S G D V E R D P G P
T.vivax 302f07.p1k_20 I L P C T C E R A T L D A R R L L L L I S G D V E R N P G P
T.vivax 1681d10.q1k_7 T L P F A R W H I A L D M R R P L L L I S G D V D S K P G P
T.vivax 1664g12.q1k_4 L L P C T C G R A T L D A W R L L L L I C G G V G R N P G P
T.vivax 1768f01.q1k_0 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
T.vivax 1768f01.q1k_7 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
T.vivax 563c09.q1k_9 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
T.vivax 696d02.p1k_1 I L P C T C G R A A L D A Q W R L L L I F V D A E R N P G P
T.vivax 395e02.q1k_1 I L P C T C G R A A L D A Q W R L L L I F V D A E R N P G P
T.vivax 938f02.q1k_5 I L P C T R G R A M L S A R W L L L L I S G G V E R K P G P
T.vivax 733e05.p1k_4 I L P F T C G R A A L D A W R L L L L I G G G V G R N P G P
T.vivax 73h08.q1k_2 I L P C L C V H A A S D A R W L L L L I S G D V E R R P C P
T.vivax 390g10.p1k_23 M L L C T S G R A M L R A R W L L L L I S G D V E R D S G P
T.vivax 892h02.p1k_5 S Q V R W S N G A E K K V Q R L L L L S G G D V E R N P G P
Accession 
number
Species
 
 
Table 16. Classification of a selection of different 2A-like sequences in T. congolense and T.vivax 
compared to FMDV 2A. Differences in the conserved motif are highlighted in red, and tryptophan 
(W) in orange. Residues in blue represent i, i+4 interactions.  
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Tryptophan residues are also found in the upstream region of some insect 2A-
like sequences (table 17). Interestingly all the tested sequences containing this bulky 
residue are active. However, some caution must be taken in making some conclusions 
since the analysis were performed in heterologous in vitro ribosomes/translation 
systems (wheat germ extracts). These sequences have not been tested yet in insect in 
vivo systems, and the in vitro insect extracts that were used in this project did not 
show any expression (see section 3.4.1). They all keep the conserved motif, and a 
very heterogenic upstream region. Eukaryotic ribosomes from different origins, such 
as insect and mammals, show distinctive features, which, in the insect case, may 
allow the presence of tryptophan.  
 
 
 
30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
EoPV-2A1 AY365064 G Q R T T E Q I V T A Q G W A P D L T Q D G D V E S N P G P
EoPV-2A2 AY365064 T R G G L Q R Q N I I G G G Q R D L T Q D G D I E S N P G P
EoPV-2A1 AY341824 G Q R T T E Q I V T A Q G W A P D L T Q D G D V E S N P G P
EoPV-2A2 AY341824 T R G G L Q R Q N I I G G G Q R D L T Q D G D I E S N P G P
PnPV-2A1 AF323747 G Q R T T E Q I V T A Q G W V P D L T V D G D V E S N P G P
PnPV-2A2 AF323747 T R G G L R R Q N I I G G G Q K D L T Q D G D I E S N P G P
IFV AB000906 P S I G N V A R T L T R A E I E D E L I R A G I E S N P G P
ABPV AF150629 T G F L N K L Y H C G S W T D I L L L L S G D V E T N P G P
ABPV AF486073 T G F L N K L Y H C G S W T D I L L L L S G D V E T N P G P
ABPV AF486072 T G F L N K L Y H C G S W T D I L L L W S G D V E T N P G P
KBV AY275710 I G F L N K L Y K C G T W E S V L N L L A G D I E L N P G P
IAPV EF219380 I G F L N K L Y R C G D W D S I L L L L S G D I E E N P G P
CrPV AF218039 L V S S N D E C R A F L R K R T Q L L M S G D V E S N P G P
DCV AF014388 Q G I G K K N P K Q E A A R Q M L L L L S G D V E T N P G P
TaV AF062037 R G P R P Q N L G V R A E G R G S L L T C G D V E E N P G P
TaV AF282930 R G P R P Q N L G V R A E G R G S L L T C G D V E E N P G P
EeV AF461742 R R L P E S A Q L P Q G A G R G S L V T C G D V E E N P G P
PrV-2A1 AF548354 L E M K E S N S G Y V V G G R G S L L T C G D V E S N P G P
PrV-2A2 AF548354 N S D D E E P E Y P R G D P I E D L T D D G D I E K N P G P
PrV-2A3 AF548354 T L M G N I M T L A G S G G R G S L L T A G D V E K N P G P
D. punctatus CPV1 AY163248 M T A F D F Q Q A V F R S N Y D L L K L C G D V E S N P G P
D. punctatus CPV1 AY185594 M T A F D F Q Q A V F R S N Y D L L K L C G D V E S N P G P
L. dispar CPV1     AF389466 M T A F D F Q Q A V F R S N Y D L L K L C G D V E S N P G P
B. mori      AF433660 R T A F D F Q Q D V F R S N Y D L L K L C G D I E S N P G P
B. mori CPV1-H  AB035733 R T A F D F Q Q D V F R S N Y D L L K L C G D I E S N P G P
B. mori CPV1-I      AB035732 R T A F D F Q Q D V F R S N Y D L L K L C G D I E S N P G P
O. brumata CPV18 DQ192245 I H A N D Y Q M A V F K S N Y D L L K L C G D V E S N P G P
Accession 
number
Species
 
 
 Table 17. Insect 2A-like amino acid sequences. The C-terminal conserved motif is highlighted in 
yellow and tryptophan (W) residues are highlighted in orange. Blue residues represent i+4 interactions. 
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Tryptophan is also observed in a minority of mammalian 2A-like sequences. 
Like observed in trypanosomal and insect 2A-like sequences (tables 16 and 17), 
where tryptophan occurs, a leucine residue is observed at the i+4 position, suggestive 
of an i/i+4 hydrophobic sidechain interaction that could occur in an alpha helical 
conformation of the nascent peptide (table 18).  
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
SVV                        DQ641257 R A W C P S M L P F R S Y K Q K M L M Q S G D I E T N P G P
SePV-1                     EU152976 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
SePV-1                     EU142040 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
SePV-1                     EU152979 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
SePV-1                     EU152978 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
SePV-1                     EU152975 C G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
SePV-1                     EU152974 C G C F C P L P N V Y V P P T H N V L L E G D V E S N P G P
SePV-1                     EU152980 S G C F C P L P N V Y V P P I H N V L L D G D V E S N P G P
SePV-1                     EU152977 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P R P
ADRV-N                     AY632079 F F D S V W V Y H L A N S S W V R D L T R E C I E S N P G P
ADRV-N (J19)            DQ113901 F F D S V W V Y H L A N S S W V R D L T R E C I E S N P G P
ADRV-N (B219)        DQ168032 F F D S I W V Y H L A N S S W V R D L T R E C I E S N P G P
Human-C (V508) AY941781 G V G Y P L I V A N S K F Q I D K I L I S G D I E L N P G P
Human-C (V966) AY941782 G V G Y P L I V A N S K F Q I D K I L I S G D I E L N P G P
Human-C (Bristol) AJ132203 G A G Y P L I V A N S K F Q I D K I L I S G D I E L N P G P
Human-C (V460) AY941780 G T G Y P L I V A N S K F Q I D K I L I S G D I E L N P G P
Bovine-C (Shintoku) L12390   G I G N P L I V A N S K F Q I D R I L I S G D I E L N P G P
Porcine-C (Cowden) M69115   G N G N P L I V A N A K F Q I D K I L I S G D V E L N P G P
Accession 
number
Species
 
 
 
Table 18. Mammalian 2A-like amino acid sequences. The C-terminal conserved motif is highlighted in 
yellow, and the point mutations in the region, in red. Tryptophan (W) residues are highlighted in orange. 
Blue residues represent i+4 interactions. 
 
  
 
In summary, all 2A-like sequences present a similar pattern: a region with low 
conservation but containing a high proportion of aliphatic hydrophobic residues 
followed by the conserved motif. We have proposed 2A adopts an α-helical 
conformation within the ribosome exit tunnel and this preliminary analysis reveals a 
series of helix stabilizing hydrogen bond and hydrophobic i,i+4 interactions. Not only 
is the length of the sequence important but also the nature of each amino acid in each 
position to achieve the correct interaction with the exit tunnel to mediate ‘cleavage’.  
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4.6 SUMMARY 
 
The concluding points that summarize this work are as follows: 
 
- A reliable and efficient artificial reporter system that allows the detection of 2A 
activity directly in live cells without the need for Western blots has been created and 
used for the screening of an active 2A in bacterial systems. In spite of the fact that no 
active 2A within prokaryotic organisms was found, this reporter system can easily be 
adapted to eukaryotic organisms for mutagenic studies of 2A’s activity.  
 
- TMEV 2A antibodies have been produced and will be used for the localization of 
TMEV 2A within the cell and, also to provide an insight into its possible role in the 
inhibition of host´s cells protein synthesis. 
 
 - The creation of a reporter of stress in the cell (from the tested pHE27 vector) will 
form the basis of future work and represents a new tool in the biotechnology field. 
 
- The study of new 2A-like sequences, found in the genome of the sea-urchin 
Strongylocentrotus purpuratus, has shown these cellular sequences to be active. These 
analyses provide useful information on 2A’s role within Strongylocentrotus cells and 
the function of the innate immune system of this organism. Recent unpublished 
experiments show these new 2A-like sequences are acting as signal sequences within 
the cell. 
 
-We know that all 2A/2A-like sequences present a conserved motif at the C-terminus, 
but what about the upstream sequence? Does it follow any pattern, any conservation, 
etc.? The bioinformatics analysis has provided insight on these questions.  
We believe that this upstream sequence is interacting with the ribosomal exit 
tunnel; therefore, some grade of conservation in the amino acid organization within 
the sequence must be present. The bioinformatics analyses reveal a clear pattern.  
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In picornaviruses, there is a large predominance of leucine residues in 
positions 11, 13, 14, 15, 18 and 19, whereas position 12 is a lysine in most sequences. 
Conservation is observed in aphtho- and teschoviruses, at positions 19-20 (Q/L, M, T) 
and 22-23 (Q/G), respectively, due to presence of 3Cpro cleavage site. In contrast, 
insect 2A-likes sequences show little conservation upstream of the conserved motif, 
and represent the most heterogenic sequences.  
 
Bulky residues with aromatic side chains (W, F and Y) seem to be widely 
avoided in the sequence except in trypanosome and insect 2A-like sequences, and also 
at position 16 in picornaviruses, where phenylalanine is present in the majority of 
cases. 
Charged hydrophobic residues are more common at the N-terminal region 
whereas neutral, polar or non-polar, residues are found in the middle of 2A-like 
sequences. A conserved patch of leucine residues is found in all non-LTR 2A-like 
sequences within trypanosomes, the sea urchin Strongylocentrotus purpuratus, and 
also insect viruses (positions 11 to 14). This patch of leucines is also found in 
CATERPILLER 2A-like sequences within Strongylocentrotus purpuratus. However, 
in that case, the patch of leucine amino acids is flanked by an acidic and a basic 
residue instead of neutral residues. This is consistent with the recently determined role 
of CATERPILLER 2A-like sequences as signal sequences.   
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Appendix 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
1 FMDV-63 AY593836 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
2 FMDV-64 AY593831 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
3 FMDV-65 AY593832 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
4 FMDV-75 AY593823 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
5 FMDV-76 AY593824 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
6 FMDV-78 AY593811 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
7 FMDV-79 AY593812 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
8 FMDV-83 AY593828 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
9 FMDV-110 AF506822 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
10 FMDV-128 AJ539138 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
11 FMDV-129 AJ539139 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
12 FMDV-130 AJ539140 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
13 FMDV-131 AJ539141 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
14 FMDV-141 DQ296518 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
15 FMDV-143 DQ296517 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
16 FMDV-149 DQ296514 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
17 FMDV-153 DQ296511 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
18 FMDV-157 DQ296507 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
19 FMDV-159 DQ296506 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
20 FMDV-160 DQ296531 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
21 FMDV-163 DQ296504 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
22 FMDV-164 DQ296528 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
23 FMDV-167 DQ296502 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
24 FMDV-169 DQ296501 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
25 FMDV-170 DQ296524 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
26 FMDV-178 AY960759 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
27 FMDV-179 AJ633821 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
28 FMDV-180 AF506822 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
29 FMDV-184 AY312587 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
30 FMDV-186 AY333431 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
31 FMDV-205 EU140964 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
32 FMDV-232 EF611987 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
33 FMDV-248 DQ296525 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
34 FMDV-256 DQ404180 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
35 FMDV-257 DQ404179 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
36 FMDV-258 DQ404178 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
37 FMDV-259 DQ404177 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
38 FMDV-260 DQ404176 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
39 FMDV-261 DQ404175 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
40 FMDV-262 DQ404174 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
41 FMDV-263 DQ404173 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
42 FMDV-264 DQ404172 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
43 FMDV-265 DQ404171 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
44 FMDV-266 DQ404169 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
45 FMDV-267 DQ404170 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
46 FMDV-269 DQ404167 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
47 FMDV-270 DQ404166 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
48 FMDV-271 DQ404165 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
49 FMDV-272 DQ404164 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
50 FMDV-273 DQ404163 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
51 FMDV-275 DQ404161 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
52 FMDV-276 DQ404160 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
53 FMDV-277 DQ404159 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
54 FMDV-278 DQ404158 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
55 FMDV-281 DQ767863 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G P
56 FMDV-185 AY312589 H K Q K I V A P V K Q L L N F D L L K L A G D V E P N P G P
57 FMDV-138 DQ296522 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G A
58 FMDV-139 DQ296519 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G A
59 FMDV-151 DQ296512 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G A
60 FMDV-161 DQ296505 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G A
61 FMDV-165 DQ296503 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G A
62 FMDV-168 DQ296526 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N P G A
63 FMDV-155 DQ296508 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N Q G A
64 FMDV-137 DQ296523 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N L G P
65 FMDV-145 DQ296516 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N L G P
66 FMDV-147 DQ296515 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N L G P
67 FMDV-166 DQ296527 H K Q K I V A P V K Q L L N F D L L K L A G D V E S N L G P
68 FMDV-1 AY593769 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
69 FMDV-2 AY593789 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
70 FMDV-3 AY593767 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
71 FMDV-13 AY593787 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
72 FMDV-14 AY593788 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
73 FMDV-19 AY593768 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
74 FMDV-21 AY593771 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
75 FMDV-22 AY593773 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
76 FMDV-24 AY593775 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
77 FMDV-28 AY593776 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
78 FMDV-33 AY593792 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
79 FMDV-39 AY593765 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
80 FMDV-41 AY593760 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
81 FMDV-43 AY593762 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
82 FMDV-44 AY593763 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
83 FMDV-45 AY593764 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
84 FMDV-46 AY593761 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
85 FMDV-47 AY593766 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
86 FMDV-115 X74812 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
87 FMDV-144 DQ296543 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
88 FMDV-148 DQ296537 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
89 FMDV-150 DQ296536 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
90 FMDV-152 DQ296535 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
91 FMDV-154 DQ296534 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
92 FMDV-156 DQ296533 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
93 FMDV-158 DQ296532 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
94 FMDV-135 DQ296548 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
95 FMDV-174 DQ063707 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
96 FMDV-176 AJ251476 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
97 FMDV-177 AY960760 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
98 FMDV-210 EF117837 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
99 FMDV-237 EF405981 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
100 FMDV-238 EF405980 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
101 FMDV-239 EF159977 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
102 FMDV-282 DQ767857 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
103 FMDV-27 AY593759 H K Q K I I A P A K Q L L N F D L L K L A G D V E P N P G P
104 FMDV-204 M38362 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
105 FMDV-243 DQ296548 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
106 FMDV-146 DQ296542 H K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G A
107 FMDV-134 X00871 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
108 FMDV-66 AY593814 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
109 FMDV-67 AY593815 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
110 FMDV-68 AY593816 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
111 FMDV-69 AY593817 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
112 FMDV-70 AY593818 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
113 FMDV-71 AY593819 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
114 FMDV-72 AY593820 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
115 FMDV-73 AY593821 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
116 FMDV-77 AY593825 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
117 FMDV-80 AY593813 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
118 FMDV-82 AY593827 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
119 FMDV-84 AY593829 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
120 FMDV-85 AY593830 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
121 FMDV-123 AJ320488 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
122 FMDV-133 V01131 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
123 FMDV-192 M95781 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
124 FMDV-190 A00276 H K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
125 FMDV-48 AY593799 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
126 FMDV-114 AY304994 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
127 FMDV-49 AY593800 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
128 FMDV-50 AY593798 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
129 FMDV-200 X88856 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
130 FMDV-211 DQ989323 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
131 FMDV-212 DQ989322 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
132 FMDV-213 DQ989321 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
133 FMDV-214 DQ989320 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
134 FMDV-215 DQ989319 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
135 FMDV-216 DQ989318 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
136 FMDV-217 DQ989317 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
137 FMDV-218 DQ989316 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
138 FMDV-219 DQ989315 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
139 FMDV-220 DQ989314 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
140 FMDV-229 DQ989305 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N P G P
141 FMDV-228 DQ989306 R K Q E I I A P E K Q V L N F D L L K L A G D V E S N L G P
142 FMDV-55 AY593804 H K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
143 FMDV-56 AY593805 H K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
144 FMDV-119 AJ133358 H K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
145 FMDV-120 AJ133359 H K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
146 FMDV-121 AJ133357 H K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
147 FMDV-175 X00130 H K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
148 FMDV-208 AM503966 H K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
149 FMDV-209 AM503965 H K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
150 FMDV-38 AY593755 H K Q R I I A P A K Q L L N F D L L K L A G D V E S N P G P
151 FMDV-140 DQ296545 H K Q R I I A P A K Q L L N F D L L K L A G D V E S N P G P
152 FMDV-142 DQ296544 H K Q R I I A P A K Q L L N F D L L K L A G D V E S N L G P
153 FMDV-136 DQ296547 H K Q R I I A P A K Q L L N F D L L K L A G D V E S N P G A
154 FMDV-244 DQ296547 H K Q R I I A P A K Q L L N F D L L K L A G D V E S N P G A
155 FMDV-116 AY317098 H K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
156 FMDV-117 AY359854 H K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
157 FMDV-111 AF511039 H K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
158 FMDV-173 DQ248888 H K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
159 FMDV-183 AY686687 H K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
160 FMDV-240 EF175732 H K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
161 FMDV-274 DQ404162 H K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
162 FMDV-268 DQ404168 H K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
163 FMDV-17 AY593756 Y K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
164 FMDV-25 AY593751 Y K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
165 FMDV-18 AY593757 Y K Q K I I A P A K Q L L N F D L L K L A G D V E S N P G P
166 FMDV-132 X00429 Y K Q K I I A P A K Q L L N F D L L K L A G D V E S N L G P
167 FMDV-255 V01130 Y K Q K I I A P A K Q L L N F D L L K L A G D V E S N L G P
168 FMDV-298 E00082 Y K Q K I I A P A K Q L L N F D L L K L A G D V E S N L G P
169 FMDV-299 BD437421 Y K Q K I I A P A K Q L L N F D L L K L A G D V E S N L G P
170 FMDV-235 AM409190 R K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
171 FMDV-283 DQ409191 R K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
172 FMDV-284 DQ409190 R K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
173 FMDV-287 DQ409187 R K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
174 FMDV-289 DQ409185 R K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
175 FMDV-290 DQ409184 R K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
176 FMDV-291 DQ409183 R K Q P L V A P A K Q L L N F D L L K L A G D V E S N P G P
177 FMDV-9 AY593786 H K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
178 FMDV-37 AY593793 H K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
179 FMDV-10 AY593790 H K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
180 FMDV-11 AY593801 H K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
181 FMDV-12 AY593802 H K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
182 FMDV-86 AY593835 H K Q R I V A P A K Q L L N F D L L K L A G D V E S N P G P
183 FMDV-87 AY593833 H K Q R I V A P A K Q L L N F D L L K L A G D V E S N P G P
184 FMDV-105 AF026168 H K Q R I V A P A K Q L L N F D L L K L A G D V E S N P G P
185 FMDV-106 AF154271 H K Q R I V A P A K Q L L N F D L L K L A G D V E S N P G P
186 FMDV-108 AF308157 H K Q R I V A P A K Q L L N F D L L K L A G D V E S N P G P
187 FMDV-29 AY593781 H K Q K I I A P A R Q L L N F D L L K L A G D V E S N P G P
188 FMDV-36 AY593754 H K Q K I I A P A R Q L L N F D L L K L A G D V E S N P G P
189 FMDV-34 AY593778 H K Q K I I A P A R Q L L N F D L L K L A G D V E S N P G P
190 FMDV-32 AY593780 H K Q K I I A P A R Q L L N F D L L K L A G D V E S N P G P
191 FMDV-54 AY593810 H K Q P L I A P A K Q L L N F D L L K L A G D V E S N P G P
192 FMDV-57 AY593806 H K Q P L I A P A K Q L L N F D L L K L A G D V E S N P G P
193 FMDV-188 AF274010 R K Q Q L V A P A K Q L L N F D L L K L A G D V E S N P G P
194 FMDV-285 DQ409189 R K Q Q L V A P A K Q L L N F D L L K L A G D V E S N P G P
195 FMDV-286 DQ409188 R K Q Q L V A P A K Q L L N F D L L K L A G D V E S N P G P
196 FMDV-288 DQ409186 R K Q Q L V A P A K Q L L N F D L L K L A G D V E S N P G P
197 FMDV-224 DQ989310 R K Q E I I A P E K Q M M N F D L L K L A G D V E S N P G P
198 FMDV-206 EF149010 R K Q E I I A P E K Q M M N F D L L K L A G D V E S N P G P
199 FMDV-223 DQ989311 R K Q E I I A P E K Q M M N F D L L K L A G D V E P N P G P
200 FMDV-162 DQ296529 R K Q E I I A P E K Q M M N F D L L K L A G D V E S N P G A
201 FMDV-6 AY593783 R K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
202 FMDV-7 AY593784 R K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
203 FMDV-8 AY593785 R K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
204 FMDV-26 AY593752 H K Q K I I A P G K Q L L N F D L L K L A G D V E S N P G P
205 FMDV-113 M10975 H K Q K I I A P G K Q L L N F D L L K L A G D V E S N P R P
206 FMDV-202 J02187 H K Q K I I A P G K Q L L N F D L L K L A G D V E S N P R P
207 FMDV-53 AY593797 R K Q E I I A P E K Q A L N F D L L K L A G D V E S N P G P
208 FMDV-118 AY390432 R K Q E I I A P E K Q A L N F D L L K L A G D V E S N P G P
209 FMDV-221 DQ989313 R K Q E I I A P E K Q A L N F D L L K L A G D V E S N P G P
210 FMDV-126 AJ539136 H K Q K I V A P V K Q L L N F N L L K L A G D V E S N P G P
211 FMDV-127 AJ539137 H K Q K I V A P V K Q L L N F N L L K L A G D V E S N P G P
212 FMDV-189 AF167307 H K Q K I V A P V K Q L L N F N L L K L A G D V E S N P G P
213 FMDV-227 DQ989307 R K Q K I I A P E K Q V L N F D L L K L A G D V E S N P G P
214 FMDV-222 DQ989312 R K Q K I I A P E K Q V L N F D L L K L A G D V E S N P G P
215 FMDV-201 X88855 R K Q K I I A P E K Q V L N F D L L K L A G D V E S N P G P
216 FMDV-16 AY593753 Y K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
217 FMDV-23 AY593758 Y K Q K I I A P E K Q L L N F D L L K L A G D V E S N P G P
218 FMDV-30 AY593777 H K Q K I I A P A K Q L L N F D L L Q L A G D V E S N P G P
219 FMDV-31 AY593779 H K Q K I I A P A K Q L L N F D L L Q L A G D V E S N P G P
220 FMDV-51 AY593795 R K Q E I I A P E K Q L L N F D L L K L A G D V E S N P G P
221 FMDV-191 AF024509 R K Q E I I A P E K Q L L N F D L L K L A G D V E S N P G P
222 FMDV-58 AY593807 H K Q P L I A P A K Q L S N F D L L K L A G D V E S N P G P
223 FMDV-60 AY593809 H K Q P L I A P A K Q L S N F D L L K L A G D V E S N P G P
224 FMDV-74 AY593822 H K Q K I V A P A K Q T L N F D L L K L A G D V E S N P G P
225 FMDV-81 AY593826 H K Q K I V A P A K Q T L N F D L L K L A G D V E S N P G P
226 FMDV-101 AY593851 Y K T P L V K P E K Q L C N F D L L K L A G D V E S N P G P
227 FMDV-102 AY593852 Y K T P L V K P E K Q L C N F D L L K L A G D V E S N P G P
228 FMDV-103 AY593853 Y K T P L V K P D K Q M C N F D L L K L A G D V E S N P G P
229 FMDV-104 AB079061 H K Q K I V A P V K Q L L S F D L L K L A G D V E S N P G P
230 FMDV-109 AF377945 H K Q K I V A P V K Q L L S F D L L K L A G D V E S N P G P
231 FMDV-124 AJ007347 Y K Q P L I A P A K Q L L N F D L L K L A G D V E S N P G P
232 FMDV-125 AJ007572 Y K Q P L I A P A K Q L L N F D L L K L A G D V E S N P G P
233 FMDV-293 DQ478937 Y K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
234 FMDV-294 DQ478936 Y K Q K I V A P A K Q L L N F D L L K L A G D V E S N P G P
235 FMDV-4 AY593770 H K Q K I I A P T K Q L L N F D L L K L A G D V E S N P G P
236 FMDV-5 AY593782 H K Q K I I A P A K Q S L N F D L L K L A G D V E S N P G P
237 FMDV-15 AY593803 H K Q S I I A P A K Q L L N F D L L K L A G D V E S N P G P
238 FMDV-20 AY593794 Y K Q Q I I A P A K Q L L N F D L L K L A G D V E S N P G P
239 FMDV-35 AY593774 H K Q R I I A P A K Q L L N F D L L Q L A G D V E S N P G P
240 FMDV-40 AY593772 H K Q K I I A P S K Q L L N F D L L K L A G D V E S N P G P
241 FMDV-42 AY593791 H K Q K I I T P V K Q L L N F D L L K L A G D V E S N P G P
242 FMDV-52 AY593796 R K Q E I I A P E K Q T L N F D L L K L A G D V E S N P G P
243 FMDV-59 AY593808 H K Q P L I A P E K Q L L N F D L L K L A G D V E S N P G P
244 FMDV-61 AY593834 H K Q K I V A P T K Q L L N F D L L K L A G D V E S N P G P
245 FMDV-62 AY593837 Y K Q K I V A P V K Q T L N F D L L K L A G D V E S N P G P
246 FMDV-88 AY593845 Y K T T L V K P A K Q L S N F D L L K L A G D V E S N P G P
247 FMDV-89 AY593846 Y K T A I T K P V K Q L C N F D L L K L A G D V E S N P G P
248 FMDV-90 AY593838 Y K T S I V R P A K Q L C N F D L L K L A G D V E S N P G P
249 FMDV-91 AY593839 Y K T A I T K P A K Q M C S F D L L K L A G D V E S N P G P
250 FMDV-92 AY593840 Y Q T A L T K P A K Q L C N F D L L K L A G D V E S N P G P
251 FMDV-93 AY593841 Y Q T A L V R P A K Q L C N F D L L M L A G D V E S N P G P
252 FMDV-94 AY593842 H K T A L V K P A K Q L C N F D L L K L A G D V E S N P G P
253 FMDV-95 AY593843 Y K T A L V K P A K Q L C N F D L L K L A G D V E S N P G P
254 FMDV-96 AY593844 Y K V S L V A P E K Q M A N F A L L K L A G D V E S N P G P
255 FMDV-97 AY593847 R F D A P I G V E K Q L F N F D L L K L A G D V E S N P G P
256 FMDV-98 AY593848 R F D A P I G V E K Q L C N C D L L K L A G D V E S N P G P
257 FMDV-99 AY593849 R F D A P I G V E K Q L L N F D L L K L A G D V E S N P G P
258 FMDV-100 AY593850 Y K I K L V A P D K Q L C N F D L L K L A G D V E S N P G P
259 FMDV-107 AF189157 H K H K I V A P V K Q L L N F D L L K L A G D M E S N P G P
260 FMDV-112 AF540910 R F D S P I G V K K Q L C N F D L L K L A G D V E S N P G P
261 FMDV-122 AJ251473 R F D A P I G V A K Q L L N F D L L K L A G D V E S N P G P
262 FMDV-171 AY687334 R K Q E I I A P E K Q V L N F D L L K L S G D V E S N P G P
263 FMDV-172 AY687333 R K Q E I I A P A K Q M M N F D L L K L A G D V E S N P G P
264 FMDV-182 AY881014 R K Q K I I A P G K Q V M N F D L L K L A G D V E L N P G P
265 FMDV-187 AY145897 H K Q K I V A P V K Q L L N F E L L K L A G D V E S N P G P
266 FMDV-193 X88862 R H N E D C A T L E Q L L N F D L L K L A G D V E S N P G P
267 FMDV-194 X88861 R H K E D C A P V K Q L L N F D L L K L A G D V E S N P G P
268 FMDV-195 X88863 R H N E D C A P V K Q L L N F D L L K L A G D V E S N P G P
269 FMDV-196 X88860 T Q T G D H C T S K Q L L N F D L L K L A G D V E S N P G P
270 FMDV-197 X88859 K Q T E D H C T N K Q L L N F D L L K L A G D V E S N P G P
271 FMDV-198 X88858 T Q T E D H C T S K Q L L N F D L L K L A G D V E S N P G P
272 FMDV-199 X88857 R K Q E I I A P K K Q V L N F D L L K L A G D V E S N P G P
273 FMDV-207 EF149009 R K Q K I I A P E K Q T L N F D L L K L A G D V E S N P G P
274 FMDV-225 DQ989309 R K Q K I I A P E K Q M M N F D L L K L A G D V E S N P G P
275 FMDV-226 DQ989308 R K Q E I I A P E K Q M M N F E L L K L A G D V E S N P G P
276 FMDV-230 DQ989304 R K Q E I I A P E K Q D L N L D L L K L A G D V E S N P G P
277 FMDV-231 DQ989303 R K Q E I I A P E K Q V L N L D L L K L A G D V E S N P G P
278 FMDV-233 EF600684 R K Q K I I A P G K Q A L N F D L L K L A G D V E L N P G P
279 FMDV-234 AM409325 R K Q P L V A P A K Q L L N F G L L K L A G D V E S N P G P
280 FMDV-236 EF405982 H K Q K I I A P V K Q L L N F D L L K L A G D V E S N P G P
281 FMDV-279 DQ119643 H K Q K I V A P A K Q S L N F D L L R L A G D V E S N P G P
282 FMDV-292 DQ533483 R K Q E I I A P E K Q A L N F D L L E L A G D V E S N P G P
283 ERAV-393/76 L43052 R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
284 ERAV-Plowright DQ272127 R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
285 ERAV-U188 DQ272128 R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
286 ERAV-T3 DQ268580 R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
287 ERAV-T10 DQ272577 R H K F P T N I N K Q C T N Y S L L K L A G D V E S N P G P
288 ERAV-PERV X96870 R H K F P T N I N K Q C T N Y A L L K L A G D V E S N P G P
289 ERAV-PERV-1 DQ272578 R H K F P T N I N K Q C T N Y A L L K L A G D V E S N P G P
290 BRV2 L R L T G E I V K Q G A T N F E L L Q Q A G D V E T N P G P
291 ERBV-1-P1436/71 X96871 E A T L S T I L S E G A T N F S L L K L A G D V E L N P G P
292 ERBV-2-P313/75 AF361253 V A D W E N L L S Q G A T N F D L L K L A G D V E S N P G P
293 PTV-1-5-D-VIII AF296106 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
294 PTV-1-D 61/96 AY392535 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
295 PTV-1-PS 34 AF296105 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
296 PTV-1-Sek 549/98 AF296101 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
297 PTV-1-Sek 655/97 AY392553 A M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
298 PTV-1-Talfan-A AF231769 A M T T L S Y Q G P G A T N F S L L K Q A G D V E E N P G P
299 PTV-1-Talfan-B AB038528 A M T T L S Y Q G P G A T N F S L L K Q A G D V E E N P G P
300 PTV-1-swine/CH/IMH/03 Q355222 A M T T L S Y Q G P G A T N F S L L K Q A G D V E E N P G P
301 PTV-1-F65 AJ011380 A M T V M A F Q G P G A T N F S L L K Q A G D V E E N P G P
302 PTV-1-Sek 65/97 AY392552 A M T V M A F Q G P G A T N F S L L K Q A G D V E E N P G P
303 PTV-1-Sek 1042/97 AY392555 A M T V M A F Q G P G A T N F S L L K Q A G D V E E N P G P
304 PTV-1-Teschen-KonraticeAF231768 A M T T M S Y Q G P G A T N F S L L K Q A G D V E E N P G P
305 PTV-1-Teschen-Tirol AF296097 A M T T M S Y Q G P G A T N F S L L K Q A G D V E E N P G P
306 PTV-1-Vir 1626/89 AF296103 D M T R M S F Q G P G A T N F S L L K Q A G D V E E N P G P
307 PTV-1-Vir 1627/89 AF296104 D M T R M S F Q G P G A T N F S L L K Q A G D V E E N P G P
308 PTV-1-Sek 2498/96 AY392551 A M T V M T F Q G P G A T N F S L L K Q A G D I E E N P G P
309 PTV-1-Sek 736/97 AY392554 A M T V M T F Q G P G A T N F S L L K Q A G D I E E N P G P
310 PTV-1-DS 562/91 AF296100 A M T T M T L Q G P G A T N F S L L K Q A G D V E E N P G P
311 PTV-1-Teschen-Bozen 654AF231767 A M T T I S Y Q G P G A T N F S L L K Q A G D V E E N P G P
312 PTV-1-Teschen-199 AF296098 A M T V V T Y Q G P G A T N F S L L K Q A G D I E E N P G P
313 PTV-1-IBRSV-VII AF296099 D M T R L S F Q G P G A T N F S L L K Q A G D V E E N P G P
314 PTV-1-Vir 2236/99 AF296102 A M T A M A F Q G P G A T N F S L L K Q A G D V E E N P G P
315 PTV-1-DS 1520/93 AY392532 D M T V M T F Q G P G A T N F S L L K Q A G D V E E N P G P
316 PTV-1-RD 181/01 AY392536 N M A R M S F Q G P G A T N F S L L K Q A G D V E E N P G P
317 PTV-2-Vir 480/87 AF296109 A M T T M S L Q G P G A T N F S L L K Q A G D V E E N P G P
318 PTV-2-Vir 6711-12/83 AF296107 A M T T M S L Q G P G A T N F S L L K Q A G D V E E N P G P
319 PTV-4-Vir 918-19/85 AF296111 A M T T M S L Q G P G A T N F S L L K Q A G D V E E N P G P
320 PTV-2-DS 183/93 AY392533 A M T T M T L Q G P G A T N F S L L K Q A G D I E E N P G P
321 PTV-2-DS 756/93 AY392534 A M T T M T L Q G P G A T N F S L L K Q A G D I E E N P G P
322 PTV-2-12-PL AY392541 T M T T M S L Q G P G A T N F S L L K Q A G D V E E N P G P
323 PTV-2-2-AK-III AY392542 T M T T M S L Q G P G A T N F S L L K Q A G D V E E N P G P
324 PTV-2-T80 AF296087 V M T T M M L Q G P G A T N F S L L K Q A G D V E E N P G P
325 PTV-2-Sek 49/99 AF296110 E M T T M S F Q G P G A T N F S L L K Q A G D V E E N P G P
326 PTV-2-Vir 6793/83 AF296108 A M T T L S L Q G P G A T N F S L L R Q A G D V E E N P G P
327 PTV-2-Stendal 2532 AY392537 A M T T M M L Q G P G A T N F S L L K Q A G D V E E N P G P
328 PTV-3-O 2b AF296088 T M T T M S F Q G P G A S S F S L L K Q A G D V E E N P G P
329 PTV-3-1-AA-VI AY392540 A M T T M T F Q G R G A T N F S L L K Q A G D V E E N P G P
330 PTV-4-PS 36 AF296089 V M T T M M L Q G P G A S N F S L L K Q A G D V E E N P G P
331 PTV-4-Vir 3764/86 AF296112 A M T A L T F Q G P G A T N F S L L K Q A G D V E E N P G P
332 PTV-4-Vir 2500/99 AF296113 A M T T L T L Q G P G A T N F S L L K Q A G D V E E N P G P
333 PTV-5-Vir 1806/89 AF296114 A M T T M S F Q G P G A T N F S L L K Q A G D V E E N P G P
334 PTV-5-F 26 AF296090 A M T T M L F Q G P G A A N F S L L R Q A G D V E E N P G P
335 PTV-6-Vir 289/89 AF296116 A M T T M M L Q G P G A T N F S L L K Q A G D V E E N P G P
336 PTV-6-21-SZ AF296117 A M T T M M L Q G P G A T N F S L L K Q A G D V E E N P G P
337 PTV-6-Vir 3634/85 AF296115 A M T T M M L Q G P G A T N F S L L K Q A G D V E E N P G P
338 PTV-6-121-E-IX AY392546 A M T T M M L Q G P G A T N F S L L K Q A G D V E E N P G P
339 PTV-6-PS 37 AF296091 A M T T M S F Q G P G A T N F S L L K Q A G D V E E N P G P
340 PTV-7-F 43 AF296092 T M T V V S F Q G P G A T N F S L L K Q A G D V E E N P G P
341 PTV-8-UKG 173/74 AF296093 A L T T M S L Q G P G A T N F S L L K Q A G D I E E N P G P
342 PTV-8-25-T-VII AF296118 A L T T M S L Q G P G A T N F S L L K Q A G D I E E N P G P
343 PTV-9-Vir 2899/84 AF296094 A M T T M A F Q G P G A T N F S L L K Q A G D V E E N P G P
344 PTV-10-UKG/170/80 AY392539 A M T T L S F Q G P G A T N F S L L K Q A G D V E E N P G P
345 PTV-10-12/15 Ge (1980) AY392547 A M T T L S F Q G P G A T N F S L L K Q A G D V E E N P G P
346 PTV-10-S 776/83 AY392548 A M T T L S F Q G P G A T N F S L L K Q A G D V E E N P G P
347 PTV-10-VS7/92 AY392549 A M T T L S F Q G P G A T N F S L L K Q A G D V E E N P G P
348 PTV-11-UKG 53/81 AF296120 A M T T L S F Q G P G A T N F S L L K Q A G D V E E N P G P
349 PTV-10-Vir 460/88 AF296095 T M T T L S F Q G P G A T N F S L L K Q A G D V E E N P G P
350 PTV-10-Vir 461/88 AF296119 T M T T L S F Q G P G A T N F S L L K Q A G D V E E N P G P
351 PTV-11-Dresden AF296096 D M T R M S F Q G P G A T N F S L L K R A G D V E E N P G P
352 PTV-11-1008/88 AY392550 D M T R M S L Q G P G A S N F S L L K Q A G D V E E N P G P
353 PTV-11-DS 1696/91 AF296121 A M T A M A L Q G P G A T N F S L L K Q A G D V E E N P G P
354 EMCV(Rueckert) M81861 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
355 EMCV X00463 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
356 EMCV (EMC-PV21) X74312 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
357 EMCV (BEL-2887A/91) AF356822 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
358 EMCV (pEC9) DQ288856 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
359 EMCV (HB1) DQ464063 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
360 EMCV (BJC3) DQ464062 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
361 EMCV (EMCV-CBNU) DQ517424 V F G L Y R I F N A H Y A G Y F A D L L I H D I E T N P G P
362 EMCV (EMC-B) M22457 V F G L Y G I F N A H Y A G Y F A D L L I H D I E T N P G P
363 EMCV (EMC-D) M22458 V F G L Y G I F N A H Y A G Y F A D L L I H D I E T N P G P
364 EMCV (PV2) X87335 V F G L Y S I F N A H Y A G Y F A D L L I H D I E T N P G P
365 EMCV (M) M37588 V F G L Y S I F N A H Y A G Y F A D L L I H D I E T N P G P
366 EMCV (EMCV-30) AY296731 I F G L Y R I F S T H Y A G Y F S D L L I H D I E T N P G P
367 MENGO (Rz-pMwt) DQ294633 V F G L Y H V F E T H Y A G Y F S D L L I H D V E T N P G P
368 TMEV (GDVII) X56019 F R E F F K A V R G Y H A D Y Y K Q R L I H D V E M N P G P
369 TMEV M20562 F R E F F K A V R G Y H A D Y Y K Q R L I H D V E M N P G P
370 TMEV (DA TO) M20301 F G E F F R A V R A Y H A D Y Y K Q R L I H D V E M N P G P
371 TMEV (BeAn 8386) M16020 F G E F F K A V R G Y H A D Y Y R Q R L I H D V E T N P G P
372 TLV(NGS910) AB090161 F S D F F K H V R E Y H A A Y Y K Q R L M H D V E T N P G P
373 SAF-V (Saffold virus) EF165067 F T D F F K A V R D Y H A S Y Y K Q R L Q H D V E T N P G P
374 SAF-V (Saffold virus) AM922293 F T D F F K A V R D Y H A S Y Y K Q R L Q H D I E A N P G P
375 LV (174F) AF327921 Y F N I M H S D E M D F A G G K F L N Q C G D V E T N P G P
376 LV (87-012) AF327920 Y F N I M H S D E M D F A G G K F L N Q C G D V E T N P G P
377 LV (87-012G) EF202833 Y F N I M H S D E M D F A G G K F L N Q C G D V E T N P G P
378 LV (145SL) AF327922 Y F N I M H N D E M D Y S G G K F L N Q C G D V E S N P G P
379 LV (M1146) AF538689 Y F K I Y H D K D M D Y A G G K F L N Q C G D V E T N P G P
380 DHV-1 (DRL-62) DQ219396 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
381 DHV-1 (R85952) DQ226541 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
382 DHV-1 (F) EU264072 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
383 DHV-HS DQ812094 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
384 DHV-HSS DQ812092 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
385 DHV-1 (03D) DQ249299 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
386 DHV-1 (R) EF585200 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
387 DHV-1 (E53) EF151313 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
388 DHV-1 (HP-1) EF151312 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
389 DHV-1 (S) EF417871 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
390 DHV-1 (ZJ) EF382778 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
391 DHV-1 (H) DQ249300 A F E L N L E I E S D Q I R N K K D L T T E G V E P N P G P
392 DHV AP-03337 DQ256132 A F E L H L E I E S D Q F R N V R D L T T E G V E P N P G P
393 DHV AP-04114 DQ812093 A F E L H L E I E S D Q F R N V R D L T T E G V E P N P G P
394 DHV AP-04203 DQ256134 A F E L H L E I E S D Q F R N V R D L T T E G V E P N P G P
395 DHV AP-04009 DQ256133 A F E L H L E I E S D Q F R N V R D L T T E G V E P N P G P
396 DHV AP-03337 DQ256132 A F E L H L E I E S D Q F R N V R D L T T E G V E P N P G P
397 DHV-1 (JX) EF093502 A F E L D L E I E S D Q I R N K K D L T T E G V E P N P G P
398 DHV-1 (A66) DQ886445 A F E L D L E I E S D Q I R N K K D L T T E G V E P N P G P
399 DHV-1 (C80) DQ864514 A F E L D L E I E S D Q I R N K K D L T T E G V E P N P G P
400 DHV-1 (90D) N-DHV EF067924 A F E L H L E I E S D Q I R N V R D L T T E G V E P N P G P
401 DHV-1 (04G) EF067923 A F E L H L E I E S D Q I R N V R D L T T E G V E P N P G P
402 DHV-1 (JX) EU371557 A F E L N L E I E S D Q I R K K K D L T T E G V E P N P G P
403 DHV-1 (5886) DQ249301 A F E L N L E I E S D Q I R N K K D L T T E G V E S N P G P
404 SVV DQ641257 R A W C P S M L P F R S Y K Q K M L M Q S G D I E T N P G P
405 SePV-1 EU152976 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
406 SePV-1 EU142040 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
407 SePV-1 EU152979 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
408 SePV-1 EU152978 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
409 SePV-1 EU152975 C G C F C P L P N V Y V P P T H N V L L D G D V E S N P G P
410 SePV-1 EU152974 C G C F C P L P N V Y V P P T H N V L L E G D V E S N P G P
411 SePV-1 EU152980 S G C F C P L P N V Y V P P I H N V L L D G D V E S N P G P
412 SePV-1 EU152977 S G C F C P L P N V Y V P P T H N V L L D G D V E S N P R P
413 ADRV-N AY632079 F F D S V W V Y H L A N S S W V R D L T R E C I E S N P G P
414 ADRV-N (J19) DQ113901 F F D S V W V Y H L A N S S W V R D L T R E C I E S N P G P
415 ADRV-N (B219) DQ168032 F F D S I W V Y H L A N S S W V R D L T R E C I E S N P G P
416 Human-C (V508) AY941781 G V G Y P L I V A N S K F Q I D K I L I S G D I E L N P G P
417 Human-C (V966) AY941782 G V G Y P L I V A N S K F Q I D K I L I S G D I E L N P G P
418 Human-C (Bristol) AJ132203 G A G Y P L I V A N S K F Q I D K I L I S G D I E L N P G P
419 Human-C (V460) AY941780 G T G Y P L I V A N S K F Q I D K I L I S G D I E L N P G P
420 Bovine-C (Shintoku) L12390 G I G N P L I V A N S K F Q I D R I L I S G D I E L N P G P
421 Porcine-C (Cowden) M69115 G N G N P L I V A N A K F Q I D K I L I S G D V E L N P G P
422 EoPV-2A1 AY365064 G Q R T T E Q I V T A Q G W A P D L T Q D G D V E S N P G P
423 EoPV-2A2 AY365064 T R G G L Q R Q N I I G G G Q R D L T Q D G D I E S N P G P
424 EoPV-2A1 AY341824 G Q R T T E Q I V T A Q G W A P D L T Q D G D V E S N P G P
425 EoPV-2A2 AY341824 T R G G L Q R Q N I I G G G Q R D L T Q D G D I E S N P G P
426 PnPV-2A1 AF323747 G Q R T T E Q I V T A Q G W V P D L T V D G D V E S N P G P
427 PnPV-2A2 AF323747 T R G G L R R Q N I I G G G Q K D L T Q D G D I E S N P G P
428 IFV AB000906 P S I G N V A R T L T R A E I E D E L I R A G I E S N P G P
429 ABPV (U.K.) AF150629 T G F L N K L Y H C G S W T D I L L L L S G D V E T N P G P
430 ABPV (Poland-1) AF486073 T G F L N K L Y H C G S W T D I L L L L S G D V E T N P G P
431 ABPV (Hungary-1) AF486072 T G F L N K L Y H C G S W T D I L L L W S G D V E T N P G P
432 KBV AY275710 I G F L N K L Y K C G T W E S V L N L L A G D I E L N P G P
433 IAPV EF219380 I G F L N K L Y R C G D W D S I L L L L S G D I E E N P G P
434 CrPV AF218039 L V S S N D E C R A F L R K R T Q L L M S G D V E S N P G P
435 DCV (EB) AF014388 Q G I G K K N P K Q E A A R Q M L L L L S G D V E T N P G P
436 TaV AF062037 R G P R P Q N L G V R A E G R G S L L T C G D V E E N P G P
437 TaV AF282930 R G P R P Q N L G V R A E G R G S L L T C G D V E E N P G P
438 EeV AF461742 R R L P E S A Q L P Q G A G R G S L V T C G D V E E N P G P
439 PrV-2A1 AF548354 L E M K E S N S G Y V V G G R G S L L T C G D V E S N P G P
440 PrV-2A2 AF548354 N S D D E E P E Y P R G D P I E D L T D D G D I E K N P G P
441 PrV-2A3 AF548354 T L M G N I M T L A G S G G R G S L L T A G D V E K N P G P
442 D. punctatus CPV1 AY163248 M T A F D F Q Q A V F R S N Y D L L K L C G D V E S N P G P
443 D. punctatus CPV1 AY185594 M T A F D F Q Q A V F R S N Y D L L K L C G D V E S N P G P
444 L. dispar CPV1 AF389466 M T A F D F Q Q A V F R S N Y D L L K L C G D V E S N P G P
445 B. mori AF433660 R T A F D F Q Q D V F R S N Y D L L K L C G D I E S N P G P
446 B. mori CPV1-H AB035733 R T A F D F Q Q D V F R S N Y D L L K L C G D I E S N P G P
447 B. mori CPV1-I AB035732 R T A F D F Q Q D V F R S N Y D L L K L C G D I E S N P G P
448 O. brumata CPV18 DQ192245 I H A N D Y Q M A V F K S N Y D L L K L C G D V E S N P G P
449 T.brucei CAA29181 R S L G T C K R A I S S I I R T K M L V S G D V E E N P G P
450 T.brucei CAD21861 R S L G T C Q R A I S S I I R T K M L L S G D V E E N P G P
451 T.brucei CAD21860 R S L G T C Q R A I S S I I R T K M L L S G D V E E N P G P
452 T.congolense 354h04.q1k_6 I L P C T C G R A T L D A R R I L L L V S G D I E R N P G P
453 T.congolense 335b10.q1k_3 I L P C T C G R A T L D A R R I L L L V S G D I E R N P G P
454 T.congolense 432g10.q1k_7 I L P C T C G C A T L D A R R I L L L V S G D V E R N P G P
455 T.congolense 400g12.q1k_4 I L P C T C G R T T L D A R R I L L L V S G D I E R N P G P
456 T.congolense 876g11.p1k_3 I L P C T C G R T T L D A R R I L L L V S G D I E R N P G P
457 T.congolense 1381h11.q1k_4 I V P C T C G R T T L D A R R I L L L V S G D I E R N P G P
458 T.congolense 1071g10.p1k_14 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
459 T.congolense 1294e07.p1k_3 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
460 T.congolense 1473f10.p1k_5 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
461 T.congolense 1305b04.p1k_2 I L P C T C G R A T L D A R R F L L P V R G D V G R N P G P
462 T.congolense 530f06.q1kbw_10 I L P C T C I C P T L E A R R L L V L V S G G I E R N P R P
463 T.congolense 1463e05.p1k_0 A L S C V C G H G N S L L C R L L L F L S G D V E Y N P G S
464 T.congolense 800b12.p1k_3 A L S C V C G H G N S L L C R L L L F L S G N V E Y N P G S
465 T.congolense 47d01.q1k_6 A L S C V C G H G N S L L C R L L L F L S G N V E Y N P G S
466 T.congolense 987a11.q1k_0 A L S C V C G H G N S L L C R L L L F L S G N V E Y N P G S
467 T.congolense 1423d04.p1k_0 T L S C T C G S A L P K A L G P L L L L S R V E D H N P G P
468 T.congolense 1182h09.q1k_0 F T C T C W R G R A L L C R P F L M P L S G D V G Q N P E P
469 T.congolense 1264h04.p1k_15 L L S T C G S A L P K A L R P P L L L L S R D E D H N P G P
470 T.congolense 245e02.p1k_7 T V P P N R Q C A L Q E A L R K K L L L C G D V E S N P W N
471 T.congolense 372c07.q1k_4 L R H P N R Q Y A L Q E A L R Q K F L L C G D V E S N P G P
472 T.congolense endsN14h02.p1k_0 L R H P N R Q C A L Q E A L R Q K L L L C G D V E A N P G P
473 T.congolense 1158a09.p1k_3 L R H P N R Q C A L Q E A L R Q K L P L C G D V E A N P G P
474 T.congolense 791f06.q1k_6 L R H P N R Q C A L Q E A L R Q K L L L C G D V E A N P G P
475 T.congolense 664f07.p1k_5 T L S C T C G S A L P K A L R P L L L P S R D V E R N P G P
476 T.congolense 1242b10.p1k_5 I L P C M C G R A T L D A R R L L L L V S E D I E R N P G P
477 T.congolense 668g12.q1k_4 I L P C T C G R A T L D A R R I L L L V S G D V E R N P G P
478 T.congolense 276e06.p1k_0 I L P C T C G R A T L D A R R I L L L V S G D I E R N P G P
479 T.congolense 464h12.q1k_4 I L P C T C G R A T L D A Q R I L L L V S G D V E R N P G P
480 T.congolense 335e01.p1k_0 I L P R T C G R A T L D A Q R I L L L V S G D V K R N P G P
481 T.congolense _endsn12b02.p1k_2 I L P C T C G R A T L D A P R I L L L V S G D V E R N P G P
482 T.congolense 242b03.p1k_7 I L P C T C G C A T L D A R R I L L L V S G D V E R N P G P
483 T.congolense 612c08.p1k_1 I L P C T C G R A T L D A R R I L L L V S G D I E R N P G P
484 T.congolense 1476a12.p1k_1 I L P C T C G R A T L D A R R I L L L V S G D I E R N P G P
485 T.congolense 559g05.q1k_4 I L P C T C G R A T L D A R R I L L L V S G D V E R N P G P
486 T.congolense 419f08.q1k_1 I L P C T C G R A T L D A R R I L L L V S G D V E R N P G P
487 T.congolense 55d01.p1k_3 T L F C T C G S A L P K A L R P L L L L S R V E D H N P G P
488 T.congolense 519b02.p1k_8 V L P C T C G R A T L D A R R I L L L I S G D V E R N P A P
489 T.cruzi AAA67559 Q P Y T Y C L R A L C D A Q R Q K L L L I G D I E Q N P G P
490 T.cruzi CAB41692 Q R Y T Y R L R A V C D A Q R Q K L L L S G D I E Q N P G P
491 T.vivax 638g08.p1k_1 I L P Y T C E C A T L D A L R L L L L T C G D V E R N P G P
492 T.vivax 262a12.p1k_4 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
493 T.vivax 1734a06.p1k_4 I L P C T C G R A A L D V R R H L L L I I G D V E R N P G P
494 T.vivax 720g04.q1k_0 I L P C T C G R A T L D A R R T L L L I S G D V E R N P G P
495 T.vivax 814g01.p1k_9 I L P C T C G R A T L D A R R T L L L I S G D V E R N P G P
496 T.vivax 1814e03.p1k_1 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
497 T.vivax 346a10.p1k_3 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
498 T.vivax 1198e11.p1k_1 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
499 T.vivax 104g02.p1k_0 M H P C T R G R A V L D A R R L P L L I S G D V E R N P G P
500 T.vivax 961a05.q1k_2 M L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
501 T.vivax 1278c04.p1k_6 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
502 T.vivax 856h07.q1k_12 I L P C T R G R A T L D A R R P L L L I S G V V E R N P G P
503 T.vivax 1858e01.q1k_5 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
504 T.vivax 158a04.q1k_12 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
505 T.vivax 1890c02.p1k_12 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
506 T.vivax 1013b08.p1k_5 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
507 T.vivax 786e10.q1k_5 I L P C T C G R A V S D A R R L L L L I S G D V G R N P G P
508 T.vivax 1875a05.p1k_16 M L P C A C G R A T L D A R R L T L L V S G D V E R D P G P
509 T.vivax 302f07.p1k_20 I L P C T C E R A T L D A R R L L L L I S G D V E R N P G P
510 T.vivax 1681d10.q1k_7 T L P F A R W H I A L D M R R P L L L I S G D V D S K P G P
511 T.vivax 174f04.p1k_4 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
512 T.vivax 1797d11.q1k_3 I L P C T C G H A A L D A R R R P L L V G R D V K R N P G P
513 T.vivax 1152b09.q1k_1 I L P C T C G R A T L D A R R L L L L A S G D V E R N P G P
514 T.vivax 992d03.q1k_1 I L P C T C G R A T L D A R R L L L L A S G D V E R N P G P
515 T.vivax 333f01.p1k_22 I L P R T C G S A T L D A R R R L L L I S G D V E R T P G P
516 T.vivax 1108e04.q1k_0 I L P C T C G R A T L D V L R L L L L V S G D V E R N S G P
517 T.vivax 676h09.p1k_0 I L P C T C G R A A S D V R R L L L L I G G D A E R N P G P
518 T.vivax 580d11.p1k_4 I L P C T C G R A T L D A R R L L L L I S G A V E R N P G P
519 T.vivax 13b07.q1k_4 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
520 T.vivax 697h03.p1k_0 I L P C T C G R A T L D A R R L L L L I S G D V E R N P G P
521 T.vivax 208f09.q1k_0 I L P C T C G R A A L D A R R L L L L I S G N V E C N P G P
522 T.vivax 1664g12.q1k_4 L L P C T C G R A T L D A W R L L L L I C G G V G R N P G P
523 T.vivax 615g10.p1k_36 I L P R T C G S A T L D A R R R L L L I S G D V E R M P G P
524 T.vivax 1296c04.p1k_1 I L P C T R G R A T L D A R R L L L L V S G G V E R N P G P
525 T.vivax 389g02.q1k_2 I L P C T C G R A M L D A R R L L L L I S V D V E R N P G P
526 T.vivax 915h11.q1k_1 I L P C T C G R A T L G A R R L L L L I S V D V E R N P G P
527 T.vivax 395d11.q1k_1 I L P C A C G R A T L D A R R L L V L I S G D V E R N P G A
528 T.vivax 1090d05.q1k_9 L L P C T C G R A A L D A R R L L L L I I G G V E R K P G P
529 T.vivax 749d12.p1k_0 I L P R T C G R A T L D A R R L L L L I D G D V E R I P G P
530 T.vivax 407c12.p1k_11 I L P R T C G R A T L D A R R L L L L I D G D V E R I P G P
531 T.vivax 1357e07.q1k_4 L L A C T C G R A A L D V R R R L L L I S G T V K R N P G P
532 T.vivax 396d05.q1k_10 I L P C T C G H A A L D A R R R L L L I S G D V E R N P G A
533 T.vivax 936e06.q1k_21 I L P C A C G R A A L D A R R L L L L A S G D V G R N P G P
534 T.vivax 1768f01.q1k_0 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
535 T.vivax 1768f01.q1k_7 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
536 T.vivax 563c09.q1k_9 M L L C T R G R A M L R A R W L L L L I S G D V E R D P G P
537 T.vivax 169g11.q1k_0 I L P C T C G R A T L D A R R L L L L I S G D V E R N P V P
538 T.vivax 1062d12.p1k_10 K L P C T C R R A A L D A R R L L L L I N G G V E R N P G P
539 T.vivax 604d12.p1k_1 M L L C T R G C A M L D A R R L L L P V R G D V E R N P G T
540 T.vivax 1362h08.p1k_4 I L P R T C G R A T L D A R R R P L L V G R G V E R N P G P
541 T.vivax 915e09.p1k_12 L L P C T C G R A T L D A R R L L L L I N G D V E R N P G P
542 T.vivax 242g08.q1k_7 I L P C A C G R A T L G A R R L L L L I S G D V E R N P G P
543 T.vivax 1878e03.p1k_0 A L P C T C G R A A L D A R R L L L L A S G D V E R N P G P
544 T.vivax 1143a11.p1k_25 M L P C T C G R A T L D A R R L L L L I I G D V E R D P G P
545 T.vivax 127f05.p1k_10 I L P C A C G R A V S D A L R L L L L I S G D V E C N P G P
546 T.vivax 696d02.p1k_1 I L P C T C G R A A L D A Q W R L L L I F V D A E R N P G P
547 T.vivax 395e02.q1k_1 I L P C T C G R A A L D A Q W R L L L I F V D A E R N P G P
548 T.vivax 1204f09.p1k_16 S F L N T S L R V R V R H V G C A L F I S V D V E L N P G P
549 T.vivax 1669f09.p1k_0 S S L N T S L R V R V C H V G C A L F I S V D V E L N P G P
550 T.vivax 379d02.q1k_1 L E K L V E R R T R V C H V G C A L F I S V D V E L N P G P
551 T.vivax 1208b05.q1k_3 S S L S T S L R V R V C H V G C A L F I S V D V E L N P G P
552 T.vivax 610d02.p1k_6 S S L S T S L R V R V C H V G C A L F I S V D V E L N P G P
553 T.vivax 1368b05.p1k_6 S S L S T S L R V R L C H V G C A L F I S V D V E L N P G P
554 T.vivax 532f08.q1k_24 S S L S T S L R V R V C H V G C A L F I S V D V E L N P G P
555 T.vivax 1322e01.p1k_12 S S L S T S L R V R V C H V G C A L F I S V D V E L N P G P
556 T.vivax 252g03.p1k_8 S S L S T S L R V R V C H V G C A L F I S V D V E L N P G P
557 T.vivax 357e12.q1k_5 S S L S T S L R V R V C H V G C A L F I S V D V E L N P G P
558 T.vivax 1265f12.p1k_12 S S L S T S L R V R V C H V G C A L F I S V D V E L N P G P
559 T.vivax 1660h01.q1k_4 S S L S T S L R V R V C H V G C A L F I S V D V E L N P G P
560 T.vivax 960h06.q1k_1 Y F A C T C E R A A L D A P R L P V L I S G D V E R N P G P
561 T.vivax 631h12.q1k_13 S S L S T S L R V R V C H V G C A L F I S V D V E L N P G P
562 T.vivax 1351h04.q1k_31 I L P F T C G R A G L D T R R L L L L I S G G V G R N P G P
563 T.vivax 87c09.p1k_2 L L A C T C G R A A L D V R R R L L R I T G T V K R N P G P
564 T.vivax 615c05.p1k_1 I L P F T C G R A G L D T R R L P L L I S G G V G R N P G P
565 T.vivax 533b05.q1k_2 V L P C A C G R A T L D A R R L L L P V G G G V E R N A G P
566 T.vivax 938f02.q1k_5 I L P C T R G R A M L S A R W L L L L I S G G V E R K P G P
567 T.vivax 314e11.q1k_9 L L A C T C G R A A L D V R R R L L L I S G T V K R D P G P
568 T.vivax 733e05.p1k_4 I L P F T C G R A A L D A W R L L L L I G G G V G R N P G P
569 T.vivax 73h08.q1k_2 I L P C L C V H A A S D A R W L L L L I S G D V E R R P C P
570 T.vivax 772h12.q1k_1 N T S L R V L A C C V R R A A A P A V Y Q R D V E R K P G P
571 T.vivax 390g10.p1k_23 M L L C T S G R A M L R A R W L L L L I S G D V E R D S G P
572 T.vivax 1122f12.p1k_3 L L A C T F G R A A L D E R R R L L R I S G T V K R D P G P
573 T.vivax 892h02.p1k_5 S Q V R W S N G A E K K V Q R L L L L S G G D V E R N P G P
574 T.vivax 1351h04.q1k_31 I L P F T C G R A G L D T R R L L L L I S G G V G R N P G P
575 T.vivax 87c09.p1k_2 L L A C T C G R A A L D V R R R L L R I T G T V K R N P G P
576 T.vivax 615c05.p1k_1 I L P F T C G R A G L D T R R L P L L I S G G V G R N P G P
577 T.vivax 533b05.q1k_2 V L P C A C G R A T L D A R R L L L P V G G G V E R N A G P
578 T.vivax 938f02.q1k_5 I L P C T R G R A M L S A R W L L L L I S G G V E R K P G P
579 T.vivax 314e11.q1k_9 L L A C T C G R A A L D V R R R L L L I S G T V K R D P G P
580 T.vivax 733e05.p1k_4 I L P F T C G R A A L D A W R L L L L I G G G V G R N P G P
581 T.vivax 73h08.q1k_2 I L P C L C V H A A S D A R W L L L L I S G D V E R R P C P
582 T.vivax 772h12.q1k_1 N T S L R V L A C C V R R A A A P A V Y Q R D V E R K P G P
583 T.vivax 390g10.p1k_23 M L L C T S G R A M L R A R W L L L L I S G D V E R D S G P
584 T.vivax 1122f12.p1k_3 L L A C T F G R A A L D E R R R L L R I S G T V K R D P G P
585 T.vivax 892h02.p1k_5 S Q V R W S N G A E K K V Q R L L L L S G G D V E R N P G P
586 STR-20 XP_001196456 S K T D L I S G Q F P P L S E L L L L K S G D V E L N P G P
587 STR-50 GLEAN3_03186 S K T D L I S G Q I P H L S E L L L M K S G D V E L N P G P
588 STR-65 GLEAN3_09160 S K T E L M S G Q I P P L S E L L L L K S G D V E L N P G P
589 STR-70 GLEAN3_22394 S K T D L I S G Q I P S L S E L L L L K S G D V E L N P G P
590 STR-76 GLEAN3_03448 S K T D L I S G Q I P P L S K L L L L K S G D V E L N P G P
591 STR-81 GLEAN3_21478 S K T D L I S G Q I P P L S E L L L L K S G D V E L N P G P
592 STR-83 GLEAN3_22780 S K T D L I S G Q I P P L S E L L L M K S G D V E L N P G P
593 STR-100 GLEAN3_15340 S K T D L I S G Q I P P L S E L L L L K S G D V E L N P G P
594 STR-111 GLEAN3_20436 S K T D L I S G Q F P P L S E L L L L K S G D V E L N P G P
595 STR-127 GLEAN3_23550 S K T D L I S G Q I P P L S E L L L L K S G D V E L N P G P
596 STR-147 GLEAN3_11433 S K T D L I S G Q I P P L S E L L L L K S G D V E L N P G P
597 STR-23 XP_001198729 L H P A I L C S A S L C F R P Y L L L M A G D V E P N P G P
598 STR-35 XP_001200466 N S S C V L N I R S T S H L A I L L L L S G Q V E P N P G P
599 STR-54 GLEAN3_25204 S Q N I D V L S Q Q P Y L T E L L L V K A G D V E L N P G P
600 STR-60 GLEAN3_09111 Q N L D F N L Y L L M I L L M I L L M R S G D V E T N P G P
601 STR-67 GLEAN3_08283 P Q Q D L Q G F C L L Y L L M I L L M R S G D V E T N P G P
602 STR-82 GLEAN3_25914 T T D D P V V Q E S T C L P E M I L V K A G D V E Q N P G P
603 STR-106 GLEAN3_23532 L H P A I L C S A S L C F R P Y L L L M A G D V E P N P G P
604 STR-110 GLEAN3_06203 Q D L D V K E A D K P H I T Q S L I L K A G D V E S N P G P
605 STR-136 GLEAN3_20380 G A V D V V L S Q Q P Y L T E L L L V K A G D V E L N P G P
606 STR-143 GLEAN3_22449 S R P I L Y Y S N T T A S F Q L S T L L S G D I E P N P G P
607 STR-1 XP_797143 N S T P A A M F V C A F I L I S V L L L S G D V E I N P G P
608 STR-34 XP_001196844 N S T P A A M F V C V F I L I S V L L L S G D V E I S P G P
609 STR-24 XP_001196407 S Q R D L S C S Q P R T I I L G L I M C A G D V Q P N P G P
610 STR-25 XP_001186348 S Q R D L S C S Q P R T I I L G L I M C A G D V Q P N P G P
611 STR-32 XP_001185404 N S S C V L N I R S T S H L A I L L L L S G Q V E P N P G P
612 STR-35 XP_001200466 N S S C V L N I R S T S H L A I L L L L S G Q V E P N P G P
613 STR-164 XR_025775 N S S C V L N I R S T S H L A I L L L L S G Q V E P N P G P
614 STR-27 XP_001185149 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
615 STR-28 XP_001179204 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
616 STR-29 XP_791376 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
617 STR-30 XP_001199602 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
618 STR-31 XP_001200060 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
619 STR-33 XP_001184905 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
620 STR-36 XP_001180489 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P G P
621 STR-163 XP_001192137 L C P L D F R S T S L S H L T I L L L L S G Q V E T N P D P
622 STR-116/160 XR_026225 T T C Q C K A L S V M Y L T L L L L T N A S D I E L N P G P
623 STR-40/141 GLEAN3_18025 K S C I S Y Y S N S T A C F N I E I M C C G D V K S N P G P
624 STR-55 GLEAN3_24854 G A R I S Y H P N T T A T F Q L R L L V S G D V N P N P G P
625 STR-61 GLEAN3_22393 G A R I R Y Y N N S S A T F Q T I L M T C G D V D P N P G P
626 STR-89 GLEAN3_19055 G R R I Q Y Y N N S I S T F R S E L L R C G D V E S N P G P
627 STR-38 XP_793501 K T R I P Y S V N S N A S F Q L E L L H A G D V H P N P G P
628 STR-51 GLEAN3_22449 S R P I L Y Y S N T T A S F Q L S T L L S G D I E P N P G P
629 STR-69 GLEAN3_27016 C R R I A Y Y S N S D C T F R L E L L K S G D I Q S N P G P
630 STR-133 GLEAN3_00868 K R R I P Y N P N S T A S F Q L E L L H A G D V H P N P G P
